#FORMAT=WebAnno TSV 3.3
#T_SP=de.tudarmstadt.ukp.dkpro.core.api.syntax.type.chunk.Chunk|chunkValue
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Dopamine-related disruption of functional topography of striatal connections in unmedicated patients with schizophrenia
1-1	0-16	Dopamine-related	_	_	
1-2	17-27	disruption	_	_	
1-3	28-30	of	_	_	
1-4	31-41	functional	_	_	
1-5	42-52	topography	_	_	
1-6	53-55	of	_	_	
1-7	56-64	striatal	_	_	
1-8	65-76	connections	_	_	
1-9	77-79	in	_	_	
1-10	80-91	unmedicated	_	_	
1-11	92-100	patients	_	_	
1-12	101-105	with	_	_	
1-13	106-119	schizophrenia	_	_	

#Text=Importance
2-1	120-130	Importance	_	_	

#Text=Despite the well-established role of striatal dopamine in psychosis, current views generally agree that cortical dysfunction is likely necessary for the emergence of psychotic symptoms. The topographical organization of striatal-cortical connections is central to gating and integration of higher-order information, so a disruption of such topography via dysregulated dopamine could lead to cortical dysfunction in schizophrenia. However, this hypothesis remains to be tested using multivariate methods ascertaining the global pattern of striatal connectivity and without the confounding effects of anti-dopaminergic medication.
3-1	131-138	Despite	_	_	
3-2	139-142	the	_	_	
3-3	143-159	well-established	_	_	
3-4	160-164	role	_	_	
3-5	165-167	of	_	_	
3-6	168-176	striatal	_	_	
3-7	177-185	dopamine	_	_	
3-8	186-188	in	_	_	
3-9	189-198	psychosis	_	_	
3-10	198-199	,	_	_	
3-11	200-207	current	_	_	
3-12	208-213	views	_	_	
3-13	214-223	generally	_	_	
3-14	224-229	agree	_	_	
3-15	230-234	that	_	_	
3-16	235-243	cortical	_	_	
3-17	244-255	dysfunction	_	_	
3-18	256-258	is	_	_	
3-19	259-265	likely	_	_	
3-20	266-275	necessary	_	_	
3-21	276-279	for	_	_	
3-22	280-283	the	_	_	
3-23	284-293	emergence	_	_	
3-24	294-296	of	_	_	
3-25	297-306	psychotic	_	_	
3-26	307-315	symptoms	_	_	
3-27	315-316	.	_	_	
3-28	317-320	The	_	_	
3-29	321-334	topographical	_	_	
3-30	335-347	organization	_	_	
3-31	348-350	of	_	_	
3-32	351-368	striatal-cortical	_	_	
3-33	369-380	connections	_	_	
3-34	381-383	is	_	_	
3-35	384-391	central	_	_	
3-36	392-394	to	_	_	
3-37	395-401	gating	_	_	
3-38	402-405	and	_	_	
3-39	406-417	integration	_	_	
3-40	418-420	of	_	_	
3-41	421-433	higher-order	_	_	
3-42	434-445	information	_	_	
3-43	445-446	,	_	_	
3-44	447-449	so	_	_	
3-45	450-451	a	_	_	
3-46	452-462	disruption	_	_	
3-47	463-465	of	_	_	
3-48	466-470	such	_	_	
3-49	471-481	topography	_	_	
3-50	482-485	via	_	_	
3-51	486-498	dysregulated	_	_	
3-52	499-507	dopamine	_	_	
3-53	508-513	could	_	_	
3-54	514-518	lead	_	_	
3-55	519-521	to	_	_	
3-56	522-530	cortical	_	_	
3-57	531-542	dysfunction	_	_	
3-58	543-545	in	_	_	
3-59	546-559	schizophrenia	Schizophrenia	_	
3-60	559-560	.	_	_	
3-61	561-568	However	_	_	
3-62	568-569	,	_	_	
3-63	570-574	this	_	_	
3-64	575-585	hypothesis	_	_	
3-65	586-593	remains	_	_	
3-66	594-596	to	_	_	
3-67	597-599	be	_	_	
3-68	600-606	tested	_	_	
3-69	607-612	using	_	_	
3-70	613-625	multivariate	_	_	
3-71	626-633	methods	_	_	
3-72	634-646	ascertaining	_	_	
3-73	647-650	the	_	_	
3-74	651-657	global	_	_	
3-75	658-665	pattern	_	_	
3-76	666-668	of	_	_	
3-77	669-677	striatal	_	_	
3-78	678-690	connectivity	_	_	
3-79	691-694	and	_	_	
3-80	695-702	without	_	_	
3-81	703-706	the	_	_	
3-82	707-718	confounding	_	_	
3-83	719-726	effects	_	_	
3-84	727-729	of	_	_	
3-85	730-747	anti-dopaminergic	_	_	
3-86	748-758	medication	_	_	
3-87	758-759	.	_	_	

#Text=Objective
4-1	760-769	Objective	_	_	

#Text=To determine whether the pattern of brain connectivity across striatal subregions is abnormal in unmedicated patients with schizophrenia, and whether this abnormality relates to psychotic symptoms and extrastriatal dopaminergic transmission.
5-1	770-772	To	_	_	
5-2	773-782	determine	_	_	
5-3	783-790	whether	_	_	
5-4	791-794	the	_	_	
5-5	795-802	pattern	_	_	
5-6	803-805	of	_	_	
5-7	806-811	brain	_	_	
5-8	812-824	connectivity	_	_	
5-9	825-831	across	_	_	
5-10	832-840	striatal	_	_	
5-11	841-851	subregions	_	_	
5-12	852-854	is	_	_	
5-13	855-863	abnormal	_	_	
5-14	864-866	in	_	_	
5-15	867-878	unmedicated	_	_	
5-16	879-887	patients	_	_	
5-17	888-892	with	_	_	
5-18	893-906	schizophrenia	_	_	
5-19	906-907	,	_	_	
5-20	908-911	and	_	_	
5-21	912-919	whether	_	_	
5-22	920-924	this	_	_	
5-23	925-936	abnormality	_	_	
5-24	937-944	relates	_	_	
5-25	945-947	to	_	_	
5-26	948-957	psychotic	_	_	
5-27	958-966	symptoms	_	_	
5-28	967-970	and	_	_	
5-29	971-984	extrastriatal	_	_	
5-30	985-997	dopaminergic	_	_	
5-31	998-1010	transmission	_	_	
5-32	1010-1011	.	_	_	

#Text=Design and Participants
6-1	1012-1018	Design	_	_	
6-2	1019-1022	and	_	_	
6-3	1023-1035	Participants	_	_	

#Text=In this multimodal, case-control study, we obtained resting-state functional Magnetic Resonance Imaging (fMRI) data in 18 unmedicated patients with schizophrenia and 24 matched healthy controls. A subset of these (12 and 17, respectively) underwent Positron Emission Tomographic (PET) imaging with the dopamine D2-receptor radiotracer [11C]FLB457, before and after amphetamine. Data were acquired between June 16, 2011, and February 25, 2014.
7-1	1036-1038	In	_	_	
7-2	1039-1043	this	_	_	
7-3	1044-1054	multimodal	_	_	
7-4	1054-1055	,	_	_	
7-5	1056-1068	case-control	_	_	
7-6	1069-1074	study	_	_	
7-7	1074-1075	,	_	_	
7-8	1076-1078	we	_	_	
7-9	1079-1087	obtained	_	_	
7-10	1088-1101	resting-state	_	_	
7-11	1102-1112	functional	_	_	
7-12	1113-1121	Magnetic	_	_	
7-13	1122-1131	Resonance	_	_	
7-14	1132-1139	Imaging	_	_	
7-15	1140-1141	(	_	_	
7-16	1141-1145	fMRI	_	_	
7-17	1145-1146	)	_	_	
7-18	1147-1151	data	_	_	
7-19	1152-1154	in	_	_	
7-20	1155-1157	18	_	_	
7-21	1158-1169	unmedicated	_	_	
7-22	1170-1178	patients	_	_	
7-23	1179-1183	with	_	_	
7-24	1184-1197	schizophrenia	_	_	
7-25	1198-1201	and	_	_	
7-26	1202-1204	24	_	_	
7-27	1205-1212	matched	_	_	
7-28	1213-1220	healthy	_	_	
7-29	1221-1229	controls	_	_	
7-30	1229-1230	.	_	_	
7-31	1231-1232	A	_	_	
7-32	1233-1239	subset	_	_	
7-33	1240-1242	of	_	_	
7-34	1243-1248	these	_	_	
7-35	1249-1250	(	_	_	
7-36	1250-1252	12	_	_	
7-37	1253-1256	and	_	_	
7-38	1257-1259	17	_	_	
7-39	1259-1260	,	_	_	
7-40	1261-1273	respectively	_	_	
7-41	1273-1274	)	_	_	
7-42	1275-1284	underwent	_	_	
7-43	1285-1293	Positron	_	_	
7-44	1294-1302	Emission	_	_	
7-45	1303-1314	Tomographic	_	_	
7-46	1315-1316	(	_	_	
7-47	1316-1319	PET	_	_	
7-48	1319-1320	)	_	_	
7-49	1321-1328	imaging	_	_	
7-50	1329-1333	with	_	_	
7-51	1334-1337	the	_	_	
7-52	1338-1346	dopamine	_	_	
7-53	1347-1349	D2	_	_	
7-54	1349-1350	-	_	_	
7-55	1350-1358	receptor	_	_	
7-56	1359-1370	radiotracer	_	_	
7-57	1371-1372	[	_	_	
7-58	1372-1375	11C	_	_	
7-59	1375-1376	]	_	_	
7-60	1376-1382	FLB457	_	_	
7-61	1382-1383	,	_	_	
7-62	1384-1390	before	_	_	
7-63	1391-1394	and	_	_	
7-64	1395-1400	after	_	_	
7-65	1401-1412	amphetamine	_	_	
7-66	1412-1413	.	_	_	
7-67	1414-1418	Data	_	_	
7-68	1419-1423	were	_	_	
7-69	1424-1432	acquired	_	_	
7-70	1433-1440	between	_	_	
7-71	1441-1445	June	_	_	
7-72	1446-1448	16	_	_	
7-73	1448-1449	,	_	_	
7-74	1450-1454	2011	_	_	
7-75	1454-1455	,	_	_	
7-76	1456-1459	and	_	_	
7-77	1460-1468	February	_	_	
7-78	1469-1471	25	_	_	
7-79	1471-1472	,	_	_	
7-80	1473-1477	2014	_	_	
7-81	1477-1478	.	_	_	

#Text=Main Outcomes
8-1	1479-1483	Main	_	_	
8-2	1484-1492	Outcomes	_	_	

#Text=(1) Group differences in the striatal connectivity pattern (assessed via multivariable logistic regression) across striatal subregions, and the relationship between the multivariate striatal connectivity pattern (2) with extrastriatal baseline D2-receptor binding potential and its change following amphetamine (BPND and ΔBPND), and (3) with severity of positive symptoms evaluated with the PANSS scale.
9-1	1493-1494	(	_	_	
9-2	1494-1495	1	_	_	
9-3	1495-1496	)	_	_	
9-4	1497-1502	Group	_	_	
9-5	1503-1514	differences	_	_	
9-6	1515-1517	in	_	_	
9-7	1518-1521	the	_	_	
9-8	1522-1530	striatal	_	_	
9-9	1531-1543	connectivity	_	_	
9-10	1544-1551	pattern	_	_	
9-11	1552-1553	(	_	_	
9-12	1553-1561	assessed	_	_	
9-13	1562-1565	via	_	_	
9-14	1566-1579	multivariable	_	_	
9-15	1580-1588	logistic	_	_	
9-16	1589-1599	regression	_	_	
9-17	1599-1600	)	_	_	
9-18	1601-1607	across	_	_	
9-19	1608-1616	striatal	_	_	
9-20	1617-1627	subregions	_	_	
9-21	1627-1628	,	_	_	
9-22	1629-1632	and	_	_	
9-23	1633-1636	the	_	_	
9-24	1637-1649	relationship	_	_	
9-25	1650-1657	between	_	_	
9-26	1658-1661	the	_	_	
9-27	1662-1674	multivariate	_	_	
9-28	1675-1683	striatal	_	_	
9-29	1684-1696	connectivity	_	_	
9-30	1697-1704	pattern	_	_	
9-31	1705-1706	(	_	_	
9-32	1706-1707	2	_	_	
9-33	1707-1708	)	_	_	
9-34	1709-1713	with	_	_	
9-35	1714-1727	extrastriatal	_	_	
9-36	1728-1736	baseline	_	_	
9-37	1737-1739	D2	_	_	
9-38	1739-1740	-	_	_	
9-39	1740-1748	receptor	_	_	
9-40	1749-1756	binding	_	_	
9-41	1757-1766	potential	_	_	
9-42	1767-1770	and	_	_	
9-43	1771-1774	its	_	_	
9-44	1775-1781	change	_	_	
9-45	1782-1791	following	_	_	
9-46	1792-1803	amphetamine	_	_	
9-47	1804-1805	(	_	_	
9-48	1805-1809	BPND	_	_	
9-49	1810-1813	and	_	_	
9-50	1814-1819	ΔBPND	_	_	
9-51	1819-1820	)	_	_	
9-52	1820-1821	,	_	_	
9-53	1822-1825	and	_	_	
9-54	1826-1827	(	_	_	
9-55	1827-1828	3	_	_	
9-56	1828-1829	)	_	_	
9-57	1830-1834	with	_	_	
9-58	1835-1843	severity	_	_	
9-59	1844-1846	of	_	_	
9-60	1847-1855	positive	_	_	
9-61	1856-1864	symptoms	_	_	
9-62	1865-1874	evaluated	_	_	
9-63	1875-1879	with	_	_	
9-64	1880-1883	the	_	_	
9-65	1884-1889	PANSS	_	_	
9-66	1890-1895	scale	_	_	
9-67	1895-1896	.	_	_	

#Text=Results
10-1	1897-1904	Results	_	_	

#Text=Patients exhibited an abnormal pattern of striatal connectivity, which included abnormal caudate connections with a distributed set of associative cortex regions (p=0.0036). In patients, more deviation from the multivariate pattern of striatal connectivity found in controls correlated specifically with more severe positive symptoms (p=0.0021). Striatal connectivity also correlated with baseline BPND across cortical and extrastriatal subcortical regions (p=0.0116, Bonferroni-corrected) but not with ΔBPND.
11-1	1905-1913	Patients	_	_	
11-2	1914-1923	exhibited	_	_	
11-3	1924-1926	an	_	_	
11-4	1927-1935	abnormal	_	_	
11-5	1936-1943	pattern	_	_	
11-6	1944-1946	of	_	_	
11-7	1947-1955	striatal	_	_	
11-8	1956-1968	connectivity	_	_	
11-9	1968-1969	,	_	_	
11-10	1970-1975	which	_	_	
11-11	1976-1984	included	_	_	
11-12	1985-1993	abnormal	_	_	
11-13	1994-2001	caudate	_	_	
11-14	2002-2013	connections	_	_	
11-15	2014-2018	with	_	_	
11-16	2019-2020	a	_	_	
11-17	2021-2032	distributed	_	_	
11-18	2033-2036	set	_	_	
11-19	2037-2039	of	_	_	
11-20	2040-2051	associative	_	_	
11-21	2052-2058	cortex	_	_	
11-22	2059-2066	regions	_	_	
11-23	2067-2068	(	_	_	
11-24	2068-2069	p	_	_	
11-25	2069-2070	=	_	_	
11-26	2070-2076	0.0036	_	_	
11-27	2076-2077	)	_	_	
11-28	2077-2078	.	_	_	
11-29	2079-2081	In	_	_	
11-30	2082-2090	patients	_	_	
11-31	2090-2091	,	_	_	
11-32	2092-2096	more	_	_	
11-33	2097-2106	deviation	_	_	
11-34	2107-2111	from	_	_	
11-35	2112-2115	the	_	_	
11-36	2116-2128	multivariate	_	_	
11-37	2129-2136	pattern	_	_	
11-38	2137-2139	of	_	_	
11-39	2140-2148	striatal	_	_	
11-40	2149-2161	connectivity	_	_	
11-41	2162-2167	found	_	_	
11-42	2168-2170	in	_	_	
11-43	2171-2179	controls	_	_	
11-44	2180-2190	correlated	_	_	
11-45	2191-2203	specifically	_	_	
11-46	2204-2208	with	_	_	
11-47	2209-2213	more	_	_	
11-48	2214-2220	severe	_	_	
11-49	2221-2229	positive	_	_	
11-50	2230-2238	symptoms	_	_	
11-51	2239-2240	(	_	_	
11-52	2240-2241	p	_	_	
11-53	2241-2242	=	_	_	
11-54	2242-2248	0.0021	_	_	
11-55	2248-2249	)	_	_	
11-56	2249-2250	.	_	_	
11-57	2251-2259	Striatal	_	_	
11-58	2260-2272	connectivity	_	_	
11-59	2273-2277	also	_	_	
11-60	2278-2288	correlated	_	_	
11-61	2289-2293	with	_	_	
11-62	2294-2302	baseline	_	_	
11-63	2303-2307	BPND	_	_	
11-64	2308-2314	across	_	_	
11-65	2315-2323	cortical	_	_	
11-66	2324-2327	and	_	_	
11-67	2328-2341	extrastriatal	_	_	
11-68	2342-2353	subcortical	_	_	
11-69	2354-2361	regions	_	_	
11-70	2362-2363	(	_	_	
11-71	2363-2364	p	_	_	
11-72	2364-2365	=	_	_	
11-73	2365-2371	0.0116	_	_	
11-74	2371-2372	,	_	_	
11-75	2373-2393	Bonferroni-corrected	_	_	
11-76	2393-2394	)	_	_	
11-77	2395-2398	but	_	_	
11-78	2399-2402	not	_	_	
11-79	2403-2407	with	_	_	
11-80	2408-2413	ΔBPND	_	_	
11-81	2413-2414	.	_	_	

#Text=Conclusions and Relevance
12-1	2415-2426	Conclusions	_	_	
12-2	2427-2430	and	_	_	
12-3	2431-2440	Relevance	_	_	

#Text=Using a multimodal, circuit-level interrogation of striatal-cortical connections, we provide a first demonstration that the functional topography of these connections is globally disrupted in unmedicated patients with schizophrenia. These findings suggest that striatal-cortical dysconnectivity may underlie the effects of dopamine dysregulation on the pathophysiology of psychotic symptoms.
13-1	2441-2446	Using	_	_	
13-2	2447-2448	a	_	_	
13-3	2449-2459	multimodal	_	_	
13-4	2459-2460	,	_	_	
13-5	2461-2474	circuit-level	_	_	
13-6	2475-2488	interrogation	_	_	
13-7	2489-2491	of	_	_	
13-8	2492-2509	striatal-cortical	_	_	
13-9	2510-2521	connections	_	_	
13-10	2521-2522	,	_	_	
13-11	2523-2525	we	_	_	
13-12	2526-2533	provide	_	_	
13-13	2534-2535	a	_	_	
13-14	2536-2541	first	_	_	
13-15	2542-2555	demonstration	_	_	
13-16	2556-2560	that	_	_	
13-17	2561-2564	the	_	_	
13-18	2565-2575	functional	_	_	
13-19	2576-2586	topography	_	_	
13-20	2587-2589	of	_	_	
13-21	2590-2595	these	_	_	
13-22	2596-2607	connections	_	_	
13-23	2608-2610	is	_	_	
13-24	2611-2619	globally	_	_	
13-25	2620-2629	disrupted	_	_	
13-26	2630-2632	in	_	_	
13-27	2633-2644	unmedicated	_	_	
13-28	2645-2653	patients	_	_	
13-29	2654-2658	with	_	_	
13-30	2659-2672	schizophrenia	_	_	
13-31	2672-2673	.	_	_	
13-32	2674-2679	These	_	_	
13-33	2680-2688	findings	_	_	
13-34	2689-2696	suggest	_	_	
13-35	2697-2701	that	_	_	
13-36	2702-2719	striatal-cortical	_	_	
13-37	2720-2735	dysconnectivity	_	_	
13-38	2736-2739	may	_	_	
13-39	2740-2748	underlie	_	_	
13-40	2749-2752	the	_	_	
13-41	2753-2760	effects	_	_	
13-42	2761-2763	of	_	_	
13-43	2764-2772	dopamine	_	_	
13-44	2773-2786	dysregulation	_	_	
13-45	2787-2789	on	_	_	
13-46	2790-2793	the	_	_	
13-47	2794-2809	pathophysiology	_	_	
13-48	2810-2812	of	_	_	
13-49	2813-2822	psychotic	_	_	
13-50	2823-2831	symptoms	_	_	
13-51	2831-2832	.	_	_	

#Text=INTRODUCTION
14-1	2833-2845	INTRODUCTION	_	_	

#Text=The striatum, in particular the associative striatum, is a central site of pathology in schizophrenia. Excessive dopamine in the associative striatum is an established finding in unmedicated patients with schizophrenia, in whom capacity for amphetamine-induced dopamine release correlates with worsening of psychotic symptoms. Such striatal excess of dopamine is thought to mediate its effects on cognition via basal-ganglia-thalamo-cortical (BGTC) circuits, which normally modulate cortical function by gating incoming information to the cortex. A topographical organization within BGTC circuits is thus crucial for anatomically selective gating of information to relevant cortical targets, and its disruption could produce various symptoms characteristic of schizophrenia.
15-1	2846-2849	The	_	_	
15-2	2850-2858	striatum	_	_	
15-3	2858-2859	,	_	_	
15-4	2860-2862	in	_	_	
15-5	2863-2873	particular	_	_	
15-6	2874-2877	the	_	_	
15-7	2878-2889	associative	_	_	
15-8	2890-2898	striatum	_	_	
15-9	2898-2899	,	_	_	
15-10	2900-2902	is	_	_	
15-11	2903-2904	a	_	_	
15-12	2905-2912	central	_	_	
15-13	2913-2917	site	_	_	
15-14	2918-2920	of	_	_	
15-15	2921-2930	pathology	_	_	
15-16	2931-2933	in	_	_	
15-17	2934-2947	schizophrenia	_	_	
15-18	2947-2948	.	_	_	
15-19	2949-2958	Excessive	_	_	
15-20	2959-2967	dopamine	_	_	
15-21	2968-2970	in	_	_	
15-22	2971-2974	the	_	_	
15-23	2975-2986	associative	_	_	
15-24	2987-2995	striatum	_	_	
15-25	2996-2998	is	_	_	
15-26	2999-3001	an	_	_	
15-27	3002-3013	established	_	_	
15-28	3014-3021	finding	_	_	
15-29	3022-3024	in	_	_	
15-30	3025-3036	unmedicated	_	_	
15-31	3037-3045	patients	_	_	
15-32	3046-3050	with	_	_	
15-33	3051-3064	schizophrenia	_	_	
15-34	3064-3065	,	_	_	
15-35	3066-3068	in	_	_	
15-36	3069-3073	whom	_	_	
15-37	3074-3082	capacity	_	_	
15-38	3083-3086	for	_	_	
15-39	3087-3106	amphetamine-induced	_	_	
15-40	3107-3115	dopamine	_	_	
15-41	3116-3123	release	_	_	
15-42	3124-3134	correlates	_	_	
15-43	3135-3139	with	_	_	
15-44	3140-3149	worsening	_	_	
15-45	3150-3152	of	_	_	
15-46	3153-3162	psychotic	_	_	
15-47	3163-3171	symptoms	_	_	
15-48	3171-3172	.	_	_	
15-49	3173-3177	Such	_	_	
15-50	3178-3186	striatal	_	_	
15-51	3187-3193	excess	_	_	
15-52	3194-3196	of	_	_	
15-53	3197-3205	dopamine	_	_	
15-54	3206-3208	is	_	_	
15-55	3209-3216	thought	_	_	
15-56	3217-3219	to	_	_	
15-57	3220-3227	mediate	_	_	
15-58	3228-3231	its	_	_	
15-59	3232-3239	effects	_	_	
15-60	3240-3242	on	_	_	
15-61	3243-3252	cognition	_	_	
15-62	3253-3256	via	_	_	
15-63	3257-3287	basal-ganglia-thalamo-cortical	_	_	
15-64	3288-3289	(	_	_	
15-65	3289-3293	BGTC	_	_	
15-66	3293-3294	)	_	_	
15-67	3295-3303	circuits	_	_	
15-68	3303-3304	,	_	_	
15-69	3305-3310	which	_	_	
15-70	3311-3319	normally	_	_	
15-71	3320-3328	modulate	_	_	
15-72	3329-3337	cortical	_	_	
15-73	3338-3346	function	_	_	
15-74	3347-3349	by	_	_	
15-75	3350-3356	gating	_	_	
15-76	3357-3365	incoming	_	_	
15-77	3366-3377	information	_	_	
15-78	3378-3380	to	_	_	
15-79	3381-3384	the	_	_	
15-80	3385-3391	cortex	_	_	
15-81	3391-3392	.	_	_	
15-82	3393-3394	A	_	_	
15-83	3395-3408	topographical	_	_	
15-84	3409-3421	organization	_	_	
15-85	3422-3428	within	_	_	
15-86	3429-3433	BGTC	_	_	
15-87	3434-3442	circuits	_	_	
15-88	3443-3445	is	_	_	
15-89	3446-3450	thus	_	_	
15-90	3451-3458	crucial	_	_	
15-91	3459-3462	for	_	_	
15-92	3463-3475	anatomically	_	_	
15-93	3476-3485	selective	_	_	
15-94	3486-3492	gating	_	_	
15-95	3493-3495	of	_	_	
15-96	3496-3507	information	_	_	
15-97	3508-3510	to	_	_	
15-98	3511-3519	relevant	_	_	
15-99	3520-3528	cortical	_	_	
15-100	3529-3536	targets	_	_	
15-101	3536-3537	,	_	_	
15-102	3538-3541	and	_	_	
15-103	3542-3545	its	_	_	
15-104	3546-3556	disruption	_	_	
15-105	3557-3562	could	_	_	
15-106	3563-3570	produce	_	_	
15-107	3571-3578	various	_	_	
15-108	3579-3587	symptoms	_	_	
15-109	3588-3602	characteristic	_	_	
15-110	3603-3605	of	_	_	
15-111	3606-3619	schizophrenia	_	_	
15-112	3619-3620	.	_	_	

#Text=In health, cortical inputs to the striatum are topographically organized in semi-parallel loops. In addition, ‘hotspot’ territories of converging inputs exist in the associative striatum which may be necessary to integrate disparate sources of reward and cognitive information. In schizophrenia, although the pairwise connectivity of specific striatal subregions with other brain regions has been assessed to some extent with univariate fMRI analyses, it is largely unknown whether such functional topography of striatal connections as a whole (i.e., the global pattern of connections across striatal subregions rather than connection strengths between specific pairs of striatal subregions and extrastriatal regions) is disrupted.
16-1	3621-3623	In	_	_	
16-2	3624-3630	health	_	_	
16-3	3630-3631	,	_	_	
16-4	3632-3640	cortical	_	_	
16-5	3641-3647	inputs	_	_	
16-6	3648-3650	to	_	_	
16-7	3651-3654	the	_	_	
16-8	3655-3663	striatum	_	_	
16-9	3664-3667	are	_	_	
16-10	3668-3683	topographically	_	_	
16-11	3684-3693	organized	_	_	
16-12	3694-3696	in	_	_	
16-13	3697-3710	semi-parallel	_	_	
16-14	3711-3716	loops	_	_	
16-15	3716-3717	.	_	_	
16-16	3718-3720	In	_	_	
16-17	3721-3729	addition	_	_	
16-18	3729-3730	,	_	_	
16-19	3731-3732	‘	_	_	
16-20	3732-3739	hotspot	_	_	
16-21	3739-3740	’	_	_	
16-22	3741-3752	territories	_	_	
16-23	3753-3755	of	_	_	
16-24	3756-3766	converging	_	_	
16-25	3767-3773	inputs	_	_	
16-26	3774-3779	exist	_	_	
16-27	3780-3782	in	_	_	
16-28	3783-3786	the	_	_	
16-29	3787-3798	associative	_	_	
16-30	3799-3807	striatum	_	_	
16-31	3808-3813	which	_	_	
16-32	3814-3817	may	_	_	
16-33	3818-3820	be	_	_	
16-34	3821-3830	necessary	_	_	
16-35	3831-3833	to	_	_	
16-36	3834-3843	integrate	_	_	
16-37	3844-3853	disparate	_	_	
16-38	3854-3861	sources	_	_	
16-39	3862-3864	of	_	_	
16-40	3865-3871	reward	_	_	
16-41	3872-3875	and	_	_	
16-42	3876-3885	cognitive	_	_	
16-43	3886-3897	information	_	_	
16-44	3897-3898	.	_	_	
16-45	3899-3901	In	_	_	
16-46	3902-3915	schizophrenia	_	_	
16-47	3915-3916	,	_	_	
16-48	3917-3925	although	_	_	
16-49	3926-3929	the	_	_	
16-50	3930-3938	pairwise	_	_	
16-51	3939-3951	connectivity	_	_	
16-52	3952-3954	of	_	_	
16-53	3955-3963	specific	_	_	
16-54	3964-3972	striatal	_	_	
16-55	3973-3983	subregions	_	_	
16-56	3984-3988	with	_	_	
16-57	3989-3994	other	_	_	
16-58	3995-4000	brain	_	_	
16-59	4001-4008	regions	_	_	
16-60	4009-4012	has	_	_	
16-61	4013-4017	been	_	_	
16-62	4018-4026	assessed	_	_	
16-63	4027-4029	to	_	_	
16-64	4030-4034	some	_	_	
16-65	4035-4041	extent	_	_	
16-66	4042-4046	with	_	_	
16-67	4047-4057	univariate	_	_	
16-68	4058-4062	fMRI	_	_	
16-69	4063-4071	analyses	_	_	
16-70	4071-4072	,	_	_	
16-71	4073-4075	it	_	_	
16-72	4076-4078	is	_	_	
16-73	4079-4086	largely	_	_	
16-74	4087-4094	unknown	_	_	
16-75	4095-4102	whether	_	_	
16-76	4103-4107	such	_	_	
16-77	4108-4118	functional	_	_	
16-78	4119-4129	topography	_	_	
16-79	4130-4132	of	_	_	
16-80	4133-4141	striatal	_	_	
16-81	4142-4153	connections	_	_	
16-82	4154-4156	as	_	_	
16-83	4157-4158	a	_	_	
16-84	4159-4164	whole	_	_	
16-85	4165-4166	(	_	_	
16-86	4166-4169	i.e	_	_	
16-87	4169-4170	.	_	_	
16-88	4170-4171	,	_	_	
16-89	4172-4175	the	_	_	
16-90	4176-4182	global	_	_	
16-91	4183-4190	pattern	_	_	
16-92	4191-4193	of	_	_	
16-93	4194-4205	connections	_	_	
16-94	4206-4212	across	_	_	
16-95	4213-4221	striatal	_	_	
16-96	4222-4232	subregions	_	_	
16-97	4233-4239	rather	_	_	
16-98	4240-4244	than	_	_	
16-99	4245-4255	connection	_	_	
16-100	4256-4265	strengths	_	_	
16-101	4266-4273	between	_	_	
16-102	4274-4282	specific	_	_	
16-103	4283-4288	pairs	_	_	
16-104	4289-4291	of	_	_	
16-105	4292-4300	striatal	_	_	
16-106	4301-4311	subregions	_	_	
16-107	4312-4315	and	_	_	
16-108	4316-4329	extrastriatal	_	_	
16-109	4330-4337	regions	_	_	
16-110	4337-4338	)	_	_	
16-111	4339-4341	is	_	_	
16-112	4342-4351	disrupted	_	_	
16-113	4351-4352	.	_	_	

#Text=A key modulator of synaptic connectivity and plasticity in the striatum is dopamine. Indeed, a fundamental role of dopamine in learning depends on its ability to modulate synaptic plasticity, and thus the functional efficacy of neuronal connections at striatal synapses and elsewhere. Therefore, excessive dopamine transmission in the associative striatum could disrupt the organization of striatal-cortical connections, ultimately leading to aberrant information processing and psychosis. Disrupted connectivity could be further compounded by a deficit in extrastriatal dopamine, as recently demonstrated in schizophrenia. At the same time, the established effects of dopamine on striatal connectivity in health suggest that antipsychotic drugs may critically mask underlying abnormalities in striatal connectivity in medicated patients. As this confound may affect most fMRI connectivity studies in schizophrenia, conducted in medicated patients, it is therefore imperative to examine this question in unmedicated patients.
17-1	4353-4354	A	_	_	
17-2	4355-4358	key	_	_	
17-3	4359-4368	modulator	_	_	
17-4	4369-4371	of	_	_	
17-5	4372-4380	synaptic	_	_	
17-6	4381-4393	connectivity	_	_	
17-7	4394-4397	and	_	_	
17-8	4398-4408	plasticity	_	_	
17-9	4409-4411	in	_	_	
17-10	4412-4415	the	_	_	
17-11	4416-4424	striatum	_	_	
17-12	4425-4427	is	_	_	
17-13	4428-4436	dopamine	_	_	
17-14	4436-4437	.	_	_	
17-15	4438-4444	Indeed	_	_	
17-16	4444-4445	,	_	_	
17-17	4446-4447	a	_	_	
17-18	4448-4459	fundamental	_	_	
17-19	4460-4464	role	_	_	
17-20	4465-4467	of	_	_	
17-21	4468-4476	dopamine	_	_	
17-22	4477-4479	in	_	_	
17-23	4480-4488	learning	_	_	
17-24	4489-4496	depends	_	_	
17-25	4497-4499	on	_	_	
17-26	4500-4503	its	_	_	
17-27	4504-4511	ability	_	_	
17-28	4512-4514	to	_	_	
17-29	4515-4523	modulate	_	_	
17-30	4524-4532	synaptic	_	_	
17-31	4533-4543	plasticity	_	_	
17-32	4543-4544	,	_	_	
17-33	4545-4548	and	_	_	
17-34	4549-4553	thus	_	_	
17-35	4554-4557	the	_	_	
17-36	4558-4568	functional	_	_	
17-37	4569-4577	efficacy	_	_	
17-38	4578-4580	of	_	_	
17-39	4581-4589	neuronal	_	_	
17-40	4590-4601	connections	_	_	
17-41	4602-4604	at	_	_	
17-42	4605-4613	striatal	_	_	
17-43	4614-4622	synapses	_	_	
17-44	4623-4626	and	_	_	
17-45	4627-4636	elsewhere	_	_	
17-46	4636-4637	.	_	_	
17-47	4638-4647	Therefore	_	_	
17-48	4647-4648	,	_	_	
17-49	4649-4658	excessive	_	_	
17-50	4659-4667	dopamine	_	_	
17-51	4668-4680	transmission	_	_	
17-52	4681-4683	in	_	_	
17-53	4684-4687	the	_	_	
17-54	4688-4699	associative	_	_	
17-55	4700-4708	striatum	_	_	
17-56	4709-4714	could	_	_	
17-57	4715-4722	disrupt	_	_	
17-58	4723-4726	the	_	_	
17-59	4727-4739	organization	_	_	
17-60	4740-4742	of	_	_	
17-61	4743-4760	striatal-cortical	_	_	
17-62	4761-4772	connections	_	_	
17-63	4772-4773	,	_	_	
17-64	4774-4784	ultimately	_	_	
17-65	4785-4792	leading	_	_	
17-66	4793-4795	to	_	_	
17-67	4796-4804	aberrant	_	_	
17-68	4805-4816	information	_	_	
17-69	4817-4827	processing	_	_	
17-70	4828-4831	and	_	_	
17-71	4832-4841	psychosis	_	_	
17-72	4841-4842	.	_	_	
17-73	4843-4852	Disrupted	_	_	
17-74	4853-4865	connectivity	_	_	
17-75	4866-4871	could	_	_	
17-76	4872-4874	be	_	_	
17-77	4875-4882	further	_	_	
17-78	4883-4893	compounded	_	_	
17-79	4894-4896	by	_	_	
17-80	4897-4898	a	_	_	
17-81	4899-4906	deficit	_	_	
17-82	4907-4909	in	_	_	
17-83	4910-4923	extrastriatal	_	_	
17-84	4924-4932	dopamine	_	_	
17-85	4932-4933	,	_	_	
17-86	4934-4936	as	_	_	
17-87	4937-4945	recently	_	_	
17-88	4946-4958	demonstrated	_	_	
17-89	4959-4961	in	_	_	
17-90	4962-4975	schizophrenia	_	_	
17-91	4975-4976	.	_	_	
17-92	4977-4979	At	_	_	
17-93	4980-4983	the	_	_	
17-94	4984-4988	same	_	_	
17-95	4989-4993	time	_	_	
17-96	4993-4994	,	_	_	
17-97	4995-4998	the	_	_	
17-98	4999-5010	established	_	_	
17-99	5011-5018	effects	_	_	
17-100	5019-5021	of	_	_	
17-101	5022-5030	dopamine	_	_	
17-102	5031-5033	on	_	_	
17-103	5034-5042	striatal	_	_	
17-104	5043-5055	connectivity	_	_	
17-105	5056-5058	in	_	_	
17-106	5059-5065	health	_	_	
17-107	5066-5073	suggest	_	_	
17-108	5074-5078	that	_	_	
17-109	5079-5092	antipsychotic	_	_	
17-110	5093-5098	drugs	_	_	
17-111	5099-5102	may	_	_	
17-112	5103-5113	critically	_	_	
17-113	5114-5118	mask	_	_	
17-114	5119-5129	underlying	_	_	
17-115	5130-5143	abnormalities	_	_	
17-116	5144-5146	in	_	_	
17-117	5147-5155	striatal	_	_	
17-118	5156-5168	connectivity	_	_	
17-119	5169-5171	in	_	_	
17-120	5172-5181	medicated	_	_	
17-121	5182-5190	patients	_	_	
17-122	5190-5191	.	_	_	
17-123	5192-5194	As	_	_	
17-124	5195-5199	this	_	_	
17-125	5200-5208	confound	_	_	
17-126	5209-5212	may	_	_	
17-127	5213-5219	affect	_	_	
17-128	5220-5224	most	_	_	
17-129	5225-5229	fMRI	_	_	
17-130	5230-5242	connectivity	_	_	
17-131	5243-5250	studies	_	_	
17-132	5251-5253	in	_	_	
17-133	5254-5267	schizophrenia	_	_	
17-134	5267-5268	,	_	_	
17-135	5269-5278	conducted	_	_	
17-136	5279-5281	in	_	_	
17-137	5282-5291	medicated	_	_	
17-138	5292-5300	patients	_	_	
17-139	5300-5301	,	_	_	
17-140	5302-5304	it	_	_	
17-141	5305-5307	is	_	_	
17-142	5308-5317	therefore	_	_	
17-143	5318-5328	imperative	_	_	
17-144	5329-5331	to	_	_	
17-145	5332-5339	examine	_	_	
17-146	5340-5344	this	_	_	
17-147	5345-5353	question	_	_	
17-148	5354-5356	in	_	_	
17-149	5357-5368	unmedicated	_	_	
17-150	5369-5377	patients	_	_	
17-151	5377-5378	.	_	_	

#Text=Here, we investigated the pattern of resting-state functional connectivity across subregions of the striatum in unmedicated patients with schizophrenia and healthy controls using a multivariate approach. Our main aims were to test (1) whether the functional topography of striatal connections is altered in schizophrenia, and whether such abnormalities correlate with (2) severity of psychotic symptoms and with (3) amphetamine-induced dopamine release and D2 receptor (D2R) density.
18-1	5379-5383	Here	_	_	
18-2	5383-5384	,	_	_	
18-3	5385-5387	we	_	_	
18-4	5388-5400	investigated	_	_	
18-5	5401-5404	the	_	_	
18-6	5405-5412	pattern	_	_	
18-7	5413-5415	of	_	_	
18-8	5416-5429	resting-state	_	_	
18-9	5430-5440	functional	_	_	
18-10	5441-5453	connectivity	_	_	
18-11	5454-5460	across	_	_	
18-12	5461-5471	subregions	_	_	
18-13	5472-5474	of	_	_	
18-14	5475-5478	the	_	_	
18-15	5479-5487	striatum	_	_	
18-16	5488-5490	in	_	_	
18-17	5491-5502	unmedicated	_	_	
18-18	5503-5511	patients	_	_	
18-19	5512-5516	with	_	_	
18-20	5517-5530	schizophrenia	_	_	
18-21	5531-5534	and	_	_	
18-22	5535-5542	healthy	_	_	
18-23	5543-5551	controls	_	_	
18-24	5552-5557	using	_	_	
18-25	5558-5559	a	_	_	
18-26	5560-5572	multivariate	_	_	
18-27	5573-5581	approach	_	_	
18-28	5581-5582	.	_	_	
18-29	5583-5586	Our	_	_	
18-30	5587-5591	main	_	_	
18-31	5592-5596	aims	_	_	
18-32	5597-5601	were	_	_	
18-33	5602-5604	to	_	_	
18-34	5605-5609	test	_	_	
18-35	5610-5611	(	_	_	
18-36	5611-5612	1	_	_	
18-37	5612-5613	)	_	_	
18-38	5614-5621	whether	_	_	
18-39	5622-5625	the	_	_	
18-40	5626-5636	functional	_	_	
18-41	5637-5647	topography	_	_	
18-42	5648-5650	of	_	_	
18-43	5651-5659	striatal	_	_	
18-44	5660-5671	connections	_	_	
18-45	5672-5674	is	_	_	
18-46	5675-5682	altered	_	_	
18-47	5683-5685	in	_	_	
18-48	5686-5699	schizophrenia	_	_	
18-49	5699-5700	,	_	_	
18-50	5701-5704	and	_	_	
18-51	5705-5712	whether	_	_	
18-52	5713-5717	such	_	_	
18-53	5718-5731	abnormalities	_	_	
18-54	5732-5741	correlate	_	_	
18-55	5742-5746	with	_	_	
18-56	5747-5748	(	_	_	
18-57	5748-5749	2	_	_	
18-58	5749-5750	)	_	_	
18-59	5751-5759	severity	_	_	
18-60	5760-5762	of	_	_	
18-61	5763-5772	psychotic	_	_	
18-62	5773-5781	symptoms	_	_	
18-63	5782-5785	and	_	_	
18-64	5786-5790	with	_	_	
18-65	5791-5792	(	_	_	
18-66	5792-5793	3	_	_	
18-67	5793-5794	)	_	_	
18-68	5795-5814	amphetamine-induced	_	_	
18-69	5815-5823	dopamine	_	_	
18-70	5824-5831	release	_	_	
18-71	5832-5835	and	_	_	
18-72	5836-5838	D2	_	_	
18-73	5839-5847	receptor	_	_	
18-74	5848-5849	(	_	_	
18-75	5849-5852	D2R	_	_	
18-76	5852-5853	)	_	_	
18-77	5854-5861	density	_	_	
18-78	5861-5862	.	_	_	

#Text=METHODS
19-1	5863-5870	METHODS	_	_	

#Text=Participants
20-1	5871-5883	Participants	_	_	

#Text=Unmedicated patients with schizophrenia (n=19) and healthy controls (n=24) were recruited at New York State Psychiatric Institute (NYSPI) and through advertisements. All participants provided written informed consent as approved by the Institutional Review Boards of the NYSPI and Yale University. Inclusion criteria for healthy controls were: absence of (1) any DSM-IV Axis-I diagnosis and of (2) psychotic illness in first-degree relatives. Inclusion criteria for patients were: (1) lifetime DSM-IV diagnosis of schizophrenia, schizoaffective or schizophreniform disorder (based on the Diagnostic Interview for Genetic Studies and consensus diagnosis); (2) no antipsychotics for 3 weeks before study enrollment; (3) no violent behavior. Common exclusion criteria were significant medical illnesses, misuse of substances other than nicotine, positive urine drug screen, pregnancy and nursing. PET and task-based fMRI data on 28 of the 42 subjects was previously published.
21-1	5884-5895	Unmedicated	_	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[1]	
21-2	5896-5904	patients	_	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[1]	
21-3	5905-5909	with	_	_	
21-4	5910-5923	schizophrenia	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
21-5	5924-5925	(	_	_	
21-6	5925-5926	n	_	_	
21-7	5926-5927	=	_	_	
21-8	5927-5929	19	_	_	
21-9	5929-5930	)	_	_	
21-10	5931-5934	and	_	_	
21-11	5935-5942	healthy	_	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
21-12	5943-5951	controls	_	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
21-13	5952-5953	(	_	_	
21-14	5953-5954	n	_	_	
21-15	5954-5955	=	_	_	
21-16	5955-5957	24	_	_	
21-17	5957-5958	)	_	_	
21-18	5959-5963	were	_	_	
21-19	5964-5973	recruited	_	_	
21-20	5974-5976	at	_	_	
21-21	5977-5980	New	_	_	
21-22	5981-5985	York	_	_	
21-23	5986-5991	State	_	_	
21-24	5992-6003	Psychiatric	_	_	
21-25	6004-6013	Institute	_	_	
21-26	6014-6015	(	_	_	
21-27	6015-6020	NYSPI	_	_	
21-28	6020-6021	)	_	_	
21-29	6022-6025	and	_	_	
21-30	6026-6033	through	_	_	
21-31	6034-6048	advertisements	_	_	
21-32	6048-6049	.	_	_	
21-33	6050-6053	All	_	_	
21-34	6054-6066	participants	_	_	
21-35	6067-6075	provided	_	_	
21-36	6076-6083	written	_	_	
21-37	6084-6092	informed	_	_	
21-38	6093-6100	consent	_	_	
21-39	6101-6103	as	_	_	
21-40	6104-6112	approved	_	_	
21-41	6113-6115	by	_	_	
21-42	6116-6119	the	_	_	
21-43	6120-6133	Institutional	_	_	
21-44	6134-6140	Review	_	_	
21-45	6141-6147	Boards	_	_	
21-46	6148-6150	of	_	_	
21-47	6151-6154	the	_	_	
21-48	6155-6160	NYSPI	_	_	
21-49	6161-6164	and	_	_	
21-50	6165-6169	Yale	_	_	
21-51	6170-6180	University	_	_	
21-52	6180-6181	.	_	_	
21-53	6182-6191	Inclusion	_	_	
21-54	6192-6200	criteria	_	_	
21-55	6201-6204	for	_	_	
21-56	6205-6212	healthy	_	_	
21-57	6213-6221	controls	_	_	
21-58	6222-6226	were	_	_	
21-59	6226-6227	:	_	_	
21-60	6228-6235	absence	_	_	
21-61	6236-6238	of	_	_	
21-62	6239-6240	(	_	_	
21-63	6240-6241	1	_	_	
21-64	6241-6242	)	_	_	
21-65	6243-6246	any	_	_	
21-66	6247-6253	DSM-IV	_	_	
21-67	6254-6260	Axis-I	_	_	
21-68	6261-6270	diagnosis	_	_	
21-69	6271-6274	and	_	_	
21-70	6275-6277	of	_	_	
21-71	6278-6279	(	_	_	
21-72	6279-6280	2	_	_	
21-73	6280-6281	)	_	_	
21-74	6282-6291	psychotic	_	_	
21-75	6292-6299	illness	_	_	
21-76	6300-6302	in	_	_	
21-77	6303-6315	first-degree	_	_	
21-78	6316-6325	relatives	_	_	
21-79	6325-6326	.	_	_	
21-80	6327-6336	Inclusion	_	_	
21-81	6337-6345	criteria	_	_	
21-82	6346-6349	for	_	_	
21-83	6350-6358	patients	_	_	
21-84	6359-6363	were	_	_	
21-85	6363-6364	:	_	_	
21-86	6365-6366	(	_	_	
21-87	6366-6367	1	_	_	
21-88	6367-6368	)	_	_	
21-89	6369-6377	lifetime	_	_	
21-90	6378-6384	DSM-IV	_	_	
21-91	6385-6394	diagnosis	_	_	
21-92	6395-6397	of	_	_	
21-93	6398-6411	schizophrenia	_	_	
21-94	6411-6412	,	_	_	
21-95	6413-6428	schizoaffective	_	_	
21-96	6429-6431	or	_	_	
21-97	6432-6448	schizophreniform	_	_	
21-98	6449-6457	disorder	_	_	
21-99	6458-6459	(	_	_	
21-100	6459-6464	based	_	_	
21-101	6465-6467	on	_	_	
21-102	6468-6471	the	_	_	
21-103	6472-6482	Diagnostic	_	_	
21-104	6483-6492	Interview	_	_	
21-105	6493-6496	for	_	_	
21-106	6497-6504	Genetic	_	_	
21-107	6505-6512	Studies	_	_	
21-108	6513-6516	and	_	_	
21-109	6517-6526	consensus	_	_	
21-110	6527-6536	diagnosis	_	_	
21-111	6536-6537	)	_	_	
21-112	6537-6538	;	_	_	
21-113	6539-6540	(	_	_	
21-114	6540-6541	2	_	_	
21-115	6541-6542	)	_	_	
21-116	6543-6545	no	_	_	
21-117	6546-6560	antipsychotics	_	_	
21-118	6561-6564	for	_	_	
21-119	6565-6566	3	_	_	
21-120	6567-6572	weeks	_	_	
21-121	6573-6579	before	_	_	
21-122	6580-6585	study	_	_	
21-123	6586-6596	enrollment	_	_	
21-124	6596-6597	;	_	_	
21-125	6598-6599	(	_	_	
21-126	6599-6600	3	_	_	
21-127	6600-6601	)	_	_	
21-128	6602-6604	no	_	_	
21-129	6605-6612	violent	_	_	
21-130	6613-6621	behavior	_	_	
21-131	6621-6622	.	_	_	
21-132	6623-6629	Common	_	_	
21-133	6630-6639	exclusion	_	_	
21-134	6640-6648	criteria	_	_	
21-135	6649-6653	were	_	_	
21-136	6654-6665	significant	_	_	
21-137	6666-6673	medical	_	_	
21-138	6674-6683	illnesses	_	_	
21-139	6683-6684	,	_	_	
21-140	6685-6691	misuse	_	_	
21-141	6692-6694	of	_	_	
21-142	6695-6705	substances	_	_	
21-143	6706-6711	other	_	_	
21-144	6712-6716	than	_	_	
21-145	6717-6725	nicotine	_	_	
21-146	6725-6726	,	_	_	
21-147	6727-6735	positive	_	_	
21-148	6736-6741	urine	_	_	
21-149	6742-6746	drug	_	_	
21-150	6747-6753	screen	_	_	
21-151	6753-6754	,	_	_	
21-152	6755-6764	pregnancy	_	_	
21-153	6765-6768	and	_	_	
21-154	6769-6776	nursing	_	_	
21-155	6776-6777	.	_	_	
21-156	6778-6781	PET	_	_	
21-157	6782-6785	and	_	_	
21-158	6786-6796	task-based	_	_	
21-159	6797-6801	fMRI	_	_	
21-160	6802-6806	data	_	_	
21-161	6807-6809	on	_	_	
21-162	6810-6812	28	_	_	
21-163	6813-6815	of	_	_	
21-164	6816-6819	the	_	_	
21-165	6820-6822	42	_	_	
21-166	6823-6831	subjects	_	_	
21-167	6832-6835	was	_	_	
21-168	6836-6846	previously	_	_	
21-169	6847-6856	published	_	_	
21-170	6856-6857	.	_	_	

#Text=Symptom severity was assessed with the Positive and Negative Syndrome Scale (PANSS), the Scale for the Assessment of Positive Symptoms (SAPS), and the Scale for Assessment of Negative Symptoms (SANS). The Hollingshead scale, the Edinburgh Handedness Inventory and the MATRICS Consensus Cognitive Battery were also obtained.
22-1	6858-6865	Symptom	_	_	
22-2	6866-6874	severity	_	_	
22-3	6875-6878	was	_	_	
22-4	6879-6887	assessed	_	_	
22-5	6888-6892	with	_	_	
22-6	6893-6896	the	_	_	
22-7	6897-6905	Positive	_	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[3]	
22-8	6906-6909	and	_	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[3]	
22-9	6910-6918	Negative	_	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[3]	
22-10	6919-6927	Syndrome	_	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[3]	
22-11	6928-6933	Scale	_	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[3]	
22-12	6934-6935	(	_	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[3]	
22-13	6935-6940	PANSS	_	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[3]	
22-14	6940-6941	)	_	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[3]	
22-15	6941-6942	,	_	_	
22-16	6943-6946	the	_	_	
22-17	6947-6952	Scale	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[4]	
22-18	6953-6956	for	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[4]	
22-19	6957-6960	the	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[4]	
22-20	6961-6971	Assessment	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[4]	
22-21	6972-6974	of	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[4]	
22-22	6975-6983	Positive	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[4]	
22-23	6984-6992	Symptoms	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[4]	
22-24	6993-6994	(	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[4]	
22-25	6994-6998	SAPS	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[4]	
22-26	6998-6999	)	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[4]	
22-27	6999-7000	,	_	_	
22-28	7001-7004	and	_	_	
22-29	7005-7008	the	_	_	
22-30	7009-7014	Scale	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[5]	
22-31	7015-7018	for	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[5]	
22-32	7019-7029	Assessment	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[5]	
22-33	7030-7032	of	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[5]	
22-34	7033-7041	Negative	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[5]	
22-35	7042-7050	Symptoms	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[5]	
22-36	7051-7052	(	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[5]	
22-37	7052-7056	SANS	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[5]	
22-38	7056-7057	)	_	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[5]	
22-39	7057-7058	.	_	_	
22-40	7059-7062	The	_	_	
22-41	7063-7075	Hollingshead	_	_	
22-42	7076-7081	scale	_	_	
22-43	7081-7082	,	_	_	
22-44	7083-7086	the	_	_	
22-45	7087-7096	Edinburgh	_	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[6]	
22-46	7097-7107	Handedness	_	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[6]	
22-47	7108-7117	Inventory	_	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[6]	
22-48	7118-7121	and	_	_	
22-49	7122-7125	the	_	_	
22-50	7126-7133	MATRICS	_	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[7]	
22-51	7134-7143	Consensus	_	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[7]	
22-52	7144-7153	Cognitive	_	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[7]	
22-53	7154-7161	Battery	_	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[7]	
22-54	7162-7166	were	_	_	
22-55	7167-7171	also	_	_	
22-56	7172-7180	obtained	_	_	
22-57	7180-7181	.	_	_	

#Text=Resting-state fMRI data acquisition
23-1	7182-7195	Resting-state	_	_	
23-2	7196-7200	fMRI	_	_	
23-3	7201-7205	data	_	_	
23-4	7206-7217	acquisition	_	_	

#Text=Participants completed 2 runs of 165 volumes each on a Philips 1.5T scanner. They were instructed to relax and keep their eyes open. Participants were spoken to before and after each sequence to ensure wakefulness. Whole-brain functional echo-planar images were obtained using an 8-channel coil (3-mm isotropic voxels; eMethods).
24-1	7218-7230	Participants	_	_	
24-2	7231-7240	completed	_	_	
24-3	7241-7242	2	_	_	
24-4	7243-7247	runs	_	_	
24-5	7248-7250	of	_	_	
24-6	7251-7254	165	_	_	
24-7	7255-7262	volumes	_	_	
24-8	7263-7267	each	_	_	
24-9	7268-7270	on	_	_	
24-10	7271-7272	a	_	_	
24-11	7273-7280	Philips	_	_	
24-12	7281-7285	1.5T	_	_	
24-13	7286-7293	scanner	_	_	
24-14	7293-7294	.	_	_	
24-15	7295-7299	They	_	_	
24-16	7300-7304	were	_	_	
24-17	7305-7315	instructed	_	_	
24-18	7316-7318	to	_	_	
24-19	7319-7324	relax	_	_	
24-20	7325-7328	and	_	_	
24-21	7329-7333	keep	_	_	
24-22	7334-7339	their	_	_	
24-23	7340-7344	eyes	_	_	
24-24	7345-7349	open	_	_	
24-25	7349-7350	.	_	_	
24-26	7351-7363	Participants	_	_	
24-27	7364-7368	were	_	_	
24-28	7369-7375	spoken	_	_	
24-29	7376-7378	to	_	_	
24-30	7379-7385	before	_	_	
24-31	7386-7389	and	_	_	
24-32	7390-7395	after	_	_	
24-33	7396-7400	each	_	_	
24-34	7401-7409	sequence	_	_	
24-35	7410-7412	to	_	_	
24-36	7413-7419	ensure	_	_	
24-37	7420-7431	wakefulness	_	_	
24-38	7431-7432	.	_	_	
24-39	7433-7444	Whole-brain	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[8]	
24-40	7445-7455	functional	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[8]	
24-41	7456-7467	echo-planar	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[8]	
24-42	7468-7474	images	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[8]	
24-43	7475-7479	were	_	_	
24-44	7480-7488	obtained	_	_	
24-45	7489-7494	using	_	_	
24-46	7495-7497	an	_	_	
24-47	7498-7499	8	_	_	
24-48	7499-7500	-	_	_	
24-49	7500-7507	channel	_	_	
24-50	7508-7512	coil	_	_	
24-51	7513-7514	(	_	_	
24-52	7514-7515	3	_	_	
24-53	7515-7516	-	_	_	
24-54	7516-7518	mm	_	_	
24-55	7519-7528	isotropic	_	_	
24-56	7529-7535	voxels	_	_	
24-57	7535-7536	;	_	_	
24-58	7537-7545	eMethods	_	_	
24-59	7545-7546	)	_	_	
24-60	7546-7547	.	_	_	

#Text=fMRI preprocessing
25-1	7548-7552	fMRI	_	_	
25-2	7553-7566	preprocessing	_	_	

#Text=Preprocessing followed standard procedures in SPM8 and ‘scrubbing’ procedures for resting-state fMRI (eMethods). ‘Scrubbing’ cutoffs were established based on a larger dataset for two indices of motion-related data quality reflecting the rate of change in brain-wide signal (DVARS) and total instantaneous framewise displacement (FD), respectively. One patient was excluded due to excessive motion. Temporal band-pass filtering, spatial smoothing, and voxelwise z-scoring of time series were applied.
26-1	7567-7580	Preprocessing	_	_	
26-2	7581-7589	followed	_	_	
26-3	7590-7598	standard	_	_	
26-4	7599-7609	procedures	_	_	
26-5	7610-7612	in	_	_	
26-6	7613-7617	SPM8	_	_	
26-7	7618-7621	and	_	_	
26-8	7622-7623	‘	_	_	
26-9	7623-7632	scrubbing	_	_	
26-10	7632-7633	’	_	_	
26-11	7634-7644	procedures	_	_	
26-12	7645-7648	for	_	_	
26-13	7649-7662	resting-state	_	_	
26-14	7663-7667	fMRI	_	_	
26-15	7668-7669	(	_	_	
26-16	7669-7677	eMethods	_	_	
26-17	7677-7678	)	_	_	
26-18	7678-7679	.	_	_	
26-19	7680-7681	‘	_	_	
26-20	7681-7690	Scrubbing	_	_	
26-21	7690-7691	’	_	_	
26-22	7692-7699	cutoffs	_	_	
26-23	7700-7704	were	_	_	
26-24	7705-7716	established	_	_	
26-25	7717-7722	based	_	_	
26-26	7723-7725	on	_	_	
26-27	7726-7727	a	_	_	
26-28	7728-7734	larger	_	_	
26-29	7735-7742	dataset	_	_	
26-30	7743-7746	for	_	_	
26-31	7747-7750	two	_	_	
26-32	7751-7758	indices	_	_	
26-33	7759-7761	of	_	_	
26-34	7762-7776	motion-related	_	_	
26-35	7777-7781	data	_	_	
26-36	7782-7789	quality	_	_	
26-37	7790-7800	reflecting	_	_	
26-38	7801-7804	the	_	_	
26-39	7805-7809	rate	_	_	
26-40	7810-7812	of	_	_	
26-41	7813-7819	change	_	_	
26-42	7820-7822	in	_	_	
26-43	7823-7833	brain-wide	_	_	
26-44	7834-7840	signal	_	_	
26-45	7841-7842	(	_	_	
26-46	7842-7847	DVARS	_	_	
26-47	7847-7848	)	_	_	
26-48	7849-7852	and	_	_	
26-49	7853-7858	total	_	_	
26-50	7859-7872	instantaneous	_	_	
26-51	7873-7882	framewise	_	_	
26-52	7883-7895	displacement	_	_	
26-53	7896-7897	(	_	_	
26-54	7897-7899	FD	_	_	
26-55	7899-7900	)	_	_	
26-56	7900-7901	,	_	_	
26-57	7902-7914	respectively	_	_	
26-58	7914-7915	.	_	_	
26-59	7916-7919	One	_	_	
26-60	7920-7927	patient	_	_	
26-61	7928-7931	was	_	_	
26-62	7932-7940	excluded	_	_	
26-63	7941-7944	due	_	_	
26-64	7945-7947	to	_	_	
26-65	7948-7957	excessive	_	_	
26-66	7958-7964	motion	_	_	
26-67	7964-7965	.	_	_	
26-68	7966-7974	Temporal	_	_	
26-69	7975-7984	band-pass	_	_	
26-70	7985-7994	filtering	_	_	
26-71	7994-7995	,	_	_	
26-72	7996-8003	spatial	_	_	
26-73	8004-8013	smoothing	_	_	
26-74	8013-8014	,	_	_	
26-75	8015-8018	and	_	_	
26-76	8019-8028	voxelwise	_	_	
26-77	8029-8038	z-scoring	_	_	
26-78	8039-8041	of	_	_	
26-79	8042-8046	time	_	_	
26-80	8047-8053	series	_	_	
26-81	8054-8058	were	_	_	
26-82	8059-8066	applied	_	_	
26-83	8066-8067	.	_	_	

#Text=Region-of-interest (ROI) definition
27-1	8068-8086	Region-of-interest	_	_	
27-2	8087-8088	(	_	_	
27-3	8088-8091	ROI	_	_	
27-4	8091-8092	)	_	_	
27-5	8093-8103	definition	_	_	

#Text=Striatal and extrastriatal ROIs were manually drawn on individual T1-weighted scans as defined previously. The striatum was divided into 5 subregions: (1) ventral striatum, (2) anterior (pre-commissural) caudate, (3) posterior (post-commissural) caudate, (4) anterior putamen, and (5) posterior putamen. Unsmoothed fMRI data from each subregion was averaged across the containing voxels (collapsing across hemispheres; eMethods) and z-scored to construct seed timeseries. Extracting the first eigenvariate instead of the mean yielded almost identical results, indicating high functional homogeneity within subregions. Ipsilateral and contralateral connectivity were highly consistent within subregions (Supplement).
28-1	8104-8112	Striatal	_	_	
28-2	8113-8116	and	_	_	
28-3	8117-8130	extrastriatal	_	_	
28-4	8131-8135	ROIs	_	_	
28-5	8136-8140	were	_	_	
28-6	8141-8149	manually	_	_	
28-7	8150-8155	drawn	_	_	
28-8	8156-8158	on	_	_	
28-9	8159-8169	individual	_	_	
28-10	8170-8172	T1	_	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[9]	
28-11	8172-8173	-	_	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[9]	
28-12	8173-8181	weighted	_	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[9]	
28-13	8182-8187	scans	_	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[9]	
28-14	8188-8190	as	_	_	
28-15	8191-8198	defined	_	_	
28-16	8199-8209	previously	_	_	
28-17	8209-8210	.	_	_	
28-18	8211-8214	The	_	_	
28-19	8215-8223	striatum	_	_	
28-20	8224-8227	was	_	_	
28-21	8228-8235	divided	_	_	
28-22	8236-8240	into	_	_	
28-23	8241-8242	5	_	_	
28-24	8243-8253	subregions	_	_	
28-25	8253-8254	:	_	_	
28-26	8255-8256	(	_	_	
28-27	8256-8257	1	_	_	
28-28	8257-8258	)	_	_	
28-29	8259-8266	ventral	_	_	
28-30	8267-8275	striatum	_	_	
28-31	8275-8276	,	_	_	
28-32	8277-8278	(	_	_	
28-33	8278-8279	2	_	_	
28-34	8279-8280	)	_	_	
28-35	8281-8289	anterior	_	_	
28-36	8290-8291	(	_	_	
28-37	8291-8306	pre-commissural	_	_	
28-38	8306-8307	)	_	_	
28-39	8308-8315	caudate	_	_	
28-40	8315-8316	,	_	_	
28-41	8317-8318	(	_	_	
28-42	8318-8319	3	_	_	
28-43	8319-8320	)	_	_	
28-44	8321-8330	posterior	_	_	
28-45	8331-8332	(	_	_	
28-46	8332-8348	post-commissural	_	_	
28-47	8348-8349	)	_	_	
28-48	8350-8357	caudate	_	_	
28-49	8357-8358	,	_	_	
28-50	8359-8360	(	_	_	
28-51	8360-8361	4	_	_	
28-52	8361-8362	)	_	_	
28-53	8363-8371	anterior	_	_	
28-54	8372-8379	putamen	_	_	
28-55	8379-8380	,	_	_	
28-56	8381-8384	and	_	_	
28-57	8385-8386	(	_	_	
28-58	8386-8387	5	_	_	
28-59	8387-8388	)	_	_	
28-60	8389-8398	posterior	_	_	
28-61	8399-8406	putamen	_	_	
28-62	8406-8407	.	_	_	
28-63	8408-8418	Unsmoothed	_	_	
28-64	8419-8423	fMRI	_	_	
28-65	8424-8428	data	_	_	
28-66	8429-8433	from	_	_	
28-67	8434-8438	each	_	_	
28-68	8439-8448	subregion	_	_	
28-69	8449-8452	was	_	_	
28-70	8453-8461	averaged	_	_	
28-71	8462-8468	across	_	_	
28-72	8469-8472	the	_	_	
28-73	8473-8483	containing	_	_	
28-74	8484-8490	voxels	_	_	
28-75	8491-8492	(	_	_	
28-76	8492-8502	collapsing	_	_	
28-77	8503-8509	across	_	_	
28-78	8510-8521	hemispheres	_	_	
28-79	8521-8522	;	_	_	
28-80	8523-8531	eMethods	_	_	
28-81	8531-8532	)	_	_	
28-82	8533-8536	and	_	_	
28-83	8537-8545	z-scored	_	_	
28-84	8546-8548	to	_	_	
28-85	8549-8558	construct	_	_	
28-86	8559-8563	seed	_	_	
28-87	8564-8574	timeseries	_	_	
28-88	8574-8575	.	_	_	
28-89	8576-8586	Extracting	_	_	
28-90	8587-8590	the	_	_	
28-91	8591-8596	first	_	_	
28-92	8597-8609	eigenvariate	_	_	
28-93	8610-8617	instead	_	_	
28-94	8618-8620	of	_	_	
28-95	8621-8624	the	_	_	
28-96	8625-8629	mean	_	_	
28-97	8630-8637	yielded	_	_	
28-98	8638-8644	almost	_	_	
28-99	8645-8654	identical	_	_	
28-100	8655-8662	results	_	_	
28-101	8662-8663	,	_	_	
28-102	8664-8674	indicating	_	_	
28-103	8675-8679	high	_	_	
28-104	8680-8690	functional	_	_	
28-105	8691-8702	homogeneity	_	_	
28-106	8703-8709	within	_	_	
28-107	8710-8720	subregions	_	_	
28-108	8720-8721	.	_	_	
28-109	8722-8733	Ipsilateral	_	_	
28-110	8734-8737	and	_	_	
28-111	8738-8751	contralateral	_	_	
28-112	8752-8764	connectivity	_	_	
28-113	8765-8769	were	_	_	
28-114	8770-8776	highly	_	_	
28-115	8777-8787	consistent	_	_	
28-116	8788-8794	within	_	_	
28-117	8795-8805	subregions	_	_	
28-118	8806-8807	(	_	_	
28-119	8807-8817	Supplement	_	_	
28-120	8817-8818	)	_	_	
28-121	8818-8819	.	_	_	

#Text=fMRI data analysis
29-1	8820-8824	fMRI	_	_	
29-2	8825-8829	data	_	_	
29-3	8830-8838	analysis	_	_	

#Text=Subject-level analyses consisted of a Generalized Linear Model (GLM) in SPM8 including the following regressors: (1–5) spatially averaged timeseries for each of the 5 striatal subregions (seeds), (6–7) timeseries for white-matter and cerebrospinal fluid (CSF) regions-of-no-interest (eMethods), (8–19) six head motion (realignment) parameters and their first derivatives (all band-pass filtered), and (20–21) run and global intercepts. One dummy variable was additionally included to censor each artifactual set of adjacent volumes exceeding either the DVARS or FD cutoffs. The resulting regression coefficient (beta) maps for each striatal subregion, representing connection strengths for each brain voxel with one striatal subregion while controlling for the other four (and the nuisance variables), were used subsequently.
30-1	8839-8852	Subject-level	_	_	
30-2	8853-8861	analyses	_	_	
30-3	8862-8871	consisted	_	_	
30-4	8872-8874	of	_	_	
30-5	8875-8876	a	_	_	
30-6	8877-8888	Generalized	_	_	
30-7	8889-8895	Linear	_	_	
30-8	8896-8901	Model	_	_	
30-9	8902-8903	(	_	_	
30-10	8903-8906	GLM	_	_	
30-11	8906-8907	)	_	_	
30-12	8908-8910	in	_	_	
30-13	8911-8915	SPM8	_	_	
30-14	8916-8925	including	_	_	
30-15	8926-8929	the	_	_	
30-16	8930-8939	following	_	_	
30-17	8940-8950	regressors	_	_	
30-18	8950-8951	:	_	_	
30-19	8952-8953	(	_	_	
30-20	8953-8954	1	_	_	
30-21	8954-8955	–	_	_	
30-22	8955-8956	5	_	_	
30-23	8956-8957	)	_	_	
30-24	8958-8967	spatially	_	_	
30-25	8968-8976	averaged	_	_	
30-26	8977-8987	timeseries	_	_	
30-27	8988-8991	for	_	_	
30-28	8992-8996	each	_	_	
30-29	8997-8999	of	_	_	
30-30	9000-9003	the	_	_	
30-31	9004-9005	5	_	_	
30-32	9006-9014	striatal	_	_	
30-33	9015-9025	subregions	_	_	
30-34	9026-9027	(	_	_	
30-35	9027-9032	seeds	_	_	
30-36	9032-9033	)	_	_	
30-37	9033-9034	,	_	_	
30-38	9035-9036	(	_	_	
30-39	9036-9037	6	_	_	
30-40	9037-9038	–	_	_	
30-41	9038-9039	7	_	_	
30-42	9039-9040	)	_	_	
30-43	9041-9051	timeseries	_	_	
30-44	9052-9055	for	_	_	
30-45	9056-9068	white-matter	_	_	
30-46	9069-9072	and	_	_	
30-47	9073-9086	cerebrospinal	_	_	
30-48	9087-9092	fluid	_	_	
30-49	9093-9094	(	_	_	
30-50	9094-9097	CSF	_	_	
30-51	9097-9098	)	_	_	
30-52	9099-9121	regions-of-no-interest	_	_	
30-53	9122-9123	(	_	_	
30-54	9123-9131	eMethods	_	_	
30-55	9131-9132	)	_	_	
30-56	9132-9133	,	_	_	
30-57	9134-9135	(	_	_	
30-58	9135-9136	8	_	_	
30-59	9136-9137	–	_	_	
30-60	9137-9139	19	_	_	
30-61	9139-9140	)	_	_	
30-62	9141-9144	six	_	_	
30-63	9145-9149	head	_	_	
30-64	9150-9156	motion	_	_	
30-65	9157-9158	(	_	_	
30-66	9158-9169	realignment	_	_	
30-67	9169-9170	)	_	_	
30-68	9171-9181	parameters	_	_	
30-69	9182-9185	and	_	_	
30-70	9186-9191	their	_	_	
30-71	9192-9197	first	_	_	
30-72	9198-9209	derivatives	_	_	
30-73	9210-9211	(	_	_	
30-74	9211-9214	all	_	_	
30-75	9215-9224	band-pass	_	_	
30-76	9225-9233	filtered	_	_	
30-77	9233-9234	)	_	_	
30-78	9234-9235	,	_	_	
30-79	9236-9239	and	_	_	
30-80	9240-9241	(	_	_	
30-81	9241-9243	20	_	_	
30-82	9243-9244	–	_	_	
30-83	9244-9246	21	_	_	
30-84	9246-9247	)	_	_	
30-85	9248-9251	run	_	_	
30-86	9252-9255	and	_	_	
30-87	9256-9262	global	_	_	
30-88	9263-9273	intercepts	_	_	
30-89	9273-9274	.	_	_	
30-90	9275-9278	One	_	_	
30-91	9279-9284	dummy	_	_	
30-92	9285-9293	variable	_	_	
30-93	9294-9297	was	_	_	
30-94	9298-9310	additionally	_	_	
30-95	9311-9319	included	_	_	
30-96	9320-9322	to	_	_	
30-97	9323-9329	censor	_	_	
30-98	9330-9334	each	_	_	
30-99	9335-9346	artifactual	_	_	
30-100	9347-9350	set	_	_	
30-101	9351-9353	of	_	_	
30-102	9354-9362	adjacent	_	_	
30-103	9363-9370	volumes	_	_	
30-104	9371-9380	exceeding	_	_	
30-105	9381-9387	either	_	_	
30-106	9388-9391	the	_	_	
30-107	9392-9397	DVARS	_	_	
30-108	9398-9400	or	_	_	
30-109	9401-9403	FD	_	_	
30-110	9404-9411	cutoffs	_	_	
30-111	9411-9412	.	_	_	
30-112	9413-9416	The	_	_	
30-113	9417-9426	resulting	_	_	
30-114	9427-9437	regression	_	_	
30-115	9438-9449	coefficient	_	_	
30-116	9450-9451	(	_	_	
30-117	9451-9455	beta	_	_	
30-118	9455-9456	)	_	_	
30-119	9457-9461	maps	_	_	
30-120	9462-9465	for	_	_	
30-121	9466-9470	each	_	_	
30-122	9471-9479	striatal	_	_	
30-123	9480-9489	subregion	_	_	
30-124	9489-9490	,	_	_	
30-125	9491-9503	representing	_	_	
30-126	9504-9514	connection	_	_	
30-127	9515-9524	strengths	_	_	
30-128	9525-9528	for	_	_	
30-129	9529-9533	each	_	_	
30-130	9534-9539	brain	_	_	
30-131	9540-9545	voxel	_	_	
30-132	9546-9550	with	_	_	
30-133	9551-9554	one	_	_	
30-134	9555-9563	striatal	_	_	
30-135	9564-9573	subregion	_	_	
30-136	9574-9579	while	_	_	
30-137	9580-9591	controlling	_	_	
30-138	9592-9595	for	_	_	
30-139	9596-9599	the	_	_	
30-140	9600-9605	other	_	_	
30-141	9606-9610	four	_	_	
30-142	9611-9612	(	_	_	
30-143	9612-9615	and	_	_	
30-144	9616-9619	the	_	_	
30-145	9620-9628	nuisance	_	_	
30-146	9629-9638	variables	_	_	
30-147	9638-9639	)	_	_	
30-148	9639-9640	,	_	_	
30-149	9641-9645	were	_	_	
30-150	9646-9650	used	_	_	
30-151	9651-9663	subsequently	_	_	
30-152	9663-9664	.	_	_	

#Text=Multivariate fMRI analyses
31-1	9665-9677	Multivariate	_	_	
31-2	9678-9682	fMRI	_	_	
31-3	9683-9691	analyses	_	_	

#Text=Our primary goal was to test whether the overall pattern of striatal connectivity predicted group membership using logistic regression. We used a multivariate approach rather than univariate analyses because the latter can only test connectivity between individual seeds and target regions but not the overall (multivariate) pattern of connectivity across seeds. Our purpose in using logistic regression, however, was not as a diagnostic classifier, but rather as a test of multivariate differences in connectivity. Exploratory analyses (Supplement) used a multivariate recursive-feature-elimination support-vector-machine (RFE-SVM) classifier for the former purpose.
32-1	9692-9695	Our	_	_	
32-2	9696-9703	primary	_	_	
32-3	9704-9708	goal	_	_	
32-4	9709-9712	was	_	_	
32-5	9713-9715	to	_	_	
32-6	9716-9720	test	_	_	
32-7	9721-9728	whether	_	_	
32-8	9729-9732	the	_	_	
32-9	9733-9740	overall	_	_	
32-10	9741-9748	pattern	_	_	
32-11	9749-9751	of	_	_	
32-12	9752-9760	striatal	_	_	
32-13	9761-9773	connectivity	_	_	
32-14	9774-9783	predicted	_	_	
32-15	9784-9789	group	_	_	
32-16	9790-9800	membership	_	_	
32-17	9801-9806	using	_	_	
32-18	9807-9815	logistic	_	_	
32-19	9816-9826	regression	_	_	
32-20	9826-9827	.	_	_	
32-21	9828-9830	We	_	_	
32-22	9831-9835	used	_	_	
32-23	9836-9837	a	_	_	
32-24	9838-9850	multivariate	_	_	
32-25	9851-9859	approach	_	_	
32-26	9860-9866	rather	_	_	
32-27	9867-9871	than	_	_	
32-28	9872-9882	univariate	_	_	
32-29	9883-9891	analyses	_	_	
32-30	9892-9899	because	_	_	
32-31	9900-9903	the	_	_	
32-32	9904-9910	latter	_	_	
32-33	9911-9914	can	_	_	
32-34	9915-9919	only	_	_	
32-35	9920-9924	test	_	_	
32-36	9925-9937	connectivity	_	_	
32-37	9938-9945	between	_	_	
32-38	9946-9956	individual	_	_	
32-39	9957-9962	seeds	_	_	
32-40	9963-9966	and	_	_	
32-41	9967-9973	target	_	_	
32-42	9974-9981	regions	_	_	
32-43	9982-9985	but	_	_	
32-44	9986-9989	not	_	_	
32-45	9990-9993	the	_	_	
32-46	9994-10001	overall	_	_	
32-47	10002-10003	(	_	_	
32-48	10003-10015	multivariate	_	_	
32-49	10015-10016	)	_	_	
32-50	10017-10024	pattern	_	_	
32-51	10025-10027	of	_	_	
32-52	10028-10040	connectivity	_	_	
32-53	10041-10047	across	_	_	
32-54	10048-10053	seeds	_	_	
32-55	10053-10054	.	_	_	
32-56	10055-10058	Our	_	_	
32-57	10059-10066	purpose	_	_	
32-58	10067-10069	in	_	_	
32-59	10070-10075	using	_	_	
32-60	10076-10084	logistic	_	_	
32-61	10085-10095	regression	_	_	
32-62	10095-10096	,	_	_	
32-63	10097-10104	however	_	_	
32-64	10104-10105	,	_	_	
32-65	10106-10109	was	_	_	
32-66	10110-10113	not	_	_	
32-67	10114-10116	as	_	_	
32-68	10117-10118	a	_	_	
32-69	10119-10129	diagnostic	_	_	
32-70	10130-10140	classifier	_	_	
32-71	10140-10141	,	_	_	
32-72	10142-10145	but	_	_	
32-73	10146-10152	rather	_	_	
32-74	10153-10155	as	_	_	
32-75	10156-10157	a	_	_	
32-76	10158-10162	test	_	_	
32-77	10163-10165	of	_	_	
32-78	10166-10178	multivariate	_	_	
32-79	10179-10190	differences	_	_	
32-80	10191-10193	in	_	_	
32-81	10194-10206	connectivity	_	_	
32-82	10206-10207	.	_	_	
32-83	10208-10219	Exploratory	_	_	
32-84	10220-10228	analyses	_	_	
32-85	10229-10230	(	_	_	
32-86	10230-10240	Supplement	_	_	
32-87	10240-10241	)	_	_	
32-88	10242-10246	used	_	_	
32-89	10247-10248	a	_	_	
32-90	10249-10261	multivariate	_	_	
32-91	10262-10291	recursive-feature-elimination	_	_	
32-92	10292-10314	support-vector-machine	_	_	
32-93	10315-10316	(	_	_	
32-94	10316-10323	RFE-SVM	_	_	
32-95	10323-10324	)	_	_	
32-96	10325-10335	classifier	_	_	
32-97	10336-10339	for	_	_	
32-98	10340-10343	the	_	_	
32-99	10344-10350	former	_	_	
32-100	10351-10358	purpose	_	_	
32-101	10358-10359	.	_	_	

#Text=First, whole-brain connectivity beta maps for each striatal subregion were parcellated into Brodmann areas (BAs) and subcortical nuclei using the Tailarach Daemon atlas in the WFU PickAtlas toolbox (henceforth referred to as target regions), after excluding striatal voxels. Second, a data-reduction step retained only target regions exhibiting significant connectivity with any of the striatal subregions (p≤0.005, uncorrected, in ≥20% of the voxels) in either group; 29 regions met these criteria (for individual striatal subregions 1–5 the number of target regions to meet criteria were 0, 24, 2, 5, and 4, respectively). Although these selection criteria were unbiased towards any subregion, they yielded more target regions for the anterior caudate given its stronger widespread connectivity.
33-1	10360-10365	First	_	_	
33-2	10365-10366	,	_	_	
33-3	10367-10378	whole-brain	_	_	
33-4	10379-10391	connectivity	_	_	
33-5	10392-10396	beta	_	_	
33-6	10397-10401	maps	_	_	
33-7	10402-10405	for	_	_	
33-8	10406-10410	each	_	_	
33-9	10411-10419	striatal	_	_	
33-10	10420-10429	subregion	_	_	
33-11	10430-10434	were	_	_	
33-12	10435-10446	parcellated	_	_	
33-13	10447-10451	into	_	_	
33-14	10452-10460	Brodmann	_	_	
33-15	10461-10466	areas	_	_	
33-16	10467-10468	(	_	_	
33-17	10468-10471	BAs	_	_	
33-18	10471-10472	)	_	_	
33-19	10473-10476	and	_	_	
33-20	10477-10488	subcortical	_	_	
33-21	10489-10495	nuclei	_	_	
33-22	10496-10501	using	_	_	
33-23	10502-10505	the	_	_	
33-24	10506-10515	Tailarach	_	_	
33-25	10516-10522	Daemon	_	_	
33-26	10523-10528	atlas	_	_	
33-27	10529-10531	in	_	_	
33-28	10532-10535	the	_	_	
33-29	10536-10539	WFU	_	_	
33-30	10540-10549	PickAtlas	_	_	
33-31	10550-10557	toolbox	_	_	
33-32	10558-10559	(	_	_	
33-33	10559-10569	henceforth	_	_	
33-34	10570-10578	referred	_	_	
33-35	10579-10581	to	_	_	
33-36	10582-10584	as	_	_	
33-37	10585-10591	target	_	_	
33-38	10592-10599	regions	_	_	
33-39	10599-10600	)	_	_	
33-40	10600-10601	,	_	_	
33-41	10602-10607	after	_	_	
33-42	10608-10617	excluding	_	_	
33-43	10618-10626	striatal	_	_	
33-44	10627-10633	voxels	_	_	
33-45	10633-10634	.	_	_	
33-46	10635-10641	Second	_	_	
33-47	10641-10642	,	_	_	
33-48	10643-10644	a	_	_	
33-49	10645-10659	data-reduction	_	_	
33-50	10660-10664	step	_	_	
33-51	10665-10673	retained	_	_	
33-52	10674-10678	only	_	_	
33-53	10679-10685	target	_	_	
33-54	10686-10693	regions	_	_	
33-55	10694-10704	exhibiting	_	_	
33-56	10705-10716	significant	_	_	
33-57	10717-10729	connectivity	_	_	
33-58	10730-10734	with	_	_	
33-59	10735-10738	any	_	_	
33-60	10739-10741	of	_	_	
33-61	10742-10745	the	_	_	
33-62	10746-10754	striatal	_	_	
33-63	10755-10765	subregions	_	_	
33-64	10766-10767	(	_	_	
33-65	10767-10768	p	_	_	
33-66	10768-10769	≤	_	_	
33-67	10769-10774	0.005	_	_	
33-68	10774-10775	,	_	_	
33-69	10776-10787	uncorrected	_	_	
33-70	10787-10788	,	_	_	
33-71	10789-10791	in	_	_	
33-72	10792-10793	≥	_	_	
33-73	10793-10796	20%	_	_	
33-74	10797-10799	of	_	_	
33-75	10800-10803	the	_	_	
33-76	10804-10810	voxels	_	_	
33-77	10810-10811	)	_	_	
33-78	10812-10814	in	_	_	
33-79	10815-10821	either	_	_	
33-80	10822-10827	group	_	_	
33-81	10827-10828	;	_	_	
33-82	10829-10831	29	_	_	
33-83	10832-10839	regions	_	_	
33-84	10840-10843	met	_	_	
33-85	10844-10849	these	_	_	
33-86	10850-10858	criteria	_	_	
33-87	10859-10860	(	_	_	
33-88	10860-10863	for	_	_	
33-89	10864-10874	individual	_	_	
33-90	10875-10883	striatal	_	_	
33-91	10884-10894	subregions	_	_	
33-92	10895-10896	1	_	_	
33-93	10896-10897	–	_	_	
33-94	10897-10898	5	_	_	
33-95	10899-10902	the	_	_	
33-96	10903-10909	number	_	_	
33-97	10910-10912	of	_	_	
33-98	10913-10919	target	_	_	
33-99	10920-10927	regions	_	_	
33-100	10928-10930	to	_	_	
33-101	10931-10935	meet	_	_	
33-102	10936-10944	criteria	_	_	
33-103	10945-10949	were	_	_	
33-104	10950-10951	0	_	_	
33-105	10951-10952	,	_	_	
33-106	10953-10955	24	_	_	
33-107	10955-10956	,	_	_	
33-108	10957-10958	2	_	_	
33-109	10958-10959	,	_	_	
33-110	10960-10961	5	_	_	
33-111	10961-10962	,	_	_	
33-112	10963-10966	and	_	_	
33-113	10967-10968	4	_	_	
33-114	10968-10969	,	_	_	
33-115	10970-10982	respectively	_	_	
33-116	10982-10983	)	_	_	
33-117	10983-10984	.	_	_	
33-118	10985-10993	Although	_	_	
33-119	10994-10999	these	_	_	
33-120	11000-11009	selection	_	_	
33-121	11010-11018	criteria	_	_	
33-122	11019-11023	were	_	_	
33-123	11024-11032	unbiased	_	_	
33-124	11033-11040	towards	_	_	
33-125	11041-11044	any	_	_	
33-126	11045-11054	subregion	_	_	
33-127	11054-11055	,	_	_	
33-128	11056-11060	they	_	_	
33-129	11061-11068	yielded	_	_	
33-130	11069-11073	more	_	_	
33-131	11074-11080	target	_	_	
33-132	11081-11088	regions	_	_	
33-133	11089-11092	for	_	_	
33-134	11093-11096	the	_	_	
33-135	11097-11105	anterior	_	_	
33-136	11106-11113	caudate	_	_	
33-137	11114-11119	given	_	_	
33-138	11120-11123	its	_	_	
33-139	11124-11132	stronger	_	_	
33-140	11133-11143	widespread	_	_	
33-141	11144-11156	connectivity	_	_	
33-142	11156-11157	.	_	_	

#Text=Next, logistic regression was used to predict group membership based on connection strengths for striatal-target pairs (i.e., individual mean connectivity betas for each target region by striatal subregion). Because including all pairs each as a predictor variable would result in an underdetermined model, we used model building with step-forward selection to progressively include sets of predictor variables, with each of five possible sets consisting of all connectivity betas for target regions significantly associated with a given striatal subregion. First, models consisting of predictors from one set at a time were analyzed, and the set resulting in the lowest p-value was retained. Additional sets of variables were retained in the model if they significantly improved the model fit (p<0.05, likelihood-ratio test). The likelihood-ratio test for the final model was our a priori test of group differences in connectivity patterns (other p-values were only used for data-reduction and model-building steps). Once the final model was determined, the subject-wise predicted log odds of belonging to the healthy group based on the multivariate connectivity pattern was used as a summary index of degree of abnormality in the striatal connectivity pattern for further correlational analyses with clinical and PET data (note that these analyses were unbiased as the ordering of the log odds across individuals was orthogonal to all clinical and PET data except for group membership, which was controlled for appropriately; eMethods).
34-1	11158-11162	Next	_	_	
34-2	11162-11163	,	_	_	
34-3	11164-11172	logistic	_	_	
34-4	11173-11183	regression	_	_	
34-5	11184-11187	was	_	_	
34-6	11188-11192	used	_	_	
34-7	11193-11195	to	_	_	
34-8	11196-11203	predict	_	_	
34-9	11204-11209	group	_	_	
34-10	11210-11220	membership	_	_	
34-11	11221-11226	based	_	_	
34-12	11227-11229	on	_	_	
34-13	11230-11240	connection	_	_	
34-14	11241-11250	strengths	_	_	
34-15	11251-11254	for	_	_	
34-16	11255-11270	striatal-target	_	_	
34-17	11271-11276	pairs	_	_	
34-18	11277-11278	(	_	_	
34-19	11278-11281	i.e	_	_	
34-20	11281-11282	.	_	_	
34-21	11282-11283	,	_	_	
34-22	11284-11294	individual	_	_	
34-23	11295-11299	mean	_	_	
34-24	11300-11312	connectivity	_	_	
34-25	11313-11318	betas	_	_	
34-26	11319-11322	for	_	_	
34-27	11323-11327	each	_	_	
34-28	11328-11334	target	_	_	
34-29	11335-11341	region	_	_	
34-30	11342-11344	by	_	_	
34-31	11345-11353	striatal	_	_	
34-32	11354-11363	subregion	_	_	
34-33	11363-11364	)	_	_	
34-34	11364-11365	.	_	_	
34-35	11366-11373	Because	_	_	
34-36	11374-11383	including	_	_	
34-37	11384-11387	all	_	_	
34-38	11388-11393	pairs	_	_	
34-39	11394-11398	each	_	_	
34-40	11399-11401	as	_	_	
34-41	11402-11403	a	_	_	
34-42	11404-11413	predictor	_	_	
34-43	11414-11422	variable	_	_	
34-44	11423-11428	would	_	_	
34-45	11429-11435	result	_	_	
34-46	11436-11438	in	_	_	
34-47	11439-11441	an	_	_	
34-48	11442-11457	underdetermined	_	_	
34-49	11458-11463	model	_	_	
34-50	11463-11464	,	_	_	
34-51	11465-11467	we	_	_	
34-52	11468-11472	used	_	_	
34-53	11473-11478	model	_	_	
34-54	11479-11487	building	_	_	
34-55	11488-11492	with	_	_	
34-56	11493-11505	step-forward	_	_	
34-57	11506-11515	selection	_	_	
34-58	11516-11518	to	_	_	
34-59	11519-11532	progressively	_	_	
34-60	11533-11540	include	_	_	
34-61	11541-11545	sets	_	_	
34-62	11546-11548	of	_	_	
34-63	11549-11558	predictor	_	_	
34-64	11559-11568	variables	_	_	
34-65	11568-11569	,	_	_	
34-66	11570-11574	with	_	_	
34-67	11575-11579	each	_	_	
34-68	11580-11582	of	_	_	
34-69	11583-11587	five	_	_	
34-70	11588-11596	possible	_	_	
34-71	11597-11601	sets	_	_	
34-72	11602-11612	consisting	_	_	
34-73	11613-11615	of	_	_	
34-74	11616-11619	all	_	_	
34-75	11620-11632	connectivity	_	_	
34-76	11633-11638	betas	_	_	
34-77	11639-11642	for	_	_	
34-78	11643-11649	target	_	_	
34-79	11650-11657	regions	_	_	
34-80	11658-11671	significantly	_	_	
34-81	11672-11682	associated	_	_	
34-82	11683-11687	with	_	_	
34-83	11688-11689	a	_	_	
34-84	11690-11695	given	_	_	
34-85	11696-11704	striatal	_	_	
34-86	11705-11714	subregion	_	_	
34-87	11714-11715	.	_	_	
34-88	11716-11721	First	_	_	
34-89	11721-11722	,	_	_	
34-90	11723-11729	models	_	_	
34-91	11730-11740	consisting	_	_	
34-92	11741-11743	of	_	_	
34-93	11744-11754	predictors	_	_	
34-94	11755-11759	from	_	_	
34-95	11760-11763	one	_	_	
34-96	11764-11767	set	_	_	
34-97	11768-11770	at	_	_	
34-98	11771-11772	a	_	_	
34-99	11773-11777	time	_	_	
34-100	11778-11782	were	_	_	
34-101	11783-11791	analyzed	_	_	
34-102	11791-11792	,	_	_	
34-103	11793-11796	and	_	_	
34-104	11797-11800	the	_	_	
34-105	11801-11804	set	_	_	
34-106	11805-11814	resulting	_	_	
34-107	11815-11817	in	_	_	
34-108	11818-11821	the	_	_	
34-109	11822-11828	lowest	_	_	
34-110	11829-11836	p-value	_	_	
34-111	11837-11840	was	_	_	
34-112	11841-11849	retained	_	_	
34-113	11849-11850	.	_	_	
34-114	11851-11861	Additional	_	_	
34-115	11862-11866	sets	_	_	
34-116	11867-11869	of	_	_	
34-117	11870-11879	variables	_	_	
34-118	11880-11884	were	_	_	
34-119	11885-11893	retained	_	_	
34-120	11894-11896	in	_	_	
34-121	11897-11900	the	_	_	
34-122	11901-11906	model	_	_	
34-123	11907-11909	if	_	_	
34-124	11910-11914	they	_	_	
34-125	11915-11928	significantly	_	_	
34-126	11929-11937	improved	_	_	
34-127	11938-11941	the	_	_	
34-128	11942-11947	model	_	_	
34-129	11948-11951	fit	_	_	
34-130	11952-11953	(	_	_	
34-131	11953-11954	p	_	_	
34-132	11954-11955	<	_	_	
34-133	11955-11959	0.05	_	_	
34-134	11959-11960	,	_	_	
34-135	11961-11977	likelihood-ratio	_	_	
34-136	11978-11982	test	_	_	
34-137	11982-11983	)	_	_	
34-138	11983-11984	.	_	_	
34-139	11985-11988	The	_	_	
34-140	11989-12005	likelihood-ratio	_	_	
34-141	12006-12010	test	_	_	
34-142	12011-12014	for	_	_	
34-143	12015-12018	the	_	_	
34-144	12019-12024	final	_	_	
34-145	12025-12030	model	_	_	
34-146	12031-12034	was	_	_	
34-147	12035-12038	our	_	_	
34-148	12039-12040	a	_	_	
34-149	12041-12047	priori	_	_	
34-150	12048-12052	test	_	_	
34-151	12053-12055	of	_	_	
34-152	12056-12061	group	_	_	
34-153	12062-12073	differences	_	_	
34-154	12074-12076	in	_	_	
34-155	12077-12089	connectivity	_	_	
34-156	12090-12098	patterns	_	_	
34-157	12099-12100	(	_	_	
34-158	12100-12105	other	_	_	
34-159	12106-12114	p-values	_	_	
34-160	12115-12119	were	_	_	
34-161	12120-12124	only	_	_	
34-162	12125-12129	used	_	_	
34-163	12130-12133	for	_	_	
34-164	12134-12148	data-reduction	_	_	
34-165	12149-12152	and	_	_	
34-166	12153-12167	model-building	_	_	
34-167	12168-12173	steps	_	_	
34-168	12173-12174	)	_	_	
34-169	12174-12175	.	_	_	
34-170	12176-12180	Once	_	_	
34-171	12181-12184	the	_	_	
34-172	12185-12190	final	_	_	
34-173	12191-12196	model	_	_	
34-174	12197-12200	was	_	_	
34-175	12201-12211	determined	_	_	
34-176	12211-12212	,	_	_	
34-177	12213-12216	the	_	_	
34-178	12217-12229	subject-wise	_	_	
34-179	12230-12239	predicted	_	_	
34-180	12240-12243	log	_	_	
34-181	12244-12248	odds	_	_	
34-182	12249-12251	of	_	_	
34-183	12252-12261	belonging	_	_	
34-184	12262-12264	to	_	_	
34-185	12265-12268	the	_	_	
34-186	12269-12276	healthy	_	_	
34-187	12277-12282	group	_	_	
34-188	12283-12288	based	_	_	
34-189	12289-12291	on	_	_	
34-190	12292-12295	the	_	_	
34-191	12296-12308	multivariate	_	_	
34-192	12309-12321	connectivity	_	_	
34-193	12322-12329	pattern	_	_	
34-194	12330-12333	was	_	_	
34-195	12334-12338	used	_	_	
34-196	12339-12341	as	_	_	
34-197	12342-12343	a	_	_	
34-198	12344-12351	summary	_	_	
34-199	12352-12357	index	_	_	
34-200	12358-12360	of	_	_	
34-201	12361-12367	degree	_	_	
34-202	12368-12370	of	_	_	
34-203	12371-12382	abnormality	_	_	
34-204	12383-12385	in	_	_	
34-205	12386-12389	the	_	_	
34-206	12390-12398	striatal	_	_	
34-207	12399-12411	connectivity	_	_	
34-208	12412-12419	pattern	_	_	
34-209	12420-12423	for	_	_	
34-210	12424-12431	further	_	_	
34-211	12432-12445	correlational	_	_	
34-212	12446-12454	analyses	_	_	
34-213	12455-12459	with	_	_	
34-214	12460-12468	clinical	_	_	
34-215	12469-12472	and	_	_	
34-216	12473-12476	PET	_	_	
34-217	12477-12481	data	_	_	
34-218	12482-12483	(	_	_	
34-219	12483-12487	note	_	_	
34-220	12488-12492	that	_	_	
34-221	12493-12498	these	_	_	
34-222	12499-12507	analyses	_	_	
34-223	12508-12512	were	_	_	
34-224	12513-12521	unbiased	_	_	
34-225	12522-12524	as	_	_	
34-226	12525-12528	the	_	_	
34-227	12529-12537	ordering	_	_	
34-228	12538-12540	of	_	_	
34-229	12541-12544	the	_	_	
34-230	12545-12548	log	_	_	
34-231	12549-12553	odds	_	_	
34-232	12554-12560	across	_	_	
34-233	12561-12572	individuals	_	_	
34-234	12573-12576	was	_	_	
34-235	12577-12587	orthogonal	_	_	
34-236	12588-12590	to	_	_	
34-237	12591-12594	all	_	_	
34-238	12595-12603	clinical	_	_	
34-239	12604-12607	and	_	_	
34-240	12608-12611	PET	_	_	
34-241	12612-12616	data	_	_	
34-242	12617-12623	except	_	_	
34-243	12624-12627	for	_	_	
34-244	12628-12633	group	_	_	
34-245	12634-12644	membership	_	_	
34-246	12644-12645	,	_	_	
34-247	12646-12651	which	_	_	
34-248	12652-12655	was	_	_	
34-249	12656-12666	controlled	_	_	
34-250	12667-12670	for	_	_	
34-251	12671-12684	appropriately	_	_	
34-252	12684-12685	;	_	_	
34-253	12686-12694	eMethods	_	_	
34-254	12694-12695	)	_	_	
34-255	12695-12696	.	_	_	

#Text=These correlational analyses used parametric tests except when the data were not normally distributed (based on a Lilliefors test), in which case non-parametric tests were used. Spearman’s rank (partial) correlations were used to assess the relationship between connectivity and severity of positive symptoms within patients, based on the PANSS positive-subscale-total scores (PANSS-PT), while controlling for negative symptoms as measured by the PANSS negative-subscale-total scores (PANSS-NT). Robust multiple linear regression (iteratively-reweighted least squares with bisquare-weighting function) was used to assess the relationship between connectivity and PET data (baseline BPND or ΔBPND, see below) across all participants while controlling for group and nuisance variables. Spearman rank correlations were used for exploratory analyses of the MATRICS composite score. Effects surviving a p-value of 0.05 are reported. Bonferroni correction for multiple comparisons was used when necessary. Finally, the number of artifactual volumes regressed out for each participant was also used as an fMRI-data-quality score.
35-1	12697-12702	These	_	_	
35-2	12703-12716	correlational	_	_	
35-3	12717-12725	analyses	_	_	
35-4	12726-12730	used	_	_	
35-5	12731-12741	parametric	_	_	
35-6	12742-12747	tests	_	_	
35-7	12748-12754	except	_	_	
35-8	12755-12759	when	_	_	
35-9	12760-12763	the	_	_	
35-10	12764-12768	data	_	_	
35-11	12769-12773	were	_	_	
35-12	12774-12777	not	_	_	
35-13	12778-12786	normally	_	_	
35-14	12787-12798	distributed	_	_	
35-15	12799-12800	(	_	_	
35-16	12800-12805	based	_	_	
35-17	12806-12808	on	_	_	
35-18	12809-12810	a	_	_	
35-19	12811-12821	Lilliefors	_	_	
35-20	12822-12826	test	_	_	
35-21	12826-12827	)	_	_	
35-22	12827-12828	,	_	_	
35-23	12829-12831	in	_	_	
35-24	12832-12837	which	_	_	
35-25	12838-12842	case	_	_	
35-26	12843-12857	non-parametric	_	_	
35-27	12858-12863	tests	_	_	
35-28	12864-12868	were	_	_	
35-29	12869-12873	used	_	_	
35-30	12873-12874	.	_	_	
35-31	12875-12883	Spearman	_	_	
35-32	12883-12884	’	_	_	
35-33	12884-12885	s	_	_	
35-34	12886-12890	rank	_	_	
35-35	12891-12892	(	_	_	
35-36	12892-12899	partial	_	_	
35-37	12899-12900	)	_	_	
35-38	12901-12913	correlations	_	_	
35-39	12914-12918	were	_	_	
35-40	12919-12923	used	_	_	
35-41	12924-12926	to	_	_	
35-42	12927-12933	assess	_	_	
35-43	12934-12937	the	_	_	
35-44	12938-12950	relationship	_	_	
35-45	12951-12958	between	_	_	
35-46	12959-12971	connectivity	_	_	
35-47	12972-12975	and	_	_	
35-48	12976-12984	severity	_	_	
35-49	12985-12987	of	_	_	
35-50	12988-12996	positive	_	_	
35-51	12997-13005	symptoms	_	_	
35-52	13006-13012	within	_	_	
35-53	13013-13021	patients	_	_	
35-54	13021-13022	,	_	_	
35-55	13023-13028	based	_	_	
35-56	13029-13031	on	_	_	
35-57	13032-13035	the	_	_	
35-58	13036-13041	PANSS	_	_	
35-59	13042-13065	positive-subscale-total	_	_	
35-60	13066-13072	scores	_	_	
35-61	13073-13074	(	_	_	
35-62	13074-13082	PANSS-PT	_	_	
35-63	13082-13083	)	_	_	
35-64	13083-13084	,	_	_	
35-65	13085-13090	while	_	_	
35-66	13091-13102	controlling	_	_	
35-67	13103-13106	for	_	_	
35-68	13107-13115	negative	_	_	
35-69	13116-13124	symptoms	_	_	
35-70	13125-13127	as	_	_	
35-71	13128-13136	measured	_	_	
35-72	13137-13139	by	_	_	
35-73	13140-13143	the	_	_	
35-74	13144-13149	PANSS	_	_	
35-75	13150-13173	negative-subscale-total	_	_	
35-76	13174-13180	scores	_	_	
35-77	13181-13182	(	_	_	
35-78	13182-13190	PANSS-NT	_	_	
35-79	13190-13191	)	_	_	
35-80	13191-13192	.	_	_	
35-81	13193-13199	Robust	_	_	
35-82	13200-13208	multiple	_	_	
35-83	13209-13215	linear	_	_	
35-84	13216-13226	regression	_	_	
35-85	13227-13228	(	_	_	
35-86	13228-13250	iteratively-reweighted	_	_	
35-87	13251-13256	least	_	_	
35-88	13257-13264	squares	_	_	
35-89	13265-13269	with	_	_	
35-90	13270-13288	bisquare-weighting	_	_	
35-91	13289-13297	function	_	_	
35-92	13297-13298	)	_	_	
35-93	13299-13302	was	_	_	
35-94	13303-13307	used	_	_	
35-95	13308-13310	to	_	_	
35-96	13311-13317	assess	_	_	
35-97	13318-13321	the	_	_	
35-98	13322-13334	relationship	_	_	
35-99	13335-13342	between	_	_	
35-100	13343-13355	connectivity	_	_	
35-101	13356-13359	and	_	_	
35-102	13360-13363	PET	_	_	
35-103	13364-13368	data	_	_	
35-104	13369-13370	(	_	_	
35-105	13370-13378	baseline	_	_	
35-106	13379-13383	BPND	_	_	
35-107	13384-13386	or	_	_	
35-108	13387-13392	ΔBPND	_	_	
35-109	13392-13393	,	_	_	
35-110	13394-13397	see	_	_	
35-111	13398-13403	below	_	_	
35-112	13403-13404	)	_	_	
35-113	13405-13411	across	_	_	
35-114	13412-13415	all	_	_	
35-115	13416-13428	participants	_	_	
35-116	13429-13434	while	_	_	
35-117	13435-13446	controlling	_	_	
35-118	13447-13450	for	_	_	
35-119	13451-13456	group	_	_	
35-120	13457-13460	and	_	_	
35-121	13461-13469	nuisance	_	_	
35-122	13470-13479	variables	_	_	
35-123	13479-13480	.	_	_	
35-124	13481-13489	Spearman	_	_	
35-125	13490-13494	rank	_	_	
35-126	13495-13507	correlations	_	_	
35-127	13508-13512	were	_	_	
35-128	13513-13517	used	_	_	
35-129	13518-13521	for	_	_	
35-130	13522-13533	exploratory	_	_	
35-131	13534-13542	analyses	_	_	
35-132	13543-13545	of	_	_	
35-133	13546-13549	the	_	_	
35-134	13550-13557	MATRICS	_	_	
35-135	13558-13567	composite	_	_	
35-136	13568-13573	score	_	_	
35-137	13573-13574	.	_	_	
35-138	13575-13582	Effects	_	_	
35-139	13583-13592	surviving	_	_	
35-140	13593-13594	a	_	_	
35-141	13595-13602	p-value	_	_	
35-142	13603-13605	of	_	_	
35-143	13606-13610	0.05	_	_	
35-144	13611-13614	are	_	_	
35-145	13615-13623	reported	_	_	
35-146	13623-13624	.	_	_	
35-147	13625-13635	Bonferroni	_	_	
35-148	13636-13646	correction	_	_	
35-149	13647-13650	for	_	_	
35-150	13651-13659	multiple	_	_	
35-151	13660-13671	comparisons	_	_	
35-152	13672-13675	was	_	_	
35-153	13676-13680	used	_	_	
35-154	13681-13685	when	_	_	
35-155	13686-13695	necessary	_	_	
35-156	13695-13696	.	_	_	
35-157	13697-13704	Finally	_	_	
35-158	13704-13705	,	_	_	
35-159	13706-13709	the	_	_	
35-160	13710-13716	number	_	_	
35-161	13717-13719	of	_	_	
35-162	13720-13731	artifactual	_	_	
35-163	13732-13739	volumes	_	_	
35-164	13740-13749	regressed	_	_	
35-165	13750-13753	out	_	_	
35-166	13754-13757	for	_	_	
35-167	13758-13762	each	_	_	
35-168	13763-13774	participant	_	_	
35-169	13775-13778	was	_	_	
35-170	13779-13783	also	_	_	
35-171	13784-13788	used	_	_	
35-172	13789-13791	as	_	_	
35-173	13792-13794	an	_	_	
35-174	13795-13812	fMRI-data-quality	_	_	
35-175	13813-13818	score	_	_	
35-176	13818-13819	.	_	_	

#Text=PET preprocessing and data analysis
36-1	13820-13823	PET	_	_	
36-2	13824-13837	preprocessing	_	_	
36-3	13838-13841	and	_	_	
36-4	13842-13846	data	_	_	
36-5	13847-13855	analysis	_	_	

#Text=A detailed description of PET procedures and results was previously published. Participants underwent two PET scans with the D2 radiotracer [11C]FLB457 on an Siemens HR+ scanner at Yale University: a baseline scan and a second scan 3 h after oral administration of amphetamine (0.5 mg/kg). Arterial plasma was collected to form metabolite-corrected input functions. Kinetic modeling used a two-tissue compartment model that incorporated a set of shared parameter estimates across predefined ROIs. Binding potential (BPND) and its relative change from baseline following amphetamine (ΔBPND) were estimated in each ROI excluding the striatum – striatal BPND cannot be quantified with [11C]FLB457 due to its slow washout in this high D2R density region. Both BPND and ΔBPND values were highly correlated across regions (mean r~0.8). Thus, as a data-reduction step we performed principal component analyses (PCA) with varimax rotation, separately for BPND and ΔBPND, across regions. Horn’s parallel analyses yielded a 1-factor solution for baseline BPND (corresponding to D2R density across all regions) and a 1-factor solution for ΔBPND (corresponding to dopamine release across all regions). For correlational analyses, individual factor scores were calculated as the weighted sum of factor loadings by the PET measures (BPND or ΔBPND) across ROIs.
37-1	13856-13857	A	_	_	
37-2	13858-13866	detailed	_	_	
37-3	13867-13878	description	_	_	
37-4	13879-13881	of	_	_	
37-5	13882-13885	PET	_	_	
37-6	13886-13896	procedures	_	_	
37-7	13897-13900	and	_	_	
37-8	13901-13908	results	_	_	
37-9	13909-13912	was	_	_	
37-10	13913-13923	previously	_	_	
37-11	13924-13933	published	_	_	
37-12	13933-13934	.	_	_	
37-13	13935-13947	Participants	_	_	
37-14	13948-13957	underwent	_	_	
37-15	13958-13961	two	_	_	
37-16	13962-13965	PET	_	_	
37-17	13966-13971	scans	_	_	
37-18	13972-13976	with	_	_	
37-19	13977-13980	the	_	_	
37-20	13981-13983	D2	_	_	
37-21	13984-13995	radiotracer	_	_	
37-22	13996-13997	[	_	_	
37-23	13997-14000	11C	_	_	
37-24	14000-14001	]	_	_	
37-25	14001-14007	FLB457	_	_	
37-26	14008-14010	on	_	_	
37-27	14011-14013	an	_	_	
37-28	14014-14021	Siemens	_	_	
37-29	14022-14024	HR	_	_	
37-30	14024-14025	+	_	_	
37-31	14026-14033	scanner	_	_	
37-32	14034-14036	at	_	_	
37-33	14037-14041	Yale	_	_	
37-34	14042-14052	University	_	_	
37-35	14052-14053	:	_	_	
37-36	14054-14055	a	_	_	
37-37	14056-14064	baseline	_	_	
37-38	14065-14069	scan	_	_	
37-39	14070-14073	and	_	_	
37-40	14074-14075	a	_	_	
37-41	14076-14082	second	_	_	
37-42	14083-14087	scan	_	_	
37-43	14088-14089	3	_	_	
37-44	14090-14091	h	_	_	
37-45	14092-14097	after	_	_	
37-46	14098-14102	oral	_	_	
37-47	14103-14117	administration	_	_	
37-48	14118-14120	of	_	_	
37-49	14121-14132	amphetamine	_	_	
37-50	14133-14134	(	_	_	
37-51	14134-14137	0.5	_	_	
37-52	14138-14140	mg	_	_	
37-53	14140-14141	/	_	_	
37-54	14141-14143	kg	_	_	
37-55	14143-14144	)	_	_	
37-56	14144-14145	.	_	_	
37-57	14146-14154	Arterial	_	_	
37-58	14155-14161	plasma	_	_	
37-59	14162-14165	was	_	_	
37-60	14166-14175	collected	_	_	
37-61	14176-14178	to	_	_	
37-62	14179-14183	form	_	_	
37-63	14184-14204	metabolite-corrected	_	_	
37-64	14205-14210	input	_	_	
37-65	14211-14220	functions	_	_	
37-66	14220-14221	.	_	_	
37-67	14222-14229	Kinetic	_	_	
37-68	14230-14238	modeling	_	_	
37-69	14239-14243	used	_	_	
37-70	14244-14245	a	_	_	
37-71	14246-14256	two-tissue	_	_	
37-72	14257-14268	compartment	_	_	
37-73	14269-14274	model	_	_	
37-74	14275-14279	that	_	_	
37-75	14280-14292	incorporated	_	_	
37-76	14293-14294	a	_	_	
37-77	14295-14298	set	_	_	
37-78	14299-14301	of	_	_	
37-79	14302-14308	shared	_	_	
37-80	14309-14318	parameter	_	_	
37-81	14319-14328	estimates	_	_	
37-82	14329-14335	across	_	_	
37-83	14336-14346	predefined	_	_	
37-84	14347-14351	ROIs	_	_	
37-85	14351-14352	.	_	_	
37-86	14353-14360	Binding	_	_	
37-87	14361-14370	potential	_	_	
37-88	14371-14372	(	_	_	
37-89	14372-14376	BPND	_	_	
37-90	14376-14377	)	_	_	
37-91	14378-14381	and	_	_	
37-92	14382-14385	its	_	_	
37-93	14386-14394	relative	_	_	
37-94	14395-14401	change	_	_	
37-95	14402-14406	from	_	_	
37-96	14407-14415	baseline	_	_	
37-97	14416-14425	following	_	_	
37-98	14426-14437	amphetamine	_	_	
37-99	14438-14439	(	_	_	
37-100	14439-14444	ΔBPND	_	_	
37-101	14444-14445	)	_	_	
37-102	14446-14450	were	_	_	
37-103	14451-14460	estimated	_	_	
37-104	14461-14463	in	_	_	
37-105	14464-14468	each	_	_	
37-106	14469-14472	ROI	_	_	
37-107	14473-14482	excluding	_	_	
37-108	14483-14486	the	_	_	
37-109	14487-14495	striatum	_	_	
37-110	14496-14497	–	_	_	
37-111	14498-14506	striatal	_	_	
37-112	14507-14511	BPND	_	_	
37-113	14512-14518	cannot	_	_	
37-114	14519-14521	be	_	_	
37-115	14522-14532	quantified	_	_	
37-116	14533-14537	with	_	_	
37-117	14538-14539	[	_	_	
37-118	14539-14542	11C	_	_	
37-119	14542-14543	]	_	_	
37-120	14543-14549	FLB457	_	_	
37-121	14550-14553	due	_	_	
37-122	14554-14556	to	_	_	
37-123	14557-14560	its	_	_	
37-124	14561-14565	slow	_	_	
37-125	14566-14573	washout	_	_	
37-126	14574-14576	in	_	_	
37-127	14577-14581	this	_	_	
37-128	14582-14586	high	_	_	
37-129	14587-14590	D2R	_	_	
37-130	14591-14598	density	_	_	
37-131	14599-14605	region	_	_	
37-132	14605-14606	.	_	_	
37-133	14607-14611	Both	_	_	
37-134	14612-14616	BPND	_	_	
37-135	14617-14620	and	_	_	
37-136	14621-14626	ΔBPND	_	_	
37-137	14627-14633	values	_	_	
37-138	14634-14638	were	_	_	
37-139	14639-14645	highly	_	_	
37-140	14646-14656	correlated	_	_	
37-141	14657-14663	across	_	_	
37-142	14664-14671	regions	_	_	
37-143	14672-14673	(	_	_	
37-144	14673-14677	mean	_	_	
37-145	14678-14679	r	_	_	
37-146	14679-14680	~	_	_	
37-147	14680-14683	0.8	_	_	
37-148	14683-14684	)	_	_	
37-149	14684-14685	.	_	_	
37-150	14686-14690	Thus	_	_	
37-151	14690-14691	,	_	_	
37-152	14692-14694	as	_	_	
37-153	14695-14696	a	_	_	
37-154	14697-14711	data-reduction	_	_	
37-155	14712-14716	step	_	_	
37-156	14717-14719	we	_	_	
37-157	14720-14729	performed	_	_	
37-158	14730-14739	principal	_	_	
37-159	14740-14749	component	_	_	
37-160	14750-14758	analyses	_	_	
37-161	14759-14760	(	_	_	
37-162	14760-14763	PCA	_	_	
37-163	14763-14764	)	_	_	
37-164	14765-14769	with	_	_	
37-165	14770-14777	varimax	_	_	
37-166	14778-14786	rotation	_	_	
37-167	14786-14787	,	_	_	
37-168	14788-14798	separately	_	_	
37-169	14799-14802	for	_	_	
37-170	14803-14807	BPND	_	_	
37-171	14808-14811	and	_	_	
37-172	14812-14817	ΔBPND	_	_	
37-173	14817-14818	,	_	_	
37-174	14819-14825	across	_	_	
37-175	14826-14833	regions	_	_	
37-176	14833-14834	.	_	_	
37-177	14835-14839	Horn	_	_	
37-178	14839-14840	’	_	_	
37-179	14840-14841	s	_	_	
37-180	14842-14850	parallel	_	_	
37-181	14851-14859	analyses	_	_	
37-182	14860-14867	yielded	_	_	
37-183	14868-14869	a	_	_	
37-184	14870-14871	1	_	_	
37-185	14871-14872	-	_	_	
37-186	14872-14878	factor	_	_	
37-187	14879-14887	solution	_	_	
37-188	14888-14891	for	_	_	
37-189	14892-14900	baseline	_	_	
37-190	14901-14905	BPND	_	_	
37-191	14906-14907	(	_	_	
37-192	14907-14920	corresponding	_	_	
37-193	14921-14923	to	_	_	
37-194	14924-14927	D2R	_	_	
37-195	14928-14935	density	_	_	
37-196	14936-14942	across	_	_	
37-197	14943-14946	all	_	_	
37-198	14947-14954	regions	_	_	
37-199	14954-14955	)	_	_	
37-200	14956-14959	and	_	_	
37-201	14960-14961	a	_	_	
37-202	14962-14963	1	_	_	
37-203	14963-14964	-	_	_	
37-204	14964-14970	factor	_	_	
37-205	14971-14979	solution	_	_	
37-206	14980-14983	for	_	_	
37-207	14984-14989	ΔBPND	_	_	
37-208	14990-14991	(	_	_	
37-209	14991-15004	corresponding	_	_	
37-210	15005-15007	to	_	_	
37-211	15008-15016	dopamine	_	_	
37-212	15017-15024	release	_	_	
37-213	15025-15031	across	_	_	
37-214	15032-15035	all	_	_	
37-215	15036-15043	regions	_	_	
37-216	15043-15044	)	_	_	
37-217	15044-15045	.	_	_	
37-218	15046-15049	For	_	_	
37-219	15050-15063	correlational	_	_	
37-220	15064-15072	analyses	_	_	
37-221	15072-15073	,	_	_	
37-222	15074-15084	individual	_	_	
37-223	15085-15091	factor	_	_	
37-224	15092-15098	scores	_	_	
37-225	15099-15103	were	_	_	
37-226	15104-15114	calculated	_	_	
37-227	15115-15117	as	_	_	
37-228	15118-15121	the	_	_	
37-229	15122-15130	weighted	_	_	
37-230	15131-15134	sum	_	_	
37-231	15135-15137	of	_	_	
37-232	15138-15144	factor	_	_	
37-233	15145-15153	loadings	_	_	
37-234	15154-15156	by	_	_	
37-235	15157-15160	the	_	_	
37-236	15161-15164	PET	_	_	
37-237	15165-15173	measures	_	_	
37-238	15174-15175	(	_	_	
37-239	15175-15179	BPND	_	_	
37-240	15180-15182	or	_	_	
37-241	15183-15188	ΔBPND	_	_	
37-242	15188-15189	)	_	_	
37-243	15190-15196	across	_	_	
37-244	15197-15201	ROIs	_	_	
37-245	15201-15202	.	_	_	

#Text=RESULTS
38-1	15203-15210	RESULTS	_	_	

#Text=Sociodemographic and clinical characteristics
39-1	15211-15227	Sociodemographic	_	_	
39-2	15228-15231	and	_	_	
39-3	15232-15240	clinical	_	_	
39-4	15241-15256	characteristics	_	_	

#Text=Groups were matched for sociodemographic characteristics, nicotine smoking, and head motion after scrubbing (Table 1). Clinical characteristics are also shown in Table 1.
40-1	15257-15263	Groups	_	_	
40-2	15264-15268	were	_	_	
40-3	15269-15276	matched	_	_	
40-4	15277-15280	for	_	_	
40-5	15281-15297	sociodemographic	_	_	
40-6	15298-15313	characteristics	_	_	
40-7	15313-15314	,	_	_	
40-8	15315-15323	nicotine	_	_	
40-9	15324-15331	smoking	_	_	
40-10	15331-15332	,	_	_	
40-11	15333-15336	and	_	_	
40-12	15337-15341	head	_	_	
40-13	15342-15348	motion	_	_	
40-14	15349-15354	after	_	_	
40-15	15355-15364	scrubbing	_	_	
40-16	15365-15366	(	_	_	
40-17	15366-15371	Table	_	_	
40-18	15372-15373	1	_	_	
40-19	15373-15374	)	_	_	
40-20	15374-15375	.	_	_	
40-21	15376-15384	Clinical	_	_	
40-22	15385-15400	characteristics	_	_	
40-23	15401-15404	are	_	_	
40-24	15405-15409	also	_	_	
40-25	15410-15415	shown	_	_	
40-26	15416-15418	in	_	_	
40-27	15419-15424	Table	_	_	
40-28	15425-15426	1	_	_	
40-29	15426-15427	.	_	_	

#Text=Functional topography of striatal connections (multivariate fMRI analysis)
41-1	15428-15438	Functional	_	_	
41-2	15439-15449	topography	_	_	
41-3	15450-15452	of	_	_	
41-4	15453-15461	striatal	_	_	
41-5	15462-15473	connections	_	_	
41-6	15474-15475	(	_	_	
41-7	15475-15487	multivariate	_	_	
41-8	15488-15492	fMRI	_	_	
41-9	15493-15501	analysis	_	_	
41-10	15501-15502	)	_	_	

#Text=The pattern of connection strengths across striatal-target pairs differed numerically between the groups, particularly for the anterior caudate (Fig. 1). Statistically, the logistic-regression model that best explained group membership (χ2 (29)=53.55, p=0.0036, likelihood-ratio [omnibus] test) was one that included all connection pairs related to the anterior caudate (with 24 pairs) and posterior caudate (with 5 pairs; Fig. 1). Thus, the pattern of functional connections between the caudate and specific regions of the cortex and thalamus was abnormal in patients. Cortical regions individually contributing to this effect included prefrontal (BAs 8, 10, 44), sensory association (BAs 20, 22, 19, and 7), posterior cingulate (BA 23), and entorhinal (BA 28) cortices. The log odds of belonging to the healthy group did not relate to medication status or age (all p>0.19).
42-1	15503-15506	The	_	_	
42-2	15507-15514	pattern	_	_	
42-3	15515-15517	of	_	_	
42-4	15518-15528	connection	_	_	
42-5	15529-15538	strengths	_	_	
42-6	15539-15545	across	_	_	
42-7	15546-15561	striatal-target	_	_	
42-8	15562-15567	pairs	_	_	
42-9	15568-15576	differed	_	_	
42-10	15577-15588	numerically	_	_	
42-11	15589-15596	between	_	_	
42-12	15597-15600	the	_	_	
42-13	15601-15607	groups	_	_	
42-14	15607-15608	,	_	_	
42-15	15609-15621	particularly	_	_	
42-16	15622-15625	for	_	_	
42-17	15626-15629	the	_	_	
42-18	15630-15638	anterior	_	_	
42-19	15639-15646	caudate	_	_	
42-20	15647-15648	(	_	_	
42-21	15648-15651	Fig	_	_	
42-22	15651-15652	.	_	_	
42-23	15653-15654	1	_	_	
42-24	15654-15655	)	_	_	
42-25	15655-15656	.	_	_	
42-26	15657-15670	Statistically	_	_	
42-27	15670-15671	,	_	_	
42-28	15672-15675	the	_	_	
42-29	15676-15695	logistic-regression	_	_	
42-30	15696-15701	model	_	_	
42-31	15702-15706	that	_	_	
42-32	15707-15711	best	_	_	
42-33	15712-15721	explained	_	_	
42-34	15722-15727	group	_	_	
42-35	15728-15738	membership	_	_	
42-36	15739-15740	(	_	_	
42-37	15740-15742	χ2	_	_	
42-38	15743-15744	(	_	_	
42-39	15744-15746	29	_	_	
42-40	15746-15747	)	_	_	
42-41	15747-15748	=	_	_	
42-42	15748-15753	53.55	_	_	
42-43	15753-15754	,	_	_	
42-44	15755-15756	p	_	_	
42-45	15756-15757	=	_	_	
42-46	15757-15763	0.0036	_	_	
42-47	15763-15764	,	_	_	
42-48	15765-15781	likelihood-ratio	_	_	
42-49	15782-15783	[	_	_	
42-50	15783-15790	omnibus	_	_	
42-51	15790-15791	]	_	_	
42-52	15792-15796	test	_	_	
42-53	15796-15797	)	_	_	
42-54	15798-15801	was	_	_	
42-55	15802-15805	one	_	_	
42-56	15806-15810	that	_	_	
42-57	15811-15819	included	_	_	
42-58	15820-15823	all	_	_	
42-59	15824-15834	connection	_	_	
42-60	15835-15840	pairs	_	_	
42-61	15841-15848	related	_	_	
42-62	15849-15851	to	_	_	
42-63	15852-15855	the	_	_	
42-64	15856-15864	anterior	_	_	
42-65	15865-15872	caudate	_	_	
42-66	15873-15874	(	_	_	
42-67	15874-15878	with	_	_	
42-68	15879-15881	24	_	_	
42-69	15882-15887	pairs	_	_	
42-70	15887-15888	)	_	_	
42-71	15889-15892	and	_	_	
42-72	15893-15902	posterior	_	_	
42-73	15903-15910	caudate	_	_	
42-74	15911-15912	(	_	_	
42-75	15912-15916	with	_	_	
42-76	15917-15918	5	_	_	
42-77	15919-15924	pairs	_	_	
42-78	15924-15925	;	_	_	
42-79	15926-15929	Fig	_	_	
42-80	15929-15930	.	_	_	
42-81	15931-15932	1	_	_	
42-82	15932-15933	)	_	_	
42-83	15933-15934	.	_	_	
42-84	15935-15939	Thus	_	_	
42-85	15939-15940	,	_	_	
42-86	15941-15944	the	_	_	
42-87	15945-15952	pattern	_	_	
42-88	15953-15955	of	_	_	
42-89	15956-15966	functional	_	_	
42-90	15967-15978	connections	_	_	
42-91	15979-15986	between	_	_	
42-92	15987-15990	the	_	_	
42-93	15991-15998	caudate	_	_	
42-94	15999-16002	and	_	_	
42-95	16003-16011	specific	_	_	
42-96	16012-16019	regions	_	_	
42-97	16020-16022	of	_	_	
42-98	16023-16026	the	_	_	
42-99	16027-16033	cortex	_	_	
42-100	16034-16037	and	_	_	
42-101	16038-16046	thalamus	_	_	
42-102	16047-16050	was	_	_	
42-103	16051-16059	abnormal	_	_	
42-104	16060-16062	in	_	_	
42-105	16063-16071	patients	_	_	
42-106	16071-16072	.	_	_	
42-107	16073-16081	Cortical	_	_	
42-108	16082-16089	regions	_	_	
42-109	16090-16102	individually	_	_	
42-110	16103-16115	contributing	_	_	
42-111	16116-16118	to	_	_	
42-112	16119-16123	this	_	_	
42-113	16124-16130	effect	_	_	
42-114	16131-16139	included	_	_	
42-115	16140-16150	prefrontal	_	_	
42-116	16151-16152	(	_	_	
42-117	16152-16155	BAs	_	_	
42-118	16156-16157	8	_	_	
42-119	16157-16158	,	_	_	
42-120	16159-16161	10	_	_	
42-121	16161-16162	,	_	_	
42-122	16163-16165	44	_	_	
42-123	16165-16166	)	_	_	
42-124	16166-16167	,	_	_	
42-125	16168-16175	sensory	_	_	
42-126	16176-16187	association	_	_	
42-127	16188-16189	(	_	_	
42-128	16189-16192	BAs	_	_	
42-129	16193-16195	20	_	_	
42-130	16195-16196	,	_	_	
42-131	16197-16199	22	_	_	
42-132	16199-16200	,	_	_	
42-133	16201-16203	19	_	_	
42-134	16203-16204	,	_	_	
42-135	16205-16208	and	_	_	
42-136	16209-16210	7	_	_	
42-137	16210-16211	)	_	_	
42-138	16211-16212	,	_	_	
42-139	16213-16222	posterior	_	_	
42-140	16223-16232	cingulate	_	_	
42-141	16233-16234	(	_	_	
42-142	16234-16236	BA	_	_	
42-143	16237-16239	23	_	_	
42-144	16239-16240	)	_	_	
42-145	16240-16241	,	_	_	
42-146	16242-16245	and	_	_	
42-147	16246-16256	entorhinal	_	_	
42-148	16257-16258	(	_	_	
42-149	16258-16260	BA	_	_	
42-150	16261-16263	28	_	_	
42-151	16263-16264	)	_	_	
42-152	16265-16273	cortices	_	_	
42-153	16273-16274	.	_	_	
42-154	16275-16278	The	_	_	
42-155	16279-16282	log	_	_	
42-156	16283-16287	odds	_	_	
42-157	16288-16290	of	_	_	
42-158	16291-16300	belonging	_	_	
42-159	16301-16303	to	_	_	
42-160	16304-16307	the	_	_	
42-161	16308-16315	healthy	_	_	
42-162	16316-16321	group	_	_	
42-163	16322-16325	did	_	_	
42-164	16326-16329	not	_	_	
42-165	16330-16336	relate	_	_	
42-166	16337-16339	to	_	_	
42-167	16340-16350	medication	_	_	
42-168	16351-16357	status	_	_	
42-169	16358-16360	or	_	_	
42-170	16361-16364	age	_	_	
42-171	16365-16366	(	_	_	
42-172	16366-16369	all	_	_	
42-173	16370-16371	p	_	_	
42-174	16371-16372	>	_	_	
42-175	16372-16376	0.19	_	_	
42-176	16376-16377	)	_	_	
42-177	16377-16378	.	_	_	

#Text=Alternative definitions of the relevant target regions yielded similar results (Supplement). Additional analyses suggested that, although connectivity patterns for each striatal subregion could separately predict group membership, that associated with posterior caudate was most discriminative (Supplement). Finally, an RFE-SVM classifier discriminated patients and controls above chance based on the global pattern of striatal connectivity (including pairs for all subregions except for the ventral striatum; eFigure 1).
43-1	16379-16390	Alternative	_	_	
43-2	16391-16402	definitions	_	_	
43-3	16403-16405	of	_	_	
43-4	16406-16409	the	_	_	
43-5	16410-16418	relevant	_	_	
43-6	16419-16425	target	_	_	
43-7	16426-16433	regions	_	_	
43-8	16434-16441	yielded	_	_	
43-9	16442-16449	similar	_	_	
43-10	16450-16457	results	_	_	
43-11	16458-16459	(	_	_	
43-12	16459-16469	Supplement	_	_	
43-13	16469-16470	)	_	_	
43-14	16470-16471	.	_	_	
43-15	16472-16482	Additional	_	_	
43-16	16483-16491	analyses	_	_	
43-17	16492-16501	suggested	_	_	
43-18	16502-16506	that	_	_	
43-19	16506-16507	,	_	_	
43-20	16508-16516	although	_	_	
43-21	16517-16529	connectivity	_	_	
43-22	16530-16538	patterns	_	_	
43-23	16539-16542	for	_	_	
43-24	16543-16547	each	_	_	
43-25	16548-16556	striatal	_	_	
43-26	16557-16566	subregion	_	_	
43-27	16567-16572	could	_	_	
43-28	16573-16583	separately	_	_	
43-29	16584-16591	predict	_	_	
43-30	16592-16597	group	_	_	
43-31	16598-16608	membership	_	_	
43-32	16608-16609	,	_	_	
43-33	16610-16614	that	_	_	
43-34	16615-16625	associated	_	_	
43-35	16626-16630	with	_	_	
43-36	16631-16640	posterior	_	_	
43-37	16641-16648	caudate	_	_	
43-38	16649-16652	was	_	_	
43-39	16653-16657	most	_	_	
43-40	16658-16672	discriminative	_	_	
43-41	16673-16674	(	_	_	
43-42	16674-16684	Supplement	_	_	
43-43	16684-16685	)	_	_	
43-44	16685-16686	.	_	_	
43-45	16687-16694	Finally	_	_	
43-46	16694-16695	,	_	_	
43-47	16696-16698	an	_	_	
43-48	16699-16706	RFE-SVM	_	_	
43-49	16707-16717	classifier	_	_	
43-50	16718-16731	discriminated	_	_	
43-51	16732-16740	patients	_	_	
43-52	16741-16744	and	_	_	
43-53	16745-16753	controls	_	_	
43-54	16754-16759	above	_	_	
43-55	16760-16766	chance	_	_	
43-56	16767-16772	based	_	_	
43-57	16773-16775	on	_	_	
43-58	16776-16779	the	_	_	
43-59	16780-16786	global	_	_	
43-60	16787-16794	pattern	_	_	
43-61	16795-16797	of	_	_	
43-62	16798-16806	striatal	_	_	
43-63	16807-16819	connectivity	_	_	
43-64	16820-16821	(	_	_	
43-65	16821-16830	including	_	_	
43-66	16831-16836	pairs	_	_	
43-67	16837-16840	for	_	_	
43-68	16841-16844	all	_	_	
43-69	16845-16855	subregions	_	_	
43-70	16856-16862	except	_	_	
43-71	16863-16866	for	_	_	
43-72	16867-16870	the	_	_	
43-73	16871-16878	ventral	_	_	
43-74	16879-16887	striatum	_	_	
43-75	16887-16888	;	_	_	
43-76	16889-16896	eFigure	_	_	
43-77	16897-16898	1	_	_	
43-78	16898-16899	)	_	_	
43-79	16899-16900	.	_	_	

#Text=Clinical correlations
44-1	16901-16909	Clinical	_	_	
44-2	16910-16922	correlations	_	_	

#Text=Patients with a more abnormal (less control-like) striatal connectivity pattern (i.e., lower log odds of belonging to the healthy control group) had more severe positive symptoms (PANSS-PT: ρ=−0.76, p=0.0011; SAPS: ρ=−0.66, p=0.0076; Fig. 2A). This correlation was not observed with negative symptoms (PANSS-NT: ρ=−0.24, p=0.39; SANS: ρ=0.01, p=0.96; Fig. 2B). Furthermore, the correlation with PANSS-PT held after controlling for PANSS-NT and fMRI-data-quality scores (ρ=−0.77, p=0.0021). Alternative analyses cross-validated this finding (Supplement). PANSS-PT and PANSS-NT scores were not correlated among patients (ρ=0.31, p=0.26).
45-1	16923-16931	Patients	_	_	
45-2	16932-16936	with	_	_	
45-3	16937-16938	a	_	_	
45-4	16939-16943	more	_	_	
45-5	16944-16952	abnormal	_	_	
45-6	16953-16954	(	_	_	
45-7	16954-16958	less	_	_	
45-8	16959-16971	control-like	_	_	
45-9	16971-16972	)	_	_	
45-10	16973-16981	striatal	_	_	
45-11	16982-16994	connectivity	_	_	
45-12	16995-17002	pattern	_	_	
45-13	17003-17004	(	_	_	
45-14	17004-17007	i.e	_	_	
45-15	17007-17008	.	_	_	
45-16	17008-17009	,	_	_	
45-17	17010-17015	lower	_	_	
45-18	17016-17019	log	_	_	
45-19	17020-17024	odds	_	_	
45-20	17025-17027	of	_	_	
45-21	17028-17037	belonging	_	_	
45-22	17038-17040	to	_	_	
45-23	17041-17044	the	_	_	
45-24	17045-17052	healthy	_	_	
45-25	17053-17060	control	_	_	
45-26	17061-17066	group	_	_	
45-27	17066-17067	)	_	_	
45-28	17068-17071	had	_	_	
45-29	17072-17076	more	_	_	
45-30	17077-17083	severe	_	_	
45-31	17084-17092	positive	_	_	
45-32	17093-17101	symptoms	_	_	
45-33	17102-17103	(	_	_	
45-34	17103-17111	PANSS-PT	_	_	
45-35	17111-17112	:	_	_	
45-36	17113-17114	ρ	_	_	
45-37	17114-17115	=	_	_	
45-38	17115-17116	−	_	_	
45-39	17116-17120	0.76	_	_	
45-40	17120-17121	,	_	_	
45-41	17122-17123	p	_	_	
45-42	17123-17124	=	_	_	
45-43	17124-17130	0.0011	_	_	
45-44	17130-17131	;	_	_	
45-45	17132-17136	SAPS	_	_	
45-46	17136-17137	:	_	_	
45-47	17138-17139	ρ	_	_	
45-48	17139-17140	=	_	_	
45-49	17140-17141	−	_	_	
45-50	17141-17145	0.66	_	_	
45-51	17145-17146	,	_	_	
45-52	17147-17148	p	_	_	
45-53	17148-17149	=	_	_	
45-54	17149-17155	0.0076	_	_	
45-55	17155-17156	;	_	_	
45-56	17157-17160	Fig	_	_	
45-57	17160-17161	.	_	_	
45-58	17162-17164	2A	_	_	
45-59	17164-17165	)	_	_	
45-60	17165-17166	.	_	_	
45-61	17167-17171	This	_	_	
45-62	17172-17183	correlation	_	_	
45-63	17184-17187	was	_	_	
45-64	17188-17191	not	_	_	
45-65	17192-17200	observed	_	_	
45-66	17201-17205	with	_	_	
45-67	17206-17214	negative	_	_	
45-68	17215-17223	symptoms	_	_	
45-69	17224-17225	(	_	_	
45-70	17225-17233	PANSS-NT	_	_	
45-71	17233-17234	:	_	_	
45-72	17235-17236	ρ	_	_	
45-73	17236-17237	=	_	_	
45-74	17237-17238	−	_	_	
45-75	17238-17242	0.24	_	_	
45-76	17242-17243	,	_	_	
45-77	17244-17245	p	_	_	
45-78	17245-17246	=	_	_	
45-79	17246-17250	0.39	_	_	
45-80	17250-17251	;	_	_	
45-81	17252-17256	SANS	_	_	
45-82	17256-17257	:	_	_	
45-83	17258-17259	ρ	_	_	
45-84	17259-17260	=	_	_	
45-85	17260-17264	0.01	_	_	
45-86	17264-17265	,	_	_	
45-87	17266-17267	p	_	_	
45-88	17267-17268	=	_	_	
45-89	17268-17272	0.96	_	_	
45-90	17272-17273	;	_	_	
45-91	17274-17277	Fig	_	_	
45-92	17277-17278	.	_	_	
45-93	17279-17281	2B	_	_	
45-94	17281-17282	)	_	_	
45-95	17282-17283	.	_	_	
45-96	17284-17295	Furthermore	_	_	
45-97	17295-17296	,	_	_	
45-98	17297-17300	the	_	_	
45-99	17301-17312	correlation	_	_	
45-100	17313-17317	with	_	_	
45-101	17318-17326	PANSS-PT	_	_	
45-102	17327-17331	held	_	_	
45-103	17332-17337	after	_	_	
45-104	17338-17349	controlling	_	_	
45-105	17350-17353	for	_	_	
45-106	17354-17362	PANSS-NT	_	_	
45-107	17363-17366	and	_	_	
45-108	17367-17384	fMRI-data-quality	_	_	
45-109	17385-17391	scores	_	_	
45-110	17392-17393	(	_	_	
45-111	17393-17394	ρ	_	_	
45-112	17394-17395	=	_	_	
45-113	17395-17396	−	_	_	
45-114	17396-17400	0.77	_	_	
45-115	17400-17401	,	_	_	
45-116	17402-17403	p	_	_	
45-117	17403-17404	=	_	_	
45-118	17404-17410	0.0021	_	_	
45-119	17410-17411	)	_	_	
45-120	17411-17412	.	_	_	
45-121	17413-17424	Alternative	_	_	
45-122	17425-17433	analyses	_	_	
45-123	17434-17449	cross-validated	_	_	
45-124	17450-17454	this	_	_	
45-125	17455-17462	finding	_	_	
45-126	17463-17464	(	_	_	
45-127	17464-17474	Supplement	_	_	
45-128	17474-17475	)	_	_	
45-129	17475-17476	.	_	_	
45-130	17477-17485	PANSS-PT	_	_	
45-131	17486-17489	and	_	_	
45-132	17490-17498	PANSS-NT	_	_	
45-133	17499-17505	scores	_	_	
45-134	17506-17510	were	_	_	
45-135	17511-17514	not	_	_	
45-136	17515-17525	correlated	_	_	
45-137	17526-17531	among	_	_	
45-138	17532-17540	patients	_	_	
45-139	17541-17542	(	_	_	
45-140	17542-17543	ρ	_	_	
45-141	17543-17544	=	_	_	
45-142	17544-17548	0.31	_	_	
45-143	17548-17549	,	_	_	
45-144	17550-17551	p	_	_	
45-145	17551-17552	=	_	_	
45-146	17552-17556	0.26	_	_	
45-147	17556-17557	)	_	_	
45-148	17557-17558	.	_	_	

#Text=Correlations with [11C]FLB457 PET measures
46-1	17559-17571	Correlations	_	_	
46-2	17572-17576	with	_	_	
46-3	17577-17578	[	_	_	
46-4	17578-17581	11C	_	_	
46-5	17581-17582	]	_	_	
46-6	17582-17588	FLB457	_	_	
46-7	17589-17592	PET	_	_	
46-8	17593-17601	measures	_	_	

#Text=We found that more control-like striatal connectivity patterns correlated with higher baseline BPND principal-component scores, even after adjusting for fMRI-data-quality scores and group (beta=0.27, t(25)=3.01, p=0.0058, p=0.0116 Bonferroni-corrected; Fig. 2C), but no interaction of connectivity-pattern-by-group or significant relationships with ΔBPND. Excluding a potentially influential outlier did not alter this result (p=0.002). This effect was also apparent within patients only (p=0.0051) and was corroborated by alternative analyses and across individual regions (Supplement). Age was unrelated to the PET measures (all p>0.1). Baseline BPND principal-component scores were similar in both groups (t(27)=0.76, p=0.45).
47-1	17602-17604	We	_	_	
47-2	17605-17610	found	_	_	
47-3	17611-17615	that	_	_	
47-4	17616-17620	more	_	_	
47-5	17621-17633	control-like	_	_	
47-6	17634-17642	striatal	_	_	
47-7	17643-17655	connectivity	_	_	
47-8	17656-17664	patterns	_	_	
47-9	17665-17675	correlated	_	_	
47-10	17676-17680	with	_	_	
47-11	17681-17687	higher	_	_	
47-12	17688-17696	baseline	_	_	
47-13	17697-17701	BPND	_	_	
47-14	17702-17721	principal-component	_	_	
47-15	17722-17728	scores	_	_	
47-16	17728-17729	,	_	_	
47-17	17730-17734	even	_	_	
47-18	17735-17740	after	_	_	
47-19	17741-17750	adjusting	_	_	
47-20	17751-17754	for	_	_	
47-21	17755-17772	fMRI-data-quality	_	_	
47-22	17773-17779	scores	_	_	
47-23	17780-17783	and	_	_	
47-24	17784-17789	group	_	_	
47-25	17790-17791	(	_	_	
47-26	17791-17795	beta	_	_	
47-27	17795-17796	=	_	_	
47-28	17796-17800	0.27	_	_	
47-29	17800-17801	,	_	_	
47-30	17802-17803	t	_	_	
47-31	17803-17804	(	_	_	
47-32	17804-17806	25	_	_	
47-33	17806-17807	)	_	_	
47-34	17807-17808	=	_	_	
47-35	17808-17812	3.01	_	_	
47-36	17812-17813	,	_	_	
47-37	17814-17815	p	_	_	
47-38	17815-17816	=	_	_	
47-39	17816-17822	0.0058	_	_	
47-40	17822-17823	,	_	_	
47-41	17824-17825	p	_	_	
47-42	17825-17826	=	_	_	
47-43	17826-17832	0.0116	_	_	
47-44	17833-17853	Bonferroni-corrected	_	_	
47-45	17853-17854	;	_	_	
47-46	17855-17858	Fig	_	_	
47-47	17858-17859	.	_	_	
47-48	17860-17862	2C	_	_	
47-49	17862-17863	)	_	_	
47-50	17863-17864	,	_	_	
47-51	17865-17868	but	_	_	
47-52	17869-17871	no	_	_	
47-53	17872-17883	interaction	_	_	
47-54	17884-17886	of	_	_	
47-55	17887-17916	connectivity-pattern-by-group	_	_	
47-56	17917-17919	or	_	_	
47-57	17920-17931	significant	_	_	
47-58	17932-17945	relationships	_	_	
47-59	17946-17950	with	_	_	
47-60	17951-17956	ΔBPND	_	_	
47-61	17956-17957	.	_	_	
47-62	17958-17967	Excluding	_	_	
47-63	17968-17969	a	_	_	
47-64	17970-17981	potentially	_	_	
47-65	17982-17993	influential	_	_	
47-66	17994-18001	outlier	_	_	
47-67	18002-18005	did	_	_	
47-68	18006-18009	not	_	_	
47-69	18010-18015	alter	_	_	
47-70	18016-18020	this	_	_	
47-71	18021-18027	result	_	_	
47-72	18028-18029	(	_	_	
47-73	18029-18030	p	_	_	
47-74	18030-18031	=	_	_	
47-75	18031-18036	0.002	_	_	
47-76	18036-18037	)	_	_	
47-77	18037-18038	.	_	_	
47-78	18039-18043	This	_	_	
47-79	18044-18050	effect	_	_	
47-80	18051-18054	was	_	_	
47-81	18055-18059	also	_	_	
47-82	18060-18068	apparent	_	_	
47-83	18069-18075	within	_	_	
47-84	18076-18084	patients	_	_	
47-85	18085-18089	only	_	_	
47-86	18090-18091	(	_	_	
47-87	18091-18092	p	_	_	
47-88	18092-18093	=	_	_	
47-89	18093-18099	0.0051	_	_	
47-90	18099-18100	)	_	_	
47-91	18101-18104	and	_	_	
47-92	18105-18108	was	_	_	
47-93	18109-18121	corroborated	_	_	
47-94	18122-18124	by	_	_	
47-95	18125-18136	alternative	_	_	
47-96	18137-18145	analyses	_	_	
47-97	18146-18149	and	_	_	
47-98	18150-18156	across	_	_	
47-99	18157-18167	individual	_	_	
47-100	18168-18175	regions	_	_	
47-101	18176-18177	(	_	_	
47-102	18177-18187	Supplement	_	_	
47-103	18187-18188	)	_	_	
47-104	18188-18189	.	_	_	
47-105	18190-18193	Age	_	_	
47-106	18194-18197	was	_	_	
47-107	18198-18207	unrelated	_	_	
47-108	18208-18210	to	_	_	
47-109	18211-18214	the	_	_	
47-110	18215-18218	PET	_	_	
47-111	18219-18227	measures	_	_	
47-112	18228-18229	(	_	_	
47-113	18229-18232	all	_	_	
47-114	18233-18234	p	_	_	
47-115	18234-18235	>	_	_	
47-116	18235-18238	0.1	_	_	
47-117	18238-18239	)	_	_	
47-118	18239-18240	.	_	_	
47-119	18241-18249	Baseline	_	_	
47-120	18250-18254	BPND	_	_	
47-121	18255-18274	principal-component	_	_	
47-122	18275-18281	scores	_	_	
47-123	18282-18286	were	_	_	
47-124	18287-18294	similar	_	_	
47-125	18295-18297	in	_	_	
47-126	18298-18302	both	_	_	
47-127	18303-18309	groups	_	_	
47-128	18310-18311	(	_	_	
47-129	18311-18312	t	_	_	
47-130	18312-18313	(	_	_	
47-131	18313-18315	27	_	_	
47-132	18315-18316	)	_	_	
47-133	18316-18317	=	_	_	
47-134	18317-18321	0.76	_	_	
47-135	18321-18322	,	_	_	
47-136	18323-18324	p	_	_	
47-137	18324-18325	=	_	_	
47-138	18325-18329	0.45	_	_	
47-139	18329-18330	)	_	_	
47-140	18330-18331	.	_	_	

#Text=Exploratory correlations with neurocognitive measures
48-1	18332-18343	Exploratory	_	_	
48-2	18344-18356	correlations	_	_	
48-3	18357-18361	with	_	_	
48-4	18362-18376	neurocognitive	_	_	
48-5	18377-18385	measures	_	_	

#Text=Exploratory analyses showed a correlation between abnormal striatal connectivity patterns and worse MATRICS composite scores in patients (ρ=0.6809, p=0.0302) but not in controls.
49-1	18386-18397	Exploratory	_	_	
49-2	18398-18406	analyses	_	_	
49-3	18407-18413	showed	_	_	
49-4	18414-18415	a	_	_	
49-5	18416-18427	correlation	_	_	
49-6	18428-18435	between	_	_	
49-7	18436-18444	abnormal	_	_	
49-8	18445-18453	striatal	_	_	
49-9	18454-18466	connectivity	_	_	
49-10	18467-18475	patterns	_	_	
49-11	18476-18479	and	_	_	
49-12	18480-18485	worse	_	_	
49-13	18486-18493	MATRICS	_	_	
49-14	18494-18503	composite	_	_	
49-15	18504-18510	scores	_	_	
49-16	18511-18513	in	_	_	
49-17	18514-18522	patients	_	_	
49-18	18523-18524	(	_	_	
49-19	18524-18525	ρ	_	_	
49-20	18525-18526	=	_	_	
49-21	18526-18532	0.6809	_	_	
49-22	18532-18533	,	_	_	
49-23	18534-18535	p	_	_	
49-24	18535-18536	=	_	_	
49-25	18536-18542	0.0302	_	_	
49-26	18542-18543	)	_	_	
49-27	18544-18547	but	_	_	
49-28	18548-18551	not	_	_	
49-29	18552-18554	in	_	_	
49-30	18555-18563	controls	_	_	
49-31	18563-18564	.	_	_	

#Text=Exploratory analyses of univariate voxelwise functional connectivity and global-brain-connectivity (GBC)
50-1	18565-18576	Exploratory	_	_	
50-2	18577-18585	analyses	_	_	
50-3	18586-18588	of	_	_	
50-4	18589-18599	univariate	_	_	
50-5	18600-18609	voxelwise	_	_	
50-6	18610-18620	functional	_	_	
50-7	18621-18633	connectivity	_	_	
50-8	18634-18637	and	_	_	
50-9	18638-18663	global-brain-connectivity	_	_	
50-10	18664-18665	(	_	_	
50-11	18665-18668	GBC	_	_	
50-12	18668-18669	)	_	_	

#Text=A test of the group-by-striatal-subregion interaction did not yield significant results, nor did the group effects for individual subregions (Supplement). In healthy controls, but not in patients, the anterior caudate showed significantly stronger connectivity than any of the other subregions to prefrontal, parietal, and temporal association cortices, as well as to the thalamus (all p<0.05, FDR-corrected; Fig. 3). However, the group difference was not significant. Finally, the anterior caudate had higher GBC (eMethods) or weighted degree centrality, a graph-theoretic index of “hubness”, than the other striatal subregions (all p<0.0162; Fig. 4). GBC of the anterior caudate was numerically but not significantly reduced in patients (Supplement).
51-1	18670-18671	A	_	_	
51-2	18672-18676	test	_	_	
51-3	18677-18679	of	_	_	
51-4	18680-18683	the	_	_	
51-5	18684-18711	group-by-striatal-subregion	_	_	
51-6	18712-18723	interaction	_	_	
51-7	18724-18727	did	_	_	
51-8	18728-18731	not	_	_	
51-9	18732-18737	yield	_	_	
51-10	18738-18749	significant	_	_	
51-11	18750-18757	results	_	_	
51-12	18757-18758	,	_	_	
51-13	18759-18762	nor	_	_	
51-14	18763-18766	did	_	_	
51-15	18767-18770	the	_	_	
51-16	18771-18776	group	_	_	
51-17	18777-18784	effects	_	_	
51-18	18785-18788	for	_	_	
51-19	18789-18799	individual	_	_	
51-20	18800-18810	subregions	_	_	
51-21	18811-18812	(	_	_	
51-22	18812-18822	Supplement	_	_	
51-23	18822-18823	)	_	_	
51-24	18823-18824	.	_	_	
51-25	18825-18827	In	_	_	
51-26	18828-18835	healthy	_	_	
51-27	18836-18844	controls	_	_	
51-28	18844-18845	,	_	_	
51-29	18846-18849	but	_	_	
51-30	18850-18853	not	_	_	
51-31	18854-18856	in	_	_	
51-32	18857-18865	patients	_	_	
51-33	18865-18866	,	_	_	
51-34	18867-18870	the	_	_	
51-35	18871-18879	anterior	_	_	
51-36	18880-18887	caudate	_	_	
51-37	18888-18894	showed	_	_	
51-38	18895-18908	significantly	_	_	
51-39	18909-18917	stronger	_	_	
51-40	18918-18930	connectivity	_	_	
51-41	18931-18935	than	_	_	
51-42	18936-18939	any	_	_	
51-43	18940-18942	of	_	_	
51-44	18943-18946	the	_	_	
51-45	18947-18952	other	_	_	
51-46	18953-18963	subregions	_	_	
51-47	18964-18966	to	_	_	
51-48	18967-18977	prefrontal	_	_	
51-49	18977-18978	,	_	_	
51-50	18979-18987	parietal	_	_	
51-51	18987-18988	,	_	_	
51-52	18989-18992	and	_	_	
51-53	18993-19001	temporal	_	_	
51-54	19002-19013	association	_	_	
51-55	19014-19022	cortices	_	_	
51-56	19022-19023	,	_	_	
51-57	19024-19026	as	_	_	
51-58	19027-19031	well	_	_	
51-59	19032-19034	as	_	_	
51-60	19035-19037	to	_	_	
51-61	19038-19041	the	_	_	
51-62	19042-19050	thalamus	_	_	
51-63	19051-19052	(	_	_	
51-64	19052-19055	all	_	_	
51-65	19056-19057	p	_	_	
51-66	19057-19058	<	_	_	
51-67	19058-19062	0.05	_	_	
51-68	19062-19063	,	_	_	
51-69	19064-19077	FDR-corrected	_	_	
51-70	19077-19078	;	_	_	
51-71	19079-19082	Fig	_	_	
51-72	19082-19083	.	_	_	
51-73	19084-19085	3	_	_	
51-74	19085-19086	)	_	_	
51-75	19086-19087	.	_	_	
51-76	19088-19095	However	_	_	
51-77	19095-19096	,	_	_	
51-78	19097-19100	the	_	_	
51-79	19101-19106	group	_	_	
51-80	19107-19117	difference	_	_	
51-81	19118-19121	was	_	_	
51-82	19122-19125	not	_	_	
51-83	19126-19137	significant	_	_	
51-84	19137-19138	.	_	_	
51-85	19139-19146	Finally	_	_	
51-86	19146-19147	,	_	_	
51-87	19148-19151	the	_	_	
51-88	19152-19160	anterior	_	_	
51-89	19161-19168	caudate	_	_	
51-90	19169-19172	had	_	_	
51-91	19173-19179	higher	_	_	
51-92	19180-19183	GBC	_	_	
51-93	19184-19185	(	_	_	
51-94	19185-19193	eMethods	_	_	
51-95	19193-19194	)	_	_	
51-96	19195-19197	or	_	_	
51-97	19198-19206	weighted	_	_	
51-98	19207-19213	degree	_	_	
51-99	19214-19224	centrality	_	_	
51-100	19224-19225	,	_	_	
51-101	19226-19227	a	_	_	
51-102	19228-19243	graph-theoretic	_	_	
51-103	19244-19249	index	_	_	
51-104	19250-19252	of	_	_	
51-105	19253-19254	“	_	_	
51-106	19254-19261	hubness	_	_	
51-107	19261-19262	”	_	_	
51-108	19262-19263	,	_	_	
51-109	19264-19268	than	_	_	
51-110	19269-19272	the	_	_	
51-111	19273-19278	other	_	_	
51-112	19279-19287	striatal	_	_	
51-113	19288-19298	subregions	_	_	
51-114	19299-19300	(	_	_	
51-115	19300-19303	all	_	_	
51-116	19304-19305	p	_	_	
51-117	19305-19306	<	_	_	
51-118	19306-19312	0.0162	_	_	
51-119	19312-19313	;	_	_	
51-120	19314-19317	Fig	_	_	
51-121	19317-19318	.	_	_	
51-122	19319-19320	4	_	_	
51-123	19320-19321	)	_	_	
51-124	19321-19322	.	_	_	
51-125	19323-19326	GBC	_	_	
51-126	19327-19329	of	_	_	
51-127	19330-19333	the	_	_	
51-128	19334-19342	anterior	_	_	
51-129	19343-19350	caudate	_	_	
51-130	19351-19354	was	_	_	
51-131	19355-19366	numerically	_	_	
51-132	19367-19370	but	_	_	
51-133	19371-19374	not	_	_	
51-134	19375-19388	significantly	_	_	
51-135	19389-19396	reduced	_	_	
51-136	19397-19399	in	_	_	
51-137	19400-19408	patients	_	_	
51-138	19409-19410	(	_	_	
51-139	19410-19420	Supplement	_	_	
51-140	19420-19421	)	_	_	
51-141	19421-19422	.	_	_	

#Text=DISCUSSION
52-1	19423-19433	DISCUSSION	_	_	

#Text=Our results show that the normal functional topography of striatal connections, particularly but not solely of caudate connections, is disrupted in schizophrenia. As our sample was comprised exclusively of unmedicated patients, this disruption is unlikely due to antipsychotic medication and may instead be relevant to the pathophysiology of schizophrenia. Further supporting this interpretation, abnormal striatal connectivity correlated with clinical severity, specifically with severity of positive symptoms but not negative symptoms. Finally, abnormal connectivity also correlated with lower density of D2Rs across cortical and extrastriatal subcortical brain regions within the same individuals.
53-1	19434-19437	Our	_	_	
53-2	19438-19445	results	_	_	
53-3	19446-19450	show	_	_	
53-4	19451-19455	that	_	_	
53-5	19456-19459	the	_	_	
53-6	19460-19466	normal	_	_	
53-7	19467-19477	functional	_	_	
53-8	19478-19488	topography	_	_	
53-9	19489-19491	of	_	_	
53-10	19492-19500	striatal	_	_	
53-11	19501-19512	connections	_	_	
53-12	19512-19513	,	_	_	
53-13	19514-19526	particularly	_	_	
53-14	19527-19530	but	_	_	
53-15	19531-19534	not	_	_	
53-16	19535-19541	solely	_	_	
53-17	19542-19544	of	_	_	
53-18	19545-19552	caudate	_	_	
53-19	19553-19564	connections	_	_	
53-20	19564-19565	,	_	_	
53-21	19566-19568	is	_	_	
53-22	19569-19578	disrupted	_	_	
53-23	19579-19581	in	_	_	
53-24	19582-19595	schizophrenia	_	_	
53-25	19595-19596	.	_	_	
53-26	19597-19599	As	_	_	
53-27	19600-19603	our	_	_	
53-28	19604-19610	sample	_	_	
53-29	19611-19614	was	_	_	
53-30	19615-19624	comprised	_	_	
53-31	19625-19636	exclusively	_	_	
53-32	19637-19639	of	_	_	
53-33	19640-19651	unmedicated	_	_	
53-34	19652-19660	patients	_	_	
53-35	19660-19661	,	_	_	
53-36	19662-19666	this	_	_	
53-37	19667-19677	disruption	_	_	
53-38	19678-19680	is	_	_	
53-39	19681-19689	unlikely	_	_	
53-40	19690-19693	due	_	_	
53-41	19694-19696	to	_	_	
53-42	19697-19710	antipsychotic	_	_	
53-43	19711-19721	medication	_	_	
53-44	19722-19725	and	_	_	
53-45	19726-19729	may	_	_	
53-46	19730-19737	instead	_	_	
53-47	19738-19740	be	_	_	
53-48	19741-19749	relevant	_	_	
53-49	19750-19752	to	_	_	
53-50	19753-19756	the	_	_	
53-51	19757-19772	pathophysiology	_	_	
53-52	19773-19775	of	_	_	
53-53	19776-19789	schizophrenia	_	_	
53-54	19789-19790	.	_	_	
53-55	19791-19798	Further	_	_	
53-56	19799-19809	supporting	_	_	
53-57	19810-19814	this	_	_	
53-58	19815-19829	interpretation	_	_	
53-59	19829-19830	,	_	_	
53-60	19831-19839	abnormal	_	_	
53-61	19840-19848	striatal	_	_	
53-62	19849-19861	connectivity	_	_	
53-63	19862-19872	correlated	_	_	
53-64	19873-19877	with	_	_	
53-65	19878-19886	clinical	_	_	
53-66	19887-19895	severity	_	_	
53-67	19895-19896	,	_	_	
53-68	19897-19909	specifically	_	_	
53-69	19910-19914	with	_	_	
53-70	19915-19923	severity	_	_	
53-71	19924-19926	of	_	_	
53-72	19927-19935	positive	_	_	
53-73	19936-19944	symptoms	_	_	
53-74	19945-19948	but	_	_	
53-75	19949-19952	not	_	_	
53-76	19953-19961	negative	_	_	
53-77	19962-19970	symptoms	_	_	
53-78	19970-19971	.	_	_	
53-79	19972-19979	Finally	_	_	
53-80	19979-19980	,	_	_	
53-81	19981-19989	abnormal	_	_	
53-82	19990-20002	connectivity	_	_	
53-83	20003-20007	also	_	_	
53-84	20008-20018	correlated	_	_	
53-85	20019-20023	with	_	_	
53-86	20024-20029	lower	_	_	
53-87	20030-20037	density	_	_	
53-88	20038-20040	of	_	_	
53-89	20041-20045	D2Rs	_	_	
53-90	20046-20052	across	_	_	
53-91	20053-20061	cortical	_	_	
53-92	20062-20065	and	_	_	
53-93	20066-20079	extrastriatal	_	_	
53-94	20080-20091	subcortical	_	_	
53-95	20092-20097	brain	_	_	
53-96	20098-20105	regions	_	_	
53-97	20106-20112	within	_	_	
53-98	20113-20116	the	_	_	
53-99	20117-20121	same	_	_	
53-100	20122-20133	individuals	_	_	
53-101	20133-20134	.	_	_	

#Text=Our results converge in suggesting that the healthy caudate, in particular the anterior caudate, is a connectivity hub. In health, connectivity of the anterior caudate with an extended set of higher-order associative regions was stronger than that of other striatal subregions. In contrast, this primacy of the anterior caudate was not as apparent in patients. The pattern observed in health is consistent with previous work showing that the anterior caudate receives overlapping projections from various regions in fronto-parietal cortices. This previous work suggests that in addition to the semi-segregated loops supporting specialization, convergence zones within the anterior caudate may serve as information-processing hubs relevant for integration.
54-1	20135-20138	Our	_	_	
54-2	20139-20146	results	_	_	
54-3	20147-20155	converge	_	_	
54-4	20156-20158	in	_	_	
54-5	20159-20169	suggesting	_	_	
54-6	20170-20174	that	_	_	
54-7	20175-20178	the	_	_	
54-8	20179-20186	healthy	_	_	
54-9	20187-20194	caudate	_	_	
54-10	20194-20195	,	_	_	
54-11	20196-20198	in	_	_	
54-12	20199-20209	particular	_	_	
54-13	20210-20213	the	_	_	
54-14	20214-20222	anterior	_	_	
54-15	20223-20230	caudate	_	_	
54-16	20230-20231	,	_	_	
54-17	20232-20234	is	_	_	
54-18	20235-20236	a	_	_	
54-19	20237-20249	connectivity	_	_	
54-20	20250-20253	hub	_	_	
54-21	20253-20254	.	_	_	
54-22	20255-20257	In	_	_	
54-23	20258-20264	health	_	_	
54-24	20264-20265	,	_	_	
54-25	20266-20278	connectivity	_	_	
54-26	20279-20281	of	_	_	
54-27	20282-20285	the	_	_	
54-28	20286-20294	anterior	_	_	
54-29	20295-20302	caudate	_	_	
54-30	20303-20307	with	_	_	
54-31	20308-20310	an	_	_	
54-32	20311-20319	extended	_	_	
54-33	20320-20323	set	_	_	
54-34	20324-20326	of	_	_	
54-35	20327-20339	higher-order	_	_	
54-36	20340-20351	associative	_	_	
54-37	20352-20359	regions	_	_	
54-38	20360-20363	was	_	_	
54-39	20364-20372	stronger	_	_	
54-40	20373-20377	than	_	_	
54-41	20378-20382	that	_	_	
54-42	20383-20385	of	_	_	
54-43	20386-20391	other	_	_	
54-44	20392-20400	striatal	_	_	
54-45	20401-20411	subregions	_	_	
54-46	20411-20412	.	_	_	
54-47	20413-20415	In	_	_	
54-48	20416-20424	contrast	_	_	
54-49	20424-20425	,	_	_	
54-50	20426-20430	this	_	_	
54-51	20431-20438	primacy	_	_	
54-52	20439-20441	of	_	_	
54-53	20442-20445	the	_	_	
54-54	20446-20454	anterior	_	_	
54-55	20455-20462	caudate	_	_	
54-56	20463-20466	was	_	_	
54-57	20467-20470	not	_	_	
54-58	20471-20473	as	_	_	
54-59	20474-20482	apparent	_	_	
54-60	20483-20485	in	_	_	
54-61	20486-20494	patients	_	_	
54-62	20494-20495	.	_	_	
54-63	20496-20499	The	_	_	
54-64	20500-20507	pattern	_	_	
54-65	20508-20516	observed	_	_	
54-66	20517-20519	in	_	_	
54-67	20520-20526	health	_	_	
54-68	20527-20529	is	_	_	
54-69	20530-20540	consistent	_	_	
54-70	20541-20545	with	_	_	
54-71	20546-20554	previous	_	_	
54-72	20555-20559	work	_	_	
54-73	20560-20567	showing	_	_	
54-74	20568-20572	that	_	_	
54-75	20573-20576	the	_	_	
54-76	20577-20585	anterior	_	_	
54-77	20586-20593	caudate	_	_	
54-78	20594-20602	receives	_	_	
54-79	20603-20614	overlapping	_	_	
54-80	20615-20626	projections	_	_	
54-81	20627-20631	from	_	_	
54-82	20632-20639	various	_	_	
54-83	20640-20647	regions	_	_	
54-84	20648-20650	in	_	_	
54-85	20651-20666	fronto-parietal	_	_	
54-86	20667-20675	cortices	_	_	
54-87	20675-20676	.	_	_	
54-88	20677-20681	This	_	_	
54-89	20682-20690	previous	_	_	
54-90	20691-20695	work	_	_	
54-91	20696-20704	suggests	_	_	
54-92	20705-20709	that	_	_	
54-93	20710-20712	in	_	_	
54-94	20713-20721	addition	_	_	
54-95	20722-20724	to	_	_	
54-96	20725-20728	the	_	_	
54-97	20729-20744	semi-segregated	_	_	
54-98	20745-20750	loops	_	_	
54-99	20751-20761	supporting	_	_	
54-100	20762-20776	specialization	_	_	
54-101	20776-20777	,	_	_	
54-102	20778-20789	convergence	_	_	
54-103	20790-20795	zones	_	_	
54-104	20796-20802	within	_	_	
54-105	20803-20806	the	_	_	
54-106	20807-20815	anterior	_	_	
54-107	20816-20823	caudate	_	_	
54-108	20824-20827	may	_	_	
54-109	20828-20833	serve	_	_	
54-110	20834-20836	as	_	_	
54-111	20837-20859	information-processing	_	_	
54-112	20860-20864	hubs	_	_	
54-113	20865-20873	relevant	_	_	
54-114	20874-20877	for	_	_	
54-115	20878-20889	integration	_	_	
54-116	20889-20890	.	_	_	

#Text=Given this, our results of abnormal striatal connectivity patterns in schizophrenia, and its relationship to positive symptoms, may suggest that a disruption affecting, among other regions, a striatal hub for information multiplexing is involved in psychosis, in line with dysconnectivity hypotheses. Our findings may be consistent with findings of disrupted hemispheric specialization and decreased global connectivity of the caudate as well as those demonstrating deficient striato-cortical connectivity in schizophrenia and altered caudate-cortical connectivity in subjects at high-risk for psychosis. Although dysfunction and dysconnectivity of the (ventral) striatum may relate to negative symptoms, we failed to find such a relationship, although more work in this direction is warranted. Together with findings highlighting the role of striatal dopamine dysregulation in schizophrenia, our results suggest that disruptions of striatal circuitry may plausibly mediate the deleterious effects of dopamine dysregulation on cortical processes involved in perception and cognition.
55-1	20891-20896	Given	_	_	
55-2	20897-20901	this	_	_	
55-3	20901-20902	,	_	_	
55-4	20903-20906	our	_	_	
55-5	20907-20914	results	_	_	
55-6	20915-20917	of	_	_	
55-7	20918-20926	abnormal	_	_	
55-8	20927-20935	striatal	_	_	
55-9	20936-20948	connectivity	_	_	
55-10	20949-20957	patterns	_	_	
55-11	20958-20960	in	_	_	
55-12	20961-20974	schizophrenia	_	_	
55-13	20974-20975	,	_	_	
55-14	20976-20979	and	_	_	
55-15	20980-20983	its	_	_	
55-16	20984-20996	relationship	_	_	
55-17	20997-20999	to	_	_	
55-18	21000-21008	positive	_	_	
55-19	21009-21017	symptoms	_	_	
55-20	21017-21018	,	_	_	
55-21	21019-21022	may	_	_	
55-22	21023-21030	suggest	_	_	
55-23	21031-21035	that	_	_	
55-24	21036-21037	a	_	_	
55-25	21038-21048	disruption	_	_	
55-26	21049-21058	affecting	_	_	
55-27	21058-21059	,	_	_	
55-28	21060-21065	among	_	_	
55-29	21066-21071	other	_	_	
55-30	21072-21079	regions	_	_	
55-31	21079-21080	,	_	_	
55-32	21081-21082	a	_	_	
55-33	21083-21091	striatal	_	_	
55-34	21092-21095	hub	_	_	
55-35	21096-21099	for	_	_	
55-36	21100-21111	information	_	_	
55-37	21112-21124	multiplexing	_	_	
55-38	21125-21127	is	_	_	
55-39	21128-21136	involved	_	_	
55-40	21137-21139	in	_	_	
55-41	21140-21149	psychosis	_	_	
55-42	21149-21150	,	_	_	
55-43	21151-21153	in	_	_	
55-44	21154-21158	line	_	_	
55-45	21159-21163	with	_	_	
55-46	21164-21179	dysconnectivity	_	_	
55-47	21180-21190	hypotheses	_	_	
55-48	21190-21191	.	_	_	
55-49	21192-21195	Our	_	_	
55-50	21196-21204	findings	_	_	
55-51	21205-21208	may	_	_	
55-52	21209-21211	be	_	_	
55-53	21212-21222	consistent	_	_	
55-54	21223-21227	with	_	_	
55-55	21228-21236	findings	_	_	
55-56	21237-21239	of	_	_	
55-57	21240-21249	disrupted	_	_	
55-58	21250-21261	hemispheric	_	_	
55-59	21262-21276	specialization	_	_	
55-60	21277-21280	and	_	_	
55-61	21281-21290	decreased	_	_	
55-62	21291-21297	global	_	_	
55-63	21298-21310	connectivity	_	_	
55-64	21311-21313	of	_	_	
55-65	21314-21317	the	_	_	
55-66	21318-21325	caudate	_	_	
55-67	21326-21328	as	_	_	
55-68	21329-21333	well	_	_	
55-69	21334-21336	as	_	_	
55-70	21337-21342	those	_	_	
55-71	21343-21356	demonstrating	_	_	
55-72	21357-21366	deficient	_	_	
55-73	21367-21383	striato-cortical	_	_	
55-74	21384-21396	connectivity	_	_	
55-75	21397-21399	in	_	_	
55-76	21400-21413	schizophrenia	_	_	
55-77	21414-21417	and	_	_	
55-78	21418-21425	altered	_	_	
55-79	21426-21442	caudate-cortical	_	_	
55-80	21443-21455	connectivity	_	_	
55-81	21456-21458	in	_	_	
55-82	21459-21467	subjects	_	_	
55-83	21468-21470	at	_	_	
55-84	21471-21480	high-risk	_	_	
55-85	21481-21484	for	_	_	
55-86	21485-21494	psychosis	_	_	
55-87	21494-21495	.	_	_	
55-88	21496-21504	Although	_	_	
55-89	21505-21516	dysfunction	_	_	
55-90	21517-21520	and	_	_	
55-91	21521-21536	dysconnectivity	_	_	
55-92	21537-21539	of	_	_	
55-93	21540-21543	the	_	_	
55-94	21544-21545	(	_	_	
55-95	21545-21552	ventral	_	_	
55-96	21552-21553	)	_	_	
55-97	21554-21562	striatum	_	_	
55-98	21563-21566	may	_	_	
55-99	21567-21573	relate	_	_	
55-100	21574-21576	to	_	_	
55-101	21577-21585	negative	_	_	
55-102	21586-21594	symptoms	_	_	
55-103	21594-21595	,	_	_	
55-104	21596-21598	we	_	_	
55-105	21599-21605	failed	_	_	
55-106	21606-21608	to	_	_	
55-107	21609-21613	find	_	_	
55-108	21614-21618	such	_	_	
55-109	21619-21620	a	_	_	
55-110	21621-21633	relationship	_	_	
55-111	21633-21634	,	_	_	
55-112	21635-21643	although	_	_	
55-113	21644-21648	more	_	_	
55-114	21649-21653	work	_	_	
55-115	21654-21656	in	_	_	
55-116	21657-21661	this	_	_	
55-117	21662-21671	direction	_	_	
55-118	21672-21674	is	_	_	
55-119	21675-21684	warranted	_	_	
55-120	21684-21685	.	_	_	
55-121	21686-21694	Together	_	_	
55-122	21695-21699	with	_	_	
55-123	21700-21708	findings	_	_	
55-124	21709-21721	highlighting	_	_	
55-125	21722-21725	the	_	_	
55-126	21726-21730	role	_	_	
55-127	21731-21733	of	_	_	
55-128	21734-21742	striatal	_	_	
55-129	21743-21751	dopamine	_	_	
55-130	21752-21765	dysregulation	_	_	
55-131	21766-21768	in	_	_	
55-132	21769-21782	schizophrenia	_	_	
55-133	21782-21783	,	_	_	
55-134	21784-21787	our	_	_	
55-135	21788-21795	results	_	_	
55-136	21796-21803	suggest	_	_	
55-137	21804-21808	that	_	_	
55-138	21809-21820	disruptions	_	_	
55-139	21821-21823	of	_	_	
55-140	21824-21832	striatal	_	_	
55-141	21833-21842	circuitry	_	_	
55-142	21843-21846	may	_	_	
55-143	21847-21856	plausibly	_	_	
55-144	21857-21864	mediate	_	_	
55-145	21865-21868	the	_	_	
55-146	21869-21880	deleterious	_	_	
55-147	21881-21888	effects	_	_	
55-148	21889-21891	of	_	_	
55-149	21892-21900	dopamine	_	_	
55-150	21901-21914	dysregulation	_	_	
55-151	21915-21917	on	_	_	
55-152	21918-21926	cortical	_	_	
55-153	21927-21936	processes	_	_	
55-154	21937-21945	involved	_	_	
55-155	21946-21948	in	_	_	
55-156	21949-21959	perception	_	_	
55-157	21960-21963	and	_	_	
55-158	21964-21973	cognition	_	_	
55-159	21973-21974	.	_	_	

#Text=Our PET results indeed suggest that abnormal striatal connectivity in schizophrenia may depend on dopamine. We failed to detect a relationship between dysconnectivity and amphetamine-induced dopamine release, possibly due to the limited range of extrastriatal release in patients, who showed a marked deficit in release with preserved D2R levels. We did, however, observe more abnormal connectivity associated with lower baseline density of D2R across extrastriatal regions. Prefrontal dopamine exerts a bidirectional modulation of network activity by tuning recurrent network excitation, where D2 stimulation reduces inhibitory post-synaptic currents. Therefore, decreased D2Rs could potentially explain aberrant network activity propagating through BGTC circuits and leading to disruptions in activity-dependent plasticity consistent with the observed pattern of dysconnectivity in patients. Furthermore, the generalized deficit in extrastriatal dopamine release in patients is likely to compound lower D2R expression, further dampening D2 function in those patients with more manifest dysconnectivity. Finally, the observed relationships between D2R, deficient striatal connectivity, and psychosis are consistent with a study showing that improvement of psychosis following D2R-blocking medication correlated with strengthened caudate-prefrontal connectivity.
56-1	21975-21978	Our	_	_	
56-2	21979-21982	PET	_	_	
56-3	21983-21990	results	_	_	
56-4	21991-21997	indeed	_	_	
56-5	21998-22005	suggest	_	_	
56-6	22006-22010	that	_	_	
56-7	22011-22019	abnormal	_	_	
56-8	22020-22028	striatal	_	_	
56-9	22029-22041	connectivity	_	_	
56-10	22042-22044	in	_	_	
56-11	22045-22058	schizophrenia	_	_	
56-12	22059-22062	may	_	_	
56-13	22063-22069	depend	_	_	
56-14	22070-22072	on	_	_	
56-15	22073-22081	dopamine	_	_	
56-16	22081-22082	.	_	_	
56-17	22083-22085	We	_	_	
56-18	22086-22092	failed	_	_	
56-19	22093-22095	to	_	_	
56-20	22096-22102	detect	_	_	
56-21	22103-22104	a	_	_	
56-22	22105-22117	relationship	_	_	
56-23	22118-22125	between	_	_	
56-24	22126-22141	dysconnectivity	_	_	
56-25	22142-22145	and	_	_	
56-26	22146-22165	amphetamine-induced	_	_	
56-27	22166-22174	dopamine	_	_	
56-28	22175-22182	release	_	_	
56-29	22182-22183	,	_	_	
56-30	22184-22192	possibly	_	_	
56-31	22193-22196	due	_	_	
56-32	22197-22199	to	_	_	
56-33	22200-22203	the	_	_	
56-34	22204-22211	limited	_	_	
56-35	22212-22217	range	_	_	
56-36	22218-22220	of	_	_	
56-37	22221-22234	extrastriatal	_	_	
56-38	22235-22242	release	_	_	
56-39	22243-22245	in	_	_	
56-40	22246-22254	patients	_	_	
56-41	22254-22255	,	_	_	
56-42	22256-22259	who	_	_	
56-43	22260-22266	showed	_	_	
56-44	22267-22268	a	_	_	
56-45	22269-22275	marked	_	_	
56-46	22276-22283	deficit	_	_	
56-47	22284-22286	in	_	_	
56-48	22287-22294	release	_	_	
56-49	22295-22299	with	_	_	
56-50	22300-22309	preserved	_	_	
56-51	22310-22313	D2R	_	_	
56-52	22314-22320	levels	_	_	
56-53	22320-22321	.	_	_	
56-54	22322-22324	We	_	_	
56-55	22325-22328	did	_	_	
56-56	22328-22329	,	_	_	
56-57	22330-22337	however	_	_	
56-58	22337-22338	,	_	_	
56-59	22339-22346	observe	_	_	
56-60	22347-22351	more	_	_	
56-61	22352-22360	abnormal	_	_	
56-62	22361-22373	connectivity	_	_	
56-63	22374-22384	associated	_	_	
56-64	22385-22389	with	_	_	
56-65	22390-22395	lower	_	_	
56-66	22396-22404	baseline	_	_	
56-67	22405-22412	density	_	_	
56-68	22413-22415	of	_	_	
56-69	22416-22419	D2R	_	_	
56-70	22420-22426	across	_	_	
56-71	22427-22440	extrastriatal	_	_	
56-72	22441-22448	regions	_	_	
56-73	22448-22449	.	_	_	
56-74	22450-22460	Prefrontal	_	_	
56-75	22461-22469	dopamine	_	_	
56-76	22470-22476	exerts	_	_	
56-77	22477-22478	a	_	_	
56-78	22479-22492	bidirectional	_	_	
56-79	22493-22503	modulation	_	_	
56-80	22504-22506	of	_	_	
56-81	22507-22514	network	_	_	
56-82	22515-22523	activity	_	_	
56-83	22524-22526	by	_	_	
56-84	22527-22533	tuning	_	_	
56-85	22534-22543	recurrent	_	_	
56-86	22544-22551	network	_	_	
56-87	22552-22562	excitation	_	_	
56-88	22562-22563	,	_	_	
56-89	22564-22569	where	_	_	
56-90	22570-22572	D2	_	_	
56-91	22573-22584	stimulation	_	_	
56-92	22585-22592	reduces	_	_	
56-93	22593-22603	inhibitory	_	_	
56-94	22604-22617	post-synaptic	_	_	
56-95	22618-22626	currents	_	_	
56-96	22626-22627	.	_	_	
56-97	22628-22637	Therefore	_	_	
56-98	22637-22638	,	_	_	
56-99	22639-22648	decreased	_	_	
56-100	22649-22653	D2Rs	_	_	
56-101	22654-22659	could	_	_	
56-102	22660-22671	potentially	_	_	
56-103	22672-22679	explain	_	_	
56-104	22680-22688	aberrant	_	_	
56-105	22689-22696	network	_	_	
56-106	22697-22705	activity	_	_	
56-107	22706-22717	propagating	_	_	
56-108	22718-22725	through	_	_	
56-109	22726-22730	BGTC	_	_	
56-110	22731-22739	circuits	_	_	
56-111	22740-22743	and	_	_	
56-112	22744-22751	leading	_	_	
56-113	22752-22754	to	_	_	
56-114	22755-22766	disruptions	_	_	
56-115	22767-22769	in	_	_	
56-116	22770-22788	activity-dependent	_	_	
56-117	22789-22799	plasticity	_	_	
56-118	22800-22810	consistent	_	_	
56-119	22811-22815	with	_	_	
56-120	22816-22819	the	_	_	
56-121	22820-22828	observed	_	_	
56-122	22829-22836	pattern	_	_	
56-123	22837-22839	of	_	_	
56-124	22840-22855	dysconnectivity	_	_	
56-125	22856-22858	in	_	_	
56-126	22859-22867	patients	_	_	
56-127	22867-22868	.	_	_	
56-128	22869-22880	Furthermore	_	_	
56-129	22880-22881	,	_	_	
56-130	22882-22885	the	_	_	
56-131	22886-22897	generalized	_	_	
56-132	22898-22905	deficit	_	_	
56-133	22906-22908	in	_	_	
56-134	22909-22922	extrastriatal	_	_	
56-135	22923-22931	dopamine	_	_	
56-136	22932-22939	release	_	_	
56-137	22940-22942	in	_	_	
56-138	22943-22951	patients	_	_	
56-139	22952-22954	is	_	_	
56-140	22955-22961	likely	_	_	
56-141	22962-22964	to	_	_	
56-142	22965-22973	compound	_	_	
56-143	22974-22979	lower	_	_	
56-144	22980-22983	D2R	_	_	
56-145	22984-22994	expression	_	_	
56-146	22994-22995	,	_	_	
56-147	22996-23003	further	_	_	
56-148	23004-23013	dampening	_	_	
56-149	23014-23016	D2	_	_	
56-150	23017-23025	function	_	_	
56-151	23026-23028	in	_	_	
56-152	23029-23034	those	_	_	
56-153	23035-23043	patients	_	_	
56-154	23044-23048	with	_	_	
56-155	23049-23053	more	_	_	
56-156	23054-23062	manifest	_	_	
56-157	23063-23078	dysconnectivity	_	_	
56-158	23078-23079	.	_	_	
56-159	23080-23087	Finally	_	_	
56-160	23087-23088	,	_	_	
56-161	23089-23092	the	_	_	
56-162	23093-23101	observed	_	_	
56-163	23102-23115	relationships	_	_	
56-164	23116-23123	between	_	_	
56-165	23124-23127	D2R	_	_	
56-166	23127-23128	,	_	_	
56-167	23129-23138	deficient	_	_	
56-168	23139-23147	striatal	_	_	
56-169	23148-23160	connectivity	_	_	
56-170	23160-23161	,	_	_	
56-171	23162-23165	and	_	_	
56-172	23166-23175	psychosis	_	_	
56-173	23176-23179	are	_	_	
56-174	23180-23190	consistent	_	_	
56-175	23191-23195	with	_	_	
56-176	23196-23197	a	_	_	
56-177	23198-23203	study	_	_	
56-178	23204-23211	showing	_	_	
56-179	23212-23216	that	_	_	
56-180	23217-23228	improvement	_	_	
56-181	23229-23231	of	_	_	
56-182	23232-23241	psychosis	_	_	
56-183	23242-23251	following	_	_	
56-184	23252-23264	D2R-blocking	_	_	
56-185	23265-23275	medication	_	_	
56-186	23276-23286	correlated	_	_	
56-187	23287-23291	with	_	_	
56-188	23292-23304	strengthened	_	_	
56-189	23305-23323	caudate-prefrontal	_	_	
56-190	23324-23336	connectivity	_	_	
56-191	23336-23337	.	_	_	

#Text=Our study has several limitations. Our limited sample size may have increased the risk of false negatives and effect-size inflation. Our choice of radiotracer precluded measures of striatal dopamine and of D1R, which would help better understand the relationship between dopamine and dysconnectivity. Nonetheless, this is to our knowledge the first multimodal study in schizophrenia combining molecular imaging and a systems-level, fMRI connectivity approach. Exploratory univariate analyses failed to find a group difference in contrast to our primary multivariate analysis. However, this could suggest that multivariate measures provide a more powerful way to interrogate circuit pathology. Finally, a general limitation of resting-state studies is the lack of control over transient mental states experienced during data collection. Although we did not debrief participants after scanning, psychotic symptoms experienced in the scanner tend to correlate highly with pre-scanning severity scores. Thus, our findings related to psychosis severity may partly reflect psychopathological states experienced in the scanner.
57-1	23338-23341	Our	_	_	
57-2	23342-23347	study	_	_	
57-3	23348-23351	has	_	_	
57-4	23352-23359	several	_	_	
57-5	23360-23371	limitations	_	_	
57-6	23371-23372	.	_	_	
57-7	23373-23376	Our	_	_	
57-8	23377-23384	limited	_	_	
57-9	23385-23391	sample	_	_	
57-10	23392-23396	size	_	_	
57-11	23397-23400	may	_	_	
57-12	23401-23405	have	_	_	
57-13	23406-23415	increased	_	_	
57-14	23416-23419	the	_	_	
57-15	23420-23424	risk	_	_	
57-16	23425-23427	of	_	_	
57-17	23428-23433	false	_	_	
57-18	23434-23443	negatives	_	_	
57-19	23444-23447	and	_	_	
57-20	23448-23459	effect-size	_	_	
57-21	23460-23469	inflation	_	_	
57-22	23469-23470	.	_	_	
57-23	23471-23474	Our	_	_	
57-24	23475-23481	choice	_	_	
57-25	23482-23484	of	_	_	
57-26	23485-23496	radiotracer	_	_	
57-27	23497-23506	precluded	_	_	
57-28	23507-23515	measures	_	_	
57-29	23516-23518	of	_	_	
57-30	23519-23527	striatal	_	_	
57-31	23528-23536	dopamine	_	_	
57-32	23537-23540	and	_	_	
57-33	23541-23543	of	_	_	
57-34	23544-23547	D1R	_	_	
57-35	23547-23548	,	_	_	
57-36	23549-23554	which	_	_	
57-37	23555-23560	would	_	_	
57-38	23561-23565	help	_	_	
57-39	23566-23572	better	_	_	
57-40	23573-23583	understand	_	_	
57-41	23584-23587	the	_	_	
57-42	23588-23600	relationship	_	_	
57-43	23601-23608	between	_	_	
57-44	23609-23617	dopamine	_	_	
57-45	23618-23621	and	_	_	
57-46	23622-23637	dysconnectivity	_	_	
57-47	23637-23638	.	_	_	
57-48	23639-23650	Nonetheless	_	_	
57-49	23650-23651	,	_	_	
57-50	23652-23656	this	_	_	
57-51	23657-23659	is	_	_	
57-52	23660-23662	to	_	_	
57-53	23663-23666	our	_	_	
57-54	23667-23676	knowledge	_	_	
57-55	23677-23680	the	_	_	
57-56	23681-23686	first	_	_	
57-57	23687-23697	multimodal	_	_	
57-58	23698-23703	study	_	_	
57-59	23704-23706	in	_	_	
57-60	23707-23720	schizophrenia	_	_	
57-61	23721-23730	combining	_	_	
57-62	23731-23740	molecular	_	_	
57-63	23741-23748	imaging	_	_	
57-64	23749-23752	and	_	_	
57-65	23753-23754	a	_	_	
57-66	23755-23768	systems-level	_	_	
57-67	23768-23769	,	_	_	
57-68	23770-23774	fMRI	_	_	
57-69	23775-23787	connectivity	_	_	
57-70	23788-23796	approach	_	_	
57-71	23796-23797	.	_	_	
57-72	23798-23809	Exploratory	_	_	
57-73	23810-23820	univariate	_	_	
57-74	23821-23829	analyses	_	_	
57-75	23830-23836	failed	_	_	
57-76	23837-23839	to	_	_	
57-77	23840-23844	find	_	_	
57-78	23845-23846	a	_	_	
57-79	23847-23852	group	_	_	
57-80	23853-23863	difference	_	_	
57-81	23864-23866	in	_	_	
57-82	23867-23875	contrast	_	_	
57-83	23876-23878	to	_	_	
57-84	23879-23882	our	_	_	
57-85	23883-23890	primary	_	_	
57-86	23891-23903	multivariate	_	_	
57-87	23904-23912	analysis	_	_	
57-88	23912-23913	.	_	_	
57-89	23914-23921	However	_	_	
57-90	23921-23922	,	_	_	
57-91	23923-23927	this	_	_	
57-92	23928-23933	could	_	_	
57-93	23934-23941	suggest	_	_	
57-94	23942-23946	that	_	_	
57-95	23947-23959	multivariate	_	_	
57-96	23960-23968	measures	_	_	
57-97	23969-23976	provide	_	_	
57-98	23977-23978	a	_	_	
57-99	23979-23983	more	_	_	
57-100	23984-23992	powerful	_	_	
57-101	23993-23996	way	_	_	
57-102	23997-23999	to	_	_	
57-103	24000-24011	interrogate	_	_	
57-104	24012-24019	circuit	_	_	
57-105	24020-24029	pathology	_	_	
57-106	24029-24030	.	_	_	
57-107	24031-24038	Finally	_	_	
57-108	24038-24039	,	_	_	
57-109	24040-24041	a	_	_	
57-110	24042-24049	general	_	_	
57-111	24050-24060	limitation	_	_	
57-112	24061-24063	of	_	_	
57-113	24064-24077	resting-state	_	_	
57-114	24078-24085	studies	_	_	
57-115	24086-24088	is	_	_	
57-116	24089-24092	the	_	_	
57-117	24093-24097	lack	_	_	
57-118	24098-24100	of	_	_	
57-119	24101-24108	control	_	_	
57-120	24109-24113	over	_	_	
57-121	24114-24123	transient	_	_	
57-122	24124-24130	mental	_	_	
57-123	24131-24137	states	_	_	
57-124	24138-24149	experienced	_	_	
57-125	24150-24156	during	_	_	
57-126	24157-24161	data	_	_	
57-127	24162-24172	collection	_	_	
57-128	24172-24173	.	_	_	
57-129	24174-24182	Although	_	_	
57-130	24183-24185	we	_	_	
57-131	24186-24189	did	_	_	
57-132	24190-24193	not	_	_	
57-133	24194-24201	debrief	_	_	
57-134	24202-24214	participants	_	_	
57-135	24215-24220	after	_	_	
57-136	24221-24229	scanning	_	_	
57-137	24229-24230	,	_	_	
57-138	24231-24240	psychotic	_	_	
57-139	24241-24249	symptoms	_	_	
57-140	24250-24261	experienced	_	_	
57-141	24262-24264	in	_	_	
57-142	24265-24268	the	_	_	
57-143	24269-24276	scanner	_	_	
57-144	24277-24281	tend	_	_	
57-145	24282-24284	to	_	_	
57-146	24285-24294	correlate	_	_	
57-147	24295-24301	highly	_	_	
57-148	24302-24306	with	_	_	
57-149	24307-24319	pre-scanning	_	_	
57-150	24320-24328	severity	_	_	
57-151	24329-24335	scores	_	_	
57-152	24335-24336	.	_	_	
57-153	24337-24341	Thus	_	_	
57-154	24341-24342	,	_	_	
57-155	24343-24346	our	_	_	
57-156	24347-24355	findings	_	_	
57-157	24356-24363	related	_	_	
57-158	24364-24366	to	_	_	
57-159	24367-24376	psychosis	_	_	
57-160	24377-24385	severity	_	_	
57-161	24386-24389	may	_	_	
57-162	24390-24396	partly	_	_	
57-163	24397-24404	reflect	_	_	
57-164	24405-24423	psychopathological	_	_	
57-165	24424-24430	states	_	_	
57-166	24431-24442	experienced	_	_	
57-167	24443-24445	in	_	_	
57-168	24446-24449	the	_	_	
57-169	24450-24457	scanner	_	_	
57-170	24457-24458	.	_	_	

#Text=Conclusions
58-1	24459-24470	Conclusions	_	_	

#Text=Unmedicated patients with schizophrenia display abnormalities in the functional topography of striatal connections. These abnormalities correlate specifically with more severe psychotic symptoms and lower density of extrastriatal D2R, suggesting the relevance of this neural phenotype to the pathophysiology of psychosis and potentially informing new therapeutic targets at the intersection between molecules and neural systems. Our results further suggest that the striatum contains connectivity hubs relevant for cognitive integration whose disruption may impair higher-order cortical processes involved in psychosis.
59-1	24471-24482	Unmedicated	_	_	
59-2	24483-24491	patients	_	_	
59-3	24492-24496	with	_	_	
59-4	24497-24510	schizophrenia	_	_	
59-5	24511-24518	display	_	_	
59-6	24519-24532	abnormalities	_	_	
59-7	24533-24535	in	_	_	
59-8	24536-24539	the	_	_	
59-9	24540-24550	functional	_	_	
59-10	24551-24561	topography	_	_	
59-11	24562-24564	of	_	_	
59-12	24565-24573	striatal	_	_	
59-13	24574-24585	connections	_	_	
59-14	24585-24586	.	_	_	
59-15	24587-24592	These	_	_	
59-16	24593-24606	abnormalities	_	_	
59-17	24607-24616	correlate	_	_	
59-18	24617-24629	specifically	_	_	
59-19	24630-24634	with	_	_	
59-20	24635-24639	more	_	_	
59-21	24640-24646	severe	_	_	
59-22	24647-24656	psychotic	_	_	
59-23	24657-24665	symptoms	_	_	
59-24	24666-24669	and	_	_	
59-25	24670-24675	lower	_	_	
59-26	24676-24683	density	_	_	
59-27	24684-24686	of	_	_	
59-28	24687-24700	extrastriatal	_	_	
59-29	24701-24704	D2R	_	_	
59-30	24704-24705	,	_	_	
59-31	24706-24716	suggesting	_	_	
59-32	24717-24720	the	_	_	
59-33	24721-24730	relevance	_	_	
59-34	24731-24733	of	_	_	
59-35	24734-24738	this	_	_	
59-36	24739-24745	neural	_	_	
59-37	24746-24755	phenotype	_	_	
59-38	24756-24758	to	_	_	
59-39	24759-24762	the	_	_	
59-40	24763-24778	pathophysiology	_	_	
59-41	24779-24781	of	_	_	
59-42	24782-24791	psychosis	_	_	
59-43	24792-24795	and	_	_	
59-44	24796-24807	potentially	_	_	
59-45	24808-24817	informing	_	_	
59-46	24818-24821	new	_	_	
59-47	24822-24833	therapeutic	_	_	
59-48	24834-24841	targets	_	_	
59-49	24842-24844	at	_	_	
59-50	24845-24848	the	_	_	
59-51	24849-24861	intersection	_	_	
59-52	24862-24869	between	_	_	
59-53	24870-24879	molecules	_	_	
59-54	24880-24883	and	_	_	
59-55	24884-24890	neural	_	_	
59-56	24891-24898	systems	_	_	
59-57	24898-24899	.	_	_	
59-58	24900-24903	Our	_	_	
59-59	24904-24911	results	_	_	
59-60	24912-24919	further	_	_	
59-61	24920-24927	suggest	_	_	
59-62	24928-24932	that	_	_	
59-63	24933-24936	the	_	_	
59-64	24937-24945	striatum	_	_	
59-65	24946-24954	contains	_	_	
59-66	24955-24967	connectivity	_	_	
59-67	24968-24972	hubs	_	_	
59-68	24973-24981	relevant	_	_	
59-69	24982-24985	for	_	_	
59-70	24986-24995	cognitive	_	_	
59-71	24996-25007	integration	_	_	
59-72	25008-25013	whose	_	_	
59-73	25014-25024	disruption	_	_	
59-74	25025-25028	may	_	_	
59-75	25029-25035	impair	_	_	
59-76	25036-25048	higher-order	_	_	
59-77	25049-25057	cortical	_	_	
59-78	25058-25067	processes	_	_	
59-79	25068-25076	involved	_	_	
59-80	25077-25079	in	_	_	
59-81	25080-25089	psychosis	_	_	
59-82	25089-25090	.	_	_	

#Text=Supplementary Material
60-1	25091-25104	Supplementary	_	_	
60-2	25105-25113	Material	_	_	

#Text=The nature of dopamine dysfunction in schizophrenia and what this means for treatment
61-1	25114-25117	The	_	_	
61-2	25118-25124	nature	_	_	
61-3	25125-25127	of	_	_	
61-4	25128-25136	dopamine	_	_	
61-5	25137-25148	dysfunction	_	_	
61-6	25149-25151	in	_	_	
61-7	25152-25165	schizophrenia	_	_	
61-8	25166-25169	and	_	_	
61-9	25170-25174	what	_	_	
61-10	25175-25179	this	_	_	
61-11	25180-25185	means	_	_	
61-12	25186-25189	for	_	_	
61-13	25190-25199	treatment	_	_	

#Text=Increased dopamine transmission in schizophrenia: relationship to illness phases
62-1	25200-25209	Increased	_	_	
62-2	25210-25218	dopamine	_	_	
62-3	25219-25231	transmission	_	_	
62-4	25232-25234	in	_	_	
62-5	25235-25248	schizophrenia	_	_	
62-6	25248-25249	:	_	_	
62-7	25250-25262	relationship	_	_	
62-8	25263-25265	to	_	_	
62-9	25266-25273	illness	_	_	
62-10	25274-25280	phases	_	_	

#Text=Striatal dopamine release in schizophrenia comorbid with substance dependence
63-1	25281-25289	Striatal	_	_	
63-2	25290-25298	dopamine	_	_	
63-3	25299-25306	release	_	_	
63-4	25307-25309	in	_	_	
63-5	25310-25323	schizophrenia	_	_	
63-6	25324-25332	comorbid	_	_	
63-7	25333-25337	with	_	_	
63-8	25338-25347	substance	_	_	
63-9	25348-25358	dependence	_	_	

#Text=The current status of the dopamine hypothesis of schizophrenia
64-1	25359-25362	The	_	_	
64-2	25363-25370	current	_	_	
64-3	25371-25377	status	_	_	
64-4	25378-25380	of	_	_	
64-5	25381-25384	the	_	_	
64-6	25385-25393	dopamine	_	_	
64-7	25394-25404	hypothesis	_	_	
64-8	25405-25407	of	_	_	
64-9	25408-25421	schizophrenia	_	_	

#Text=Parallel organization of functionally segregated circuits linking basal ganglia and cortex
65-1	25422-25430	Parallel	_	_	
65-2	25431-25443	organization	_	_	
65-3	25444-25446	of	_	_	
65-4	25447-25459	functionally	_	_	
65-5	25460-25470	segregated	_	_	
65-6	25471-25479	circuits	_	_	
65-7	25480-25487	linking	_	_	
65-8	25488-25493	basal	_	_	
65-9	25494-25501	ganglia	_	_	
65-10	25502-25505	and	_	_	
65-11	25506-25512	cortex	_	_	

#Text=Cognitive functions and corticostriatal circuits: insights from Huntington’s disease
66-1	25513-25522	Cognitive	_	_	
66-2	25523-25532	functions	_	_	
66-3	25533-25536	and	_	_	
66-4	25537-25552	corticostriatal	_	_	
66-5	25553-25561	circuits	_	_	
66-6	25561-25562	:	_	_	
66-7	25563-25571	insights	_	_	
66-8	25572-25576	from	_	_	
66-9	25577-25587	Huntington	_	_	
66-10	25587-25588	’	_	_	
66-11	25588-25589	s	_	_	
66-12	25590-25597	disease	_	_	

#Text=The primate basal ganglia: parallel and integrative networks
67-1	25598-25601	The	_	_	
67-2	25602-25609	primate	_	_	
67-3	25610-25615	basal	_	_	
67-4	25616-25623	ganglia	_	_	
67-5	25623-25624	:	_	_	
67-6	25625-25633	parallel	_	_	
67-7	25634-25637	and	_	_	
67-8	25638-25649	integrative	_	_	
67-9	25650-25658	networks	_	_	

#Text=Estimates of projection overlap and zones of convergence within frontal-striatal circuits
68-1	25659-25668	Estimates	_	_	
68-2	25669-25671	of	_	_	
68-3	25672-25682	projection	_	_	
68-4	25683-25690	overlap	_	_	
68-5	25691-25694	and	_	_	
68-6	25695-25700	zones	_	_	
68-7	25701-25703	of	_	_	
68-8	25704-25715	convergence	_	_	
68-9	25716-25722	within	_	_	
68-10	25723-25739	frontal-striatal	_	_	
68-11	25740-25748	circuits	_	_	

#Text=Reward-related cortical inputs define a large striatal region in primates that interface with associative cortical connections, providing a substrate for incentive-based learning
69-1	25749-25763	Reward-related	_	_	
69-2	25764-25772	cortical	_	_	
69-3	25773-25779	inputs	_	_	
69-4	25780-25786	define	_	_	
69-5	25787-25788	a	_	_	
69-6	25789-25794	large	_	_	
69-7	25795-25803	striatal	_	_	
69-8	25804-25810	region	_	_	
69-9	25811-25813	in	_	_	
69-10	25814-25822	primates	_	_	
69-11	25823-25827	that	_	_	
69-12	25828-25837	interface	_	_	
69-13	25838-25842	with	_	_	
69-14	25843-25854	associative	_	_	
69-15	25855-25863	cortical	_	_	
69-16	25864-25875	connections	_	_	
69-17	25875-25876	,	_	_	
69-18	25877-25886	providing	_	_	
69-19	25887-25888	a	_	_	
69-20	25889-25898	substrate	_	_	
69-21	25899-25902	for	_	_	
69-22	25903-25918	incentive-based	_	_	
69-23	25919-25927	learning	_	_	

#Text=Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection
70-1	25928-25936	Dopamine	_	_	
70-2	25937-25940	and	_	_	
70-3	25941-25949	synaptic	_	_	
70-4	25950-25960	plasticity	_	_	
70-5	25961-25963	in	_	_	
70-6	25964-25970	dorsal	_	_	
70-7	25971-25979	striatal	_	_	
70-8	25980-25988	circuits	_	_	
70-9	25989-26000	controlling	_	_	
70-10	26001-26007	action	_	_	
70-11	26008-26017	selection	_	_	

#Text=Dopaminergic control of synaptic plasticity in the dorsal striatum
71-1	26018-26030	Dopaminergic	_	_	
71-2	26031-26038	control	_	_	
71-3	26039-26041	of	_	_	
71-4	26042-26050	synaptic	_	_	
71-5	26051-26061	plasticity	_	_	
71-6	26062-26064	in	_	_	
71-7	26065-26068	the	_	_	
71-8	26069-26075	dorsal	_	_	
71-9	26076-26084	striatum	_	_	

#Text=In vivo activity-dependent plasticity at cortico-striatal connections: evidence for physiological long-term potentiation
72-1	26085-26087	In	_	_	
72-2	26088-26092	vivo	_	_	
72-3	26093-26111	activity-dependent	_	_	
72-4	26112-26122	plasticity	_	_	
72-5	26123-26125	at	_	_	
72-6	26126-26142	cortico-striatal	_	_	
72-7	26143-26154	connections	_	_	
72-8	26154-26155	:	_	_	
72-9	26156-26164	evidence	_	_	
72-10	26165-26168	for	_	_	
72-11	26169-26182	physiological	_	_	
72-12	26183-26192	long-term	_	_	
72-13	26193-26205	potentiation	_	_	

#Text=Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism
73-1	26206-26213	Dynamic	_	_	
73-2	26214-26222	dopamine	_	_	
73-3	26223-26233	modulation	_	_	
73-4	26234-26236	in	_	_	
73-5	26237-26240	the	_	_	
73-6	26241-26246	basal	_	_	
73-7	26247-26254	ganglia	_	_	
73-8	26254-26255	:	_	_	
73-9	26256-26257	a	_	_	
73-10	26258-26276	neurocomputational	_	_	
73-11	26277-26284	account	_	_	
73-12	26285-26287	of	_	_	
73-13	26288-26297	cognitive	_	_	
73-14	26298-26306	deficits	_	_	
73-15	26307-26309	in	_	_	
73-16	26310-26319	medicated	_	_	
73-17	26320-26323	and	_	_	
73-18	26324-26336	nonmedicated	_	_	
73-19	26337-26349	Parkinsonism	_	_	

#Text=Dopamine receptor activation is required for corticostriatal spike-timing-dependent plasticity
74-1	26350-26358	Dopamine	_	_	
74-2	26359-26367	receptor	_	_	
74-3	26368-26378	activation	_	_	
74-4	26379-26381	is	_	_	
74-5	26382-26390	required	_	_	
74-6	26391-26394	for	_	_	
74-7	26395-26410	corticostriatal	_	_	
74-8	26411-26433	spike-timing-dependent	_	_	
74-9	26434-26444	plasticity	_	_	

#Text=Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study
75-1	26445-26453	Deficits	_	_	
75-2	26454-26456	in	_	_	
75-3	26457-26467	prefrontal	_	_	
75-4	26468-26476	cortical	_	_	
75-5	26477-26480	and	_	_	
75-6	26481-26494	extrastriatal	_	_	
75-7	26495-26503	dopamine	_	_	
75-8	26504-26511	release	_	_	
75-9	26512-26514	in	_	_	
75-10	26515-26528	schizophrenia	_	_	
75-11	26528-26529	:	_	_	
75-12	26530-26531	a	_	_	
75-13	26532-26540	positron	_	_	
75-14	26541-26549	emission	_	_	
75-15	26550-26561	tomographic	_	_	
75-16	26562-26572	functional	_	_	
75-17	26573-26581	magnetic	_	_	
75-18	26582-26591	resonance	_	_	
75-19	26592-26599	imaging	_	_	
75-20	26600-26605	study	_	_	

#Text=Dopamine-dependent architecture of cortico-subcortical network connectivity
76-1	26606-26624	Dopamine-dependent	_	_	
76-2	26625-26637	architecture	_	_	
76-3	26638-26640	of	_	_	
76-4	26641-26660	cortico-subcortical	_	_	
76-5	26661-26668	network	_	_	
76-6	26669-26681	connectivity	_	_	

#Text=L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study
77-1	26682-26688	L-dopa	_	_	
77-2	26689-26698	modulates	_	_	
77-3	26699-26709	functional	_	_	
77-4	26710-26722	connectivity	_	_	
77-5	26723-26725	in	_	_	
77-6	26726-26734	striatal	_	_	
77-7	26735-26744	cognitive	_	_	
77-8	26745-26748	and	_	_	
77-9	26749-26754	motor	_	_	
77-10	26755-26763	networks	_	_	
77-11	26763-26764	:	_	_	
77-12	26765-26766	a	_	_	
77-13	26767-26779	double-blind	_	_	
77-14	26780-26798	placebo-controlled	_	_	
77-15	26799-26804	study	_	_	

#Text=Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative
78-1	26805-26815	Diagnostic	_	_	
78-2	26816-26825	interview	_	_	
78-3	26826-26829	for	_	_	
78-4	26830-26837	genetic	_	_	
78-5	26838-26845	studies	_	_	
78-6	26845-26846	.	_	_	
78-7	26847-26856	Rationale	_	_	
78-8	26856-26857	,	_	_	
78-9	26858-26864	unique	_	_	
78-10	26865-26873	features	_	_	
78-11	26873-26874	,	_	_	
78-12	26875-26878	and	_	_	
78-13	26879-26887	training	_	_	
78-14	26887-26888	.	_	_	
78-15	26889-26893	NIMH	_	_	
78-16	26894-26902	Genetics	_	_	
78-17	26903-26913	Initiative	_	_	

#Text=The assessment and analysis of handedness: the Edinburgh inventory
79-1	26917-26920	The	_	_	
79-2	26921-26931	assessment	_	_	
79-3	26932-26935	and	_	_	
79-4	26936-26944	analysis	_	_	
79-5	26945-26947	of	_	_	
79-6	26948-26958	handedness	_	_	
79-7	26958-26959	:	_	_	
79-8	26960-26963	the	_	_	
79-9	26964-26973	Edinburgh	_	_	
79-10	26974-26983	inventory	_	_	

#Text=The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
80-1	26984-26987	The	_	_	
80-2	26988-26995	MATRICS	_	_	
80-3	26996-27005	Consensus	_	_	
80-4	27006-27015	Cognitive	_	_	
80-5	27016-27023	Battery	_	_	
80-6	27023-27024	,	_	_	
80-7	27025-27029	part	_	_	
80-8	27030-27031	1	_	_	
80-9	27031-27032	:	_	_	
80-10	27033-27037	test	_	_	
80-11	27038-27047	selection	_	_	
80-12	27047-27048	,	_	_	
80-13	27049-27060	reliability	_	_	
80-14	27060-27061	,	_	_	
80-15	27062-27065	and	_	_	
80-16	27066-27074	validity	_	_	

#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
81-1	27075-27083	Spurious	_	_	
81-2	27084-27087	but	_	_	
81-3	27088-27098	systematic	_	_	
81-4	27099-27111	correlations	_	_	
81-5	27112-27114	in	_	_	
81-6	27115-27125	functional	_	_	
81-7	27126-27138	connectivity	_	_	
81-8	27139-27142	MRI	_	_	
81-9	27143-27151	networks	_	_	
81-10	27152-27157	arise	_	_	
81-11	27158-27162	from	_	_	
81-12	27163-27170	subject	_	_	
81-13	27171-27177	motion	_	_	

#Text=Increased prefrontal cortical D(1) receptors in drug naive patients with schizophrenia: a PET study with [(1)(1)C]NNC112
82-1	27178-27187	Increased	_	_	
82-2	27188-27198	prefrontal	_	_	
82-3	27199-27207	cortical	_	_	
82-4	27208-27209	D	_	_	
82-5	27209-27210	(	_	_	
82-6	27210-27211	1	_	_	
82-7	27211-27212	)	_	_	
82-8	27213-27222	receptors	_	_	
82-9	27223-27225	in	_	_	
82-10	27226-27230	drug	_	_	
82-11	27231-27236	naive	_	_	
82-12	27237-27245	patients	_	_	
82-13	27246-27250	with	_	_	
82-14	27251-27264	schizophrenia	_	_	
82-15	27264-27265	:	_	_	
82-16	27266-27267	a	_	_	
82-17	27268-27271	PET	_	_	
82-18	27272-27277	study	_	_	
82-19	27278-27282	with	_	_	
82-20	27283-27284	[	_	_	
82-21	27284-27285	(	_	_	
82-22	27285-27286	1	_	_	
82-23	27286-27287	)	_	_	
82-24	27287-27288	(	_	_	
82-25	27288-27289	1	_	_	
82-26	27289-27290	)	_	_	
82-27	27290-27291	C	_	_	
82-28	27291-27292	]	_	_	
82-29	27292-27298	NNC112	_	_	

#Text=Measurement of striatal and extrastriatal dopamine D-1 receptor binding potential with [C-11]NNC 112 in humans: Validation and reproducibility
83-1	27299-27310	Measurement	_	_	
83-2	27311-27313	of	_	_	
83-3	27314-27322	striatal	_	_	
83-4	27323-27326	and	_	_	
83-5	27327-27340	extrastriatal	_	_	
83-6	27341-27349	dopamine	_	_	
83-7	27350-27351	D	_	_	
83-8	27351-27352	-	_	_	
83-9	27352-27353	1	_	_	
83-10	27354-27362	receptor	_	_	
83-11	27363-27370	binding	_	_	
83-12	27371-27380	potential	_	_	
83-13	27381-27385	with	_	_	
83-14	27386-27387	[	_	_	
83-15	27387-27388	C	_	_	
83-16	27388-27389	-	_	_	
83-17	27389-27391	11	_	_	
83-18	27391-27392	]	_	_	
83-19	27392-27395	NNC	_	_	
83-20	27396-27399	112	_	_	
83-21	27400-27402	in	_	_	
83-22	27403-27409	humans	_	_	
83-23	27409-27410	:	_	_	
83-24	27411-27421	Validation	_	_	
83-25	27422-27425	and	_	_	
83-26	27426-27441	reproducibility	_	_	

#Text=Functional connectivity of human striatum: a resting state FMRI study
84-1	27442-27452	Functional	_	_	
84-2	27453-27465	connectivity	_	_	
84-3	27466-27468	of	_	_	
84-4	27469-27474	human	_	_	
84-5	27475-27483	striatum	_	_	
84-6	27483-27484	:	_	_	
84-7	27485-27486	a	_	_	
84-8	27487-27494	resting	_	_	
84-9	27495-27500	state	_	_	
84-10	27501-27505	FMRI	_	_	
84-11	27506-27511	study	_	_	

#Text=Automated Talairach atlas labels for functional brain mapping
85-1	27512-27521	Automated	_	_	
85-2	27522-27531	Talairach	_	_	
85-3	27532-27537	atlas	_	_	
85-4	27538-27544	labels	_	_	
85-5	27545-27548	for	_	_	
85-6	27549-27559	functional	_	_	
85-7	27560-27565	brain	_	_	
85-8	27566-27573	mapping	_	_	

#Text=An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets
86-1	27574-27576	An	_	_	
86-2	27577-27586	automated	_	_	
86-3	27587-27593	method	_	_	
86-4	27594-27597	for	_	_	
86-5	27598-27611	neuroanatomic	_	_	
86-6	27612-27615	and	_	_	
86-7	27616-27633	cytoarchitectonic	_	_	
86-8	27634-27645	atlas-based	_	_	
86-9	27646-27659	interrogation	_	_	
86-10	27660-27662	of	_	_	
86-11	27663-27667	fMRI	_	_	
86-12	27668-27672	data	_	_	
86-13	27673-27677	sets	_	_	

#Text=A Rationale and Test for the Number of Factors in Factor Analysis
87-1	27678-27679	A	_	_	
87-2	27680-27689	Rationale	_	_	
87-3	27690-27693	and	_	_	
87-4	27694-27698	Test	_	_	
87-5	27699-27702	for	_	_	
87-6	27703-27706	the	_	_	
87-7	27707-27713	Number	_	_	
87-8	27714-27716	of	_	_	
87-9	27717-27724	Factors	_	_	
87-10	27725-27727	in	_	_	
87-11	27728-27734	Factor	_	_	
87-12	27735-27743	Analysis	_	_	

#Text=Converging structural and functional connectivity of orbitofrontal, dorsolateral prefrontal, and posterior parietal cortex in the human striatum
88-1	27744-27754	Converging	_	_	
88-2	27755-27765	structural	_	_	
88-3	27766-27769	and	_	_	
88-4	27770-27780	functional	_	_	
88-5	27781-27793	connectivity	_	_	
88-6	27794-27796	of	_	_	
88-7	27797-27810	orbitofrontal	_	_	
88-8	27810-27811	,	_	_	
88-9	27812-27824	dorsolateral	_	_	
88-10	27825-27835	prefrontal	_	_	
88-11	27835-27836	,	_	_	
88-12	27837-27840	and	_	_	
88-13	27841-27850	posterior	_	_	
88-14	27851-27859	parietal	_	_	
88-15	27860-27866	cortex	_	_	
88-16	27867-27869	in	_	_	
88-17	27870-27873	the	_	_	
88-18	27874-27879	human	_	_	
88-19	27880-27888	striatum	_	_	

#Text=The neural network underlying incentive-based learning: implications for interpreting circuit disruptions in psychiatric disorders
89-1	27889-27892	The	_	_	
89-2	27893-27899	neural	_	_	
89-3	27900-27907	network	_	_	
89-4	27908-27918	underlying	_	_	
89-5	27919-27934	incentive-based	_	_	
89-6	27935-27943	learning	_	_	
89-7	27943-27944	:	_	_	
89-8	27945-27957	implications	_	_	
89-9	27958-27961	for	_	_	
89-10	27962-27974	interpreting	_	_	
89-11	27975-27982	circuit	_	_	
89-12	27983-27994	disruptions	_	_	
89-13	27995-27997	in	_	_	
89-14	27998-28009	psychiatric	_	_	
89-15	28010-28019	disorders	_	_	

#Text=Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
90-1	28020-28033	Dysconnection	_	_	
90-2	28034-28036	in	_	_	
90-3	28037-28050	schizophrenia	_	_	
90-4	28050-28051	:	_	_	
90-5	28052-28056	from	_	_	
90-6	28057-28065	abnormal	_	_	
90-7	28066-28074	synaptic	_	_	
90-8	28075-28085	plasticity	_	_	
90-9	28086-28088	to	_	_	
90-10	28089-28097	failures	_	_	
90-11	28098-28100	of	_	_	
90-12	28101-28116	self-monitoring	_	_	

#Text=Abnormalities in hemispheric specialization of caudate nucleus connectivity in schizophrenia
91-1	28117-28130	Abnormalities	_	_	
91-2	28131-28133	in	_	_	
91-3	28134-28145	hemispheric	_	_	
91-4	28146-28160	specialization	_	_	
91-5	28161-28163	of	_	_	
91-6	28164-28171	caudate	_	_	
91-7	28172-28179	nucleus	_	_	
91-8	28180-28192	connectivity	_	_	
91-9	28193-28195	in	_	_	
91-10	28196-28209	schizophrenia	_	_	

#Text=Resting-state fMRI connectivity impairment in schizophrenia and bipolar disorder
92-1	28210-28223	Resting-state	_	_	
92-2	28224-28228	fMRI	_	_	
92-3	28229-28241	connectivity	_	_	
92-4	28242-28252	impairment	_	_	
92-5	28253-28255	in	_	_	
92-6	28256-28269	schizophrenia	_	_	
92-7	28270-28273	and	_	_	
92-8	28274-28281	bipolar	_	_	
92-9	28282-28290	disorder	_	_	

#Text=Task-related fronto-striatal functional connectivity during working memory performance in schizophrenia
93-1	28291-28303	Task-related	_	_	
93-2	28304-28319	fronto-striatal	_	_	
93-3	28320-28330	functional	_	_	
93-4	28331-28343	connectivity	_	_	
93-5	28344-28350	during	_	_	
93-6	28351-28358	working	_	_	
93-7	28359-28365	memory	_	_	
93-8	28366-28377	performance	_	_	
93-9	28378-28380	in	_	_	
93-10	28381-28394	schizophrenia	_	_	

#Text=Functional dysconnectivity of corticostriatal circuitry as a risk phenotype for psychosis
94-1	28395-28405	Functional	_	_	
94-2	28406-28421	dysconnectivity	_	_	
94-3	28422-28424	of	_	_	
94-4	28425-28440	corticostriatal	_	_	
94-5	28441-28450	circuitry	_	_	
94-6	28451-28453	as	_	_	
94-7	28454-28455	a	_	_	
94-8	28456-28460	risk	_	_	
94-9	28461-28470	phenotype	_	_	
94-10	28471-28474	for	_	_	
94-11	28475-28484	psychosis	_	_	

#Text=Functional connectivity and grey matter volume of the striatum in schizophrenia
95-1	28485-28495	Functional	_	_	
95-2	28496-28508	connectivity	_	_	
95-3	28509-28512	and	_	_	
95-4	28513-28517	grey	_	_	
95-5	28518-28524	matter	_	_	
95-6	28525-28531	volume	_	_	
95-7	28532-28534	of	_	_	
95-8	28535-28538	the	_	_	
95-9	28539-28547	striatum	_	_	
95-10	28548-28550	in	_	_	
95-11	28551-28564	schizophrenia	_	_	

#Text=Functional dysconnectivity of the dorsolateral prefrontal cortex in first-episode schizophrenia using resting-state fMRI
96-1	28565-28575	Functional	_	_	
96-2	28576-28591	dysconnectivity	_	_	
96-3	28592-28594	of	_	_	
96-4	28595-28598	the	_	_	
96-5	28599-28611	dorsolateral	_	_	
96-6	28612-28622	prefrontal	_	_	
96-7	28623-28629	cortex	_	_	
96-8	28630-28632	in	_	_	
96-9	28633-28646	first-episode	_	_	
96-10	28647-28660	schizophrenia	_	_	
96-11	28661-28666	using	_	_	
96-12	28667-28680	resting-state	_	_	
96-13	28681-28685	fMRI	_	_	

#Text=Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis
97-1	28686-28693	Altered	_	_	
97-2	28694-28702	striatal	_	_	
97-3	28703-28713	functional	_	_	
97-4	28714-28726	connectivity	_	_	
97-5	28727-28729	in	_	_	
97-6	28730-28738	subjects	_	_	
97-7	28739-28743	with	_	_	
97-8	28744-28746	an	_	_	
97-9	28747-28754	at-risk	_	_	
97-10	28755-28761	mental	_	_	
97-11	28762-28767	state	_	_	
97-12	28768-28771	for	_	_	
97-13	28772-28781	psychosis	_	_	

#Text=Ventral Striatal Activation During Reward Processing in Psychosis: A Neurofunctional Meta-Analysis
98-1	28782-28789	Ventral	_	_	
98-2	28790-28798	Striatal	_	_	
98-3	28799-28809	Activation	_	_	
98-4	28810-28816	During	_	_	
98-5	28817-28823	Reward	_	_	
98-6	28824-28834	Processing	_	_	
98-7	28835-28837	in	_	_	
98-8	28838-28847	Psychosis	_	_	
98-9	28847-28848	:	_	_	
98-10	28849-28850	A	_	_	
98-11	28851-28866	Neurofunctional	_	_	
98-12	28867-28880	Meta-Analysis	_	_	

#Text=Negative symptoms in schizophrenia are associated with aberrant striato-cortical connectivity in a rewarded perceptual decision-making task
99-1	28881-28889	Negative	_	_	
99-2	28890-28898	symptoms	_	_	
99-3	28899-28901	in	_	_	
99-4	28902-28915	schizophrenia	_	_	
99-5	28916-28919	are	_	_	
99-6	28920-28930	associated	_	_	
99-7	28931-28935	with	_	_	
99-8	28936-28944	aberrant	_	_	
99-9	28945-28961	striato-cortical	_	_	
99-10	28962-28974	connectivity	_	_	
99-11	28975-28977	in	_	_	
99-12	28978-28979	a	_	_	
99-13	28980-28988	rewarded	_	_	
99-14	28989-28999	perceptual	_	_	
99-15	29000-29015	decision-making	_	_	
99-16	29016-29020	task	_	_	

#Text=Differential brain glucose metabolic patterns in antipsychotic-naive first-episode schizophrenia with and without auditory verbal hallucinations
100-1	29021-29033	Differential	_	_	
100-2	29034-29039	brain	_	_	
100-3	29040-29047	glucose	_	_	
100-4	29048-29057	metabolic	_	_	
100-5	29058-29066	patterns	_	_	
100-6	29067-29069	in	_	_	
100-7	29070-29089	antipsychotic-naive	_	_	
100-8	29090-29103	first-episode	_	_	
100-9	29104-29117	schizophrenia	_	_	
100-10	29118-29122	with	_	_	
100-11	29123-29126	and	_	_	
100-12	29127-29134	without	_	_	
100-13	29135-29143	auditory	_	_	
100-14	29144-29150	verbal	_	_	
100-15	29151-29165	hallucinations	_	_	

#Text=Deficits in predictive coding underlie hallucinations in schizophrenia
101-1	29166-29174	Deficits	_	_	
101-2	29175-29177	in	_	_	
101-3	29178-29188	predictive	_	_	
101-4	29189-29195	coding	_	_	
101-5	29196-29204	underlie	_	_	
101-6	29205-29219	hallucinations	_	_	
101-7	29220-29222	in	_	_	
101-8	29223-29236	schizophrenia	_	_	

#Text=Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis
102-1	29237-29245	Cortical	_	_	
102-2	29246-29257	activations	_	_	
102-3	29258-29264	during	_	_	
102-4	29265-29273	auditory	_	_	
102-5	29274-29280	verbal	_	_	
102-6	29281-29295	hallucinations	_	_	
102-7	29296-29298	in	_	_	
102-8	29299-29312	schizophrenia	_	_	
102-9	29312-29313	:	_	_	
102-10	29314-29315	a	_	_	
102-11	29316-29332	coordinate-based	_	_	
102-12	29333-29346	meta-analysis	_	_	

#Text=Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex
103-1	29347-29364	Dopamine-mediated	_	_	
103-2	29365-29378	stabilization	_	_	
103-3	29379-29381	of	_	_	
103-4	29382-29394	delay-period	_	_	
103-5	29395-29403	activity	_	_	
103-6	29404-29406	in	_	_	
103-7	29407-29408	a	_	_	
103-8	29409-29416	network	_	_	
103-9	29417-29422	model	_	_	
103-10	29423-29425	of	_	_	
103-11	29426-29436	prefrontal	_	_	
103-12	29437-29443	cortex	_	_	

#Text=Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex
104-1	29444-29454	Mechanisms	_	_	
104-2	29455-29465	underlying	_	_	
104-3	29466-29478	differential	_	_	
104-4	29479-29481	D1	_	_	
104-5	29482-29488	versus	_	_	
104-6	29489-29491	D2	_	_	
104-7	29492-29500	dopamine	_	_	
104-8	29501-29509	receptor	_	_	
104-9	29510-29520	regulation	_	_	
104-10	29521-29523	of	_	_	
104-11	29524-29534	inhibition	_	_	
104-12	29535-29537	in	_	_	
104-13	29538-29548	prefrontal	_	_	
104-14	29549-29555	cortex	_	_	

#Text=Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia
105-1	29556-29569	Antipsychotic	_	_	
105-2	29570-29579	treatment	_	_	
105-3	29580-29583	and	_	_	
105-4	29584-29594	functional	_	_	
105-5	29595-29607	connectivity	_	_	
105-6	29608-29610	of	_	_	
105-7	29611-29614	the	_	_	
105-8	29615-29623	striatum	_	_	
105-9	29624-29626	in	_	_	
105-10	29627-29640	first-episode	_	_	
105-11	29641-29654	schizophrenia	_	_	

#Text=Differences in multivariate pattern of striatal connections between unmedicated patients with schizophrenia and healthy controls
106-1	29655-29666	Differences	_	_	
106-2	29667-29669	in	_	_	
106-3	29670-29682	multivariate	_	_	
106-4	29683-29690	pattern	_	_	
106-5	29691-29693	of	_	_	
106-6	29694-29702	striatal	_	_	
106-7	29703-29714	connections	_	_	
106-8	29715-29722	between	_	_	
106-9	29723-29734	unmedicated	_	_	
106-10	29735-29743	patients	_	_	
106-11	29744-29748	with	_	_	
106-12	29749-29762	schizophrenia	_	_	
106-13	29763-29766	and	_	_	
106-14	29767-29774	healthy	_	_	
106-15	29775-29783	controls	_	_	

#Text=Top panel: coronal views of striatal subregion seeds; voxels identified as part of each subregion in at least half of the subjects are overlaid on a group-averaged T1-weighted image. Middle panels: patterns of striatal connectivity are shown in controls (top) and patients (bottom) as bar plots of connectivity strength (group mean beta ± S.E.M.) by striatal subregion (using the same color scheme as in the top panel) and target region on the X axis (from left to right, cortical Brodmann areas [BA] followed by hippocampus, globus pallidus, and thalamic nuclei). Bottom panel: betas weights (log Odds Ratio or log OR) corresponding to each of the predictor variables or regressors included in the final logistic-regression model predicting group membership (controls=1, patients=0); this final (most parsimonious) model included only striatal-target pairs related to the anterior caudate (blue) and posterior caudate (fuchsia; see eMethods). Asterisks denote logistic-regression beta estimates significantly different than zero (single asterisks denote p<0.05; double asterisks denote p<0.01; post-hoc tests of individual beta estimates adjusted their degrees of freedom based on the total number of predictor variables, thus controlling for multiple comparisons). GP: globus pallidus; VPL: ventral posterior lateral nucleus; VPM : ventral posterior medial; MD: mediodorsal; VL: ventrolateral; VA: ventral anterior.
107-1	29784-29787	Top	_	_	
107-2	29788-29793	panel	_	_	
107-3	29793-29794	:	_	_	
107-4	29795-29802	coronal	_	_	
107-5	29803-29808	views	_	_	
107-6	29809-29811	of	_	_	
107-7	29812-29820	striatal	_	_	
107-8	29821-29830	subregion	_	_	
107-9	29831-29836	seeds	_	_	
107-10	29836-29837	;	_	_	
107-11	29838-29844	voxels	_	_	
107-12	29845-29855	identified	_	_	
107-13	29856-29858	as	_	_	
107-14	29859-29863	part	_	_	
107-15	29864-29866	of	_	_	
107-16	29867-29871	each	_	_	
107-17	29872-29881	subregion	_	_	
107-18	29882-29884	in	_	_	
107-19	29885-29887	at	_	_	
107-20	29888-29893	least	_	_	
107-21	29894-29898	half	_	_	
107-22	29899-29901	of	_	_	
107-23	29902-29905	the	_	_	
107-24	29906-29914	subjects	_	_	
107-25	29915-29918	are	_	_	
107-26	29919-29927	overlaid	_	_	
107-27	29928-29930	on	_	_	
107-28	29931-29932	a	_	_	
107-29	29933-29947	group-averaged	_	_	
107-30	29948-29950	T1	_	_	
107-31	29950-29951	-	_	_	
107-32	29951-29959	weighted	_	_	
107-33	29960-29965	image	_	_	
107-34	29965-29966	.	_	_	
107-35	29967-29973	Middle	_	_	
107-36	29974-29980	panels	_	_	
107-37	29980-29981	:	_	_	
107-38	29982-29990	patterns	_	_	
107-39	29991-29993	of	_	_	
107-40	29994-30002	striatal	_	_	
107-41	30003-30015	connectivity	_	_	
107-42	30016-30019	are	_	_	
107-43	30020-30025	shown	_	_	
107-44	30026-30028	in	_	_	
107-45	30029-30037	controls	_	_	
107-46	30038-30039	(	_	_	
107-47	30039-30042	top	_	_	
107-48	30042-30043	)	_	_	
107-49	30044-30047	and	_	_	
107-50	30048-30056	patients	_	_	
107-51	30057-30058	(	_	_	
107-52	30058-30064	bottom	_	_	
107-53	30064-30065	)	_	_	
107-54	30066-30068	as	_	_	
107-55	30069-30072	bar	_	_	
107-56	30073-30078	plots	_	_	
107-57	30079-30081	of	_	_	
107-58	30082-30094	connectivity	_	_	
107-59	30095-30103	strength	_	_	
107-60	30104-30105	(	_	_	
107-61	30105-30110	group	_	_	
107-62	30111-30115	mean	_	_	
107-63	30116-30120	beta	_	_	
107-64	30121-30122	±	_	_	
107-65	30123-30128	S.E.M	_	_	
107-66	30128-30129	.	_	_	
107-67	30129-30130	)	_	_	
107-68	30131-30133	by	_	_	
107-69	30134-30142	striatal	_	_	
107-70	30143-30152	subregion	_	_	
107-71	30153-30154	(	_	_	
107-72	30154-30159	using	_	_	
107-73	30160-30163	the	_	_	
107-74	30164-30168	same	_	_	
107-75	30169-30174	color	_	_	
107-76	30175-30181	scheme	_	_	
107-77	30182-30184	as	_	_	
107-78	30185-30187	in	_	_	
107-79	30188-30191	the	_	_	
107-80	30192-30195	top	_	_	
107-81	30196-30201	panel	_	_	
107-82	30201-30202	)	_	_	
107-83	30203-30206	and	_	_	
107-84	30207-30213	target	_	_	
107-85	30214-30220	region	_	_	
107-86	30221-30223	on	_	_	
107-87	30224-30227	the	_	_	
107-88	30228-30229	X	_	_	
107-89	30230-30234	axis	_	_	
107-90	30235-30236	(	_	_	
107-91	30236-30240	from	_	_	
107-92	30241-30245	left	_	_	
107-93	30246-30248	to	_	_	
107-94	30249-30254	right	_	_	
107-95	30254-30255	,	_	_	
107-96	30256-30264	cortical	_	_	
107-97	30265-30273	Brodmann	_	_	
107-98	30274-30279	areas	_	_	
107-99	30280-30281	[	_	_	
107-100	30281-30283	BA	_	_	
107-101	30283-30284	]	_	_	
107-102	30285-30293	followed	_	_	
107-103	30294-30296	by	_	_	
107-104	30297-30308	hippocampus	_	_	
107-105	30308-30309	,	_	_	
107-106	30310-30316	globus	_	_	
107-107	30317-30325	pallidus	_	_	
107-108	30325-30326	,	_	_	
107-109	30327-30330	and	_	_	
107-110	30331-30339	thalamic	_	_	
107-111	30340-30346	nuclei	_	_	
107-112	30346-30347	)	_	_	
107-113	30347-30348	.	_	_	
107-114	30349-30355	Bottom	_	_	
107-115	30356-30361	panel	_	_	
107-116	30361-30362	:	_	_	
107-117	30363-30368	betas	_	_	
107-118	30369-30376	weights	_	_	
107-119	30377-30378	(	_	_	
107-120	30378-30381	log	_	_	
107-121	30382-30386	Odds	_	_	
107-122	30387-30392	Ratio	_	_	
107-123	30393-30395	or	_	_	
107-124	30396-30399	log	_	_	
107-125	30400-30402	OR	_	_	
107-126	30402-30403	)	_	_	
107-127	30404-30417	corresponding	_	_	
107-128	30418-30420	to	_	_	
107-129	30421-30425	each	_	_	
107-130	30426-30428	of	_	_	
107-131	30429-30432	the	_	_	
107-132	30433-30442	predictor	_	_	
107-133	30443-30452	variables	_	_	
107-134	30453-30455	or	_	_	
107-135	30456-30466	regressors	_	_	
107-136	30467-30475	included	_	_	
107-137	30476-30478	in	_	_	
107-138	30479-30482	the	_	_	
107-139	30483-30488	final	_	_	
107-140	30489-30508	logistic-regression	_	_	
107-141	30509-30514	model	_	_	
107-142	30515-30525	predicting	_	_	
107-143	30526-30531	group	_	_	
107-144	30532-30542	membership	_	_	
107-145	30543-30544	(	_	_	
107-146	30544-30552	controls	_	_	
107-147	30552-30553	=	_	_	
107-148	30553-30554	1	_	_	
107-149	30554-30555	,	_	_	
107-150	30556-30564	patients	_	_	
107-151	30564-30565	=	_	_	
107-152	30565-30566	0	_	_	
107-153	30566-30567	)	_	_	
107-154	30567-30568	;	_	_	
107-155	30569-30573	this	_	_	
107-156	30574-30579	final	_	_	
107-157	30580-30581	(	_	_	
107-158	30581-30585	most	_	_	
107-159	30586-30598	parsimonious	_	_	
107-160	30598-30599	)	_	_	
107-161	30600-30605	model	_	_	
107-162	30606-30614	included	_	_	
107-163	30615-30619	only	_	_	
107-164	30620-30635	striatal-target	_	_	
107-165	30636-30641	pairs	_	_	
107-166	30642-30649	related	_	_	
107-167	30650-30652	to	_	_	
107-168	30653-30656	the	_	_	
107-169	30657-30665	anterior	_	_	
107-170	30666-30673	caudate	_	_	
107-171	30674-30675	(	_	_	
107-172	30675-30679	blue	_	_	
107-173	30679-30680	)	_	_	
107-174	30681-30684	and	_	_	
107-175	30685-30694	posterior	_	_	
107-176	30695-30702	caudate	_	_	
107-177	30703-30704	(	_	_	
107-178	30704-30711	fuchsia	_	_	
107-179	30711-30712	;	_	_	
107-180	30713-30716	see	_	_	
107-181	30717-30725	eMethods	_	_	
107-182	30725-30726	)	_	_	
107-183	30726-30727	.	_	_	
107-184	30728-30737	Asterisks	_	_	
107-185	30738-30744	denote	_	_	
107-186	30745-30764	logistic-regression	_	_	
107-187	30765-30769	beta	_	_	
107-188	30770-30779	estimates	_	_	
107-189	30780-30793	significantly	_	_	
107-190	30794-30803	different	_	_	
107-191	30804-30808	than	_	_	
107-192	30809-30813	zero	_	_	
107-193	30814-30815	(	_	_	
107-194	30815-30821	single	_	_	
107-195	30822-30831	asterisks	_	_	
107-196	30832-30838	denote	_	_	
107-197	30839-30840	p	_	_	
107-198	30840-30841	<	_	_	
107-199	30841-30845	0.05	_	_	
107-200	30845-30846	;	_	_	
107-201	30847-30853	double	_	_	
107-202	30854-30863	asterisks	_	_	
107-203	30864-30870	denote	_	_	
107-204	30871-30872	p	_	_	
107-205	30872-30873	<	_	_	
107-206	30873-30877	0.01	_	_	
107-207	30877-30878	;	_	_	
107-208	30879-30887	post-hoc	_	_	
107-209	30888-30893	tests	_	_	
107-210	30894-30896	of	_	_	
107-211	30897-30907	individual	_	_	
107-212	30908-30912	beta	_	_	
107-213	30913-30922	estimates	_	_	
107-214	30923-30931	adjusted	_	_	
107-215	30932-30937	their	_	_	
107-216	30938-30945	degrees	_	_	
107-217	30946-30948	of	_	_	
107-218	30949-30956	freedom	_	_	
107-219	30957-30962	based	_	_	
107-220	30963-30965	on	_	_	
107-221	30966-30969	the	_	_	
107-222	30970-30975	total	_	_	
107-223	30976-30982	number	_	_	
107-224	30983-30985	of	_	_	
107-225	30986-30995	predictor	_	_	
107-226	30996-31005	variables	_	_	
107-227	31005-31006	,	_	_	
107-228	31007-31011	thus	_	_	
107-229	31012-31023	controlling	_	_	
107-230	31024-31027	for	_	_	
107-231	31028-31036	multiple	_	_	
107-232	31037-31048	comparisons	_	_	
107-233	31048-31049	)	_	_	
107-234	31049-31050	.	_	_	
107-235	31051-31053	GP	_	_	
107-236	31053-31054	:	_	_	
107-237	31055-31061	globus	_	_	
107-238	31062-31070	pallidus	_	_	
107-239	31070-31071	;	_	_	
107-240	31072-31075	VPL	_	_	
107-241	31075-31076	:	_	_	
107-242	31077-31084	ventral	_	_	
107-243	31085-31094	posterior	_	_	
107-244	31095-31102	lateral	_	_	
107-245	31103-31110	nucleus	_	_	
107-246	31110-31111	;	_	_	
107-247	31112-31115	VPM	_	_	
107-248	31116-31117	:	_	_	
107-249	31118-31125	ventral	_	_	
107-250	31126-31135	posterior	_	_	
107-251	31136-31142	medial	_	_	
107-252	31142-31143	;	_	_	
107-253	31144-31146	MD	_	_	
107-254	31146-31147	:	_	_	
107-255	31148-31159	mediodorsal	_	_	
107-256	31159-31160	;	_	_	
107-257	31161-31163	VL	_	_	
107-258	31163-31164	:	_	_	
107-259	31165-31178	ventrolateral	_	_	
107-260	31178-31179	;	_	_	
107-261	31180-31182	VA	_	_	
107-262	31182-31183	:	_	_	
107-263	31184-31191	ventral	_	_	
107-264	31192-31200	anterior	_	_	
107-265	31200-31201	.	_	_	

#Text=Correlations of striatal connectivity pattern with symptom severity and D2 receptor density measured with [11C]FLB457 PET
108-1	31202-31214	Correlations	_	_	
108-2	31215-31217	of	_	_	
108-3	31218-31226	striatal	_	_	
108-4	31227-31239	connectivity	_	_	
108-5	31240-31247	pattern	_	_	
108-6	31248-31252	with	_	_	
108-7	31253-31260	symptom	_	_	
108-8	31261-31269	severity	_	_	
108-9	31270-31273	and	_	_	
108-10	31274-31276	D2	_	_	
108-11	31277-31285	receptor	_	_	
108-12	31286-31293	density	_	_	
108-13	31294-31302	measured	_	_	
108-14	31303-31307	with	_	_	
108-15	31308-31309	[	_	_	
108-16	31309-31312	11C	_	_	
108-17	31312-31313	]	_	_	
108-18	31313-31319	FLB457	_	_	
108-19	31320-31323	PET	_	_	

#Text=Scatterplots show relationships between connectivity pattern (log odds of belonging to the healthy group based on the multivariate pattern of striatal connectivity) and (A) severity of positive symptoms based on the PANSS-PT scores in patients, (B) severity of negative symptoms based on the PANSS-NT scores in patients, and (C) baseline BPND (corresponding to the first principal component score), adjusted by group and fMRI-data-quality score, across all subjects (note that group adjustment shifts the group means such that the connectivity pattern appears to overlap between the groups along the X axis). Values in A and B are ranked given that the appropriate corresponding tests are non-parametric.
109-1	31324-31336	Scatterplots	_	_	
109-2	31337-31341	show	_	_	
109-3	31342-31355	relationships	_	_	
109-4	31356-31363	between	_	_	
109-5	31364-31376	connectivity	_	_	
109-6	31377-31384	pattern	_	_	
109-7	31385-31386	(	_	_	
109-8	31386-31389	log	_	_	
109-9	31390-31394	odds	_	_	
109-10	31395-31397	of	_	_	
109-11	31398-31407	belonging	_	_	
109-12	31408-31410	to	_	_	
109-13	31411-31414	the	_	_	
109-14	31415-31422	healthy	_	_	
109-15	31423-31428	group	_	_	
109-16	31429-31434	based	_	_	
109-17	31435-31437	on	_	_	
109-18	31438-31441	the	_	_	
109-19	31442-31454	multivariate	_	_	
109-20	31455-31462	pattern	_	_	
109-21	31463-31465	of	_	_	
109-22	31466-31474	striatal	_	_	
109-23	31475-31487	connectivity	_	_	
109-24	31487-31488	)	_	_	
109-25	31489-31492	and	_	_	
109-26	31493-31494	(	_	_	
109-27	31494-31495	A	_	_	
109-28	31495-31496	)	_	_	
109-29	31497-31505	severity	_	_	
109-30	31506-31508	of	_	_	
109-31	31509-31517	positive	_	_	
109-32	31518-31526	symptoms	_	_	
109-33	31527-31532	based	_	_	
109-34	31533-31535	on	_	_	
109-35	31536-31539	the	_	_	
109-36	31540-31548	PANSS-PT	_	_	
109-37	31549-31555	scores	_	_	
109-38	31556-31558	in	_	_	
109-39	31559-31567	patients	_	_	
109-40	31567-31568	,	_	_	
109-41	31569-31570	(	_	_	
109-42	31570-31571	B	_	_	
109-43	31571-31572	)	_	_	
109-44	31573-31581	severity	_	_	
109-45	31582-31584	of	_	_	
109-46	31585-31593	negative	_	_	
109-47	31594-31602	symptoms	_	_	
109-48	31603-31608	based	_	_	
109-49	31609-31611	on	_	_	
109-50	31612-31615	the	_	_	
109-51	31616-31624	PANSS-NT	_	_	
109-52	31625-31631	scores	_	_	
109-53	31632-31634	in	_	_	
109-54	31635-31643	patients	_	_	
109-55	31643-31644	,	_	_	
109-56	31645-31648	and	_	_	
109-57	31649-31650	(	_	_	
109-58	31650-31651	C	_	_	
109-59	31651-31652	)	_	_	
109-60	31653-31661	baseline	_	_	
109-61	31662-31666	BPND	_	_	
109-62	31667-31668	(	_	_	
109-63	31668-31681	corresponding	_	_	
109-64	31682-31684	to	_	_	
109-65	31685-31688	the	_	_	
109-66	31689-31694	first	_	_	
109-67	31695-31704	principal	_	_	
109-68	31705-31714	component	_	_	
109-69	31715-31720	score	_	_	
109-70	31720-31721	)	_	_	
109-71	31721-31722	,	_	_	
109-72	31723-31731	adjusted	_	_	
109-73	31732-31734	by	_	_	
109-74	31735-31740	group	_	_	
109-75	31741-31744	and	_	_	
109-76	31745-31762	fMRI-data-quality	_	_	
109-77	31763-31768	score	_	_	
109-78	31768-31769	,	_	_	
109-79	31770-31776	across	_	_	
109-80	31777-31780	all	_	_	
109-81	31781-31789	subjects	_	_	
109-82	31790-31791	(	_	_	
109-83	31791-31795	note	_	_	
109-84	31796-31800	that	_	_	
109-85	31801-31806	group	_	_	
109-86	31807-31817	adjustment	_	_	
109-87	31818-31824	shifts	_	_	
109-88	31825-31828	the	_	_	
109-89	31829-31834	group	_	_	
109-90	31835-31840	means	_	_	
109-91	31841-31845	such	_	_	
109-92	31846-31850	that	_	_	
109-93	31851-31854	the	_	_	
109-94	31855-31867	connectivity	_	_	
109-95	31868-31875	pattern	_	_	
109-96	31876-31883	appears	_	_	
109-97	31884-31886	to	_	_	
109-98	31887-31894	overlap	_	_	
109-99	31895-31902	between	_	_	
109-100	31903-31906	the	_	_	
109-101	31907-31913	groups	_	_	
109-102	31914-31919	along	_	_	
109-103	31920-31923	the	_	_	
109-104	31924-31925	X	_	_	
109-105	31926-31930	axis	_	_	
109-106	31930-31931	)	_	_	
109-107	31931-31932	.	_	_	
109-108	31933-31939	Values	_	_	
109-109	31940-31942	in	_	_	
109-110	31943-31944	A	_	_	
109-111	31945-31948	and	_	_	
109-112	31949-31950	B	_	_	
109-113	31951-31954	are	_	_	
109-114	31955-31961	ranked	_	_	
109-115	31962-31967	given	_	_	
109-116	31968-31972	that	_	_	
109-117	31973-31976	the	_	_	
109-118	31977-31988	appropriate	_	_	
109-119	31989-32002	corresponding	_	_	
109-120	32003-32008	tests	_	_	
109-121	32009-32012	are	_	_	
109-122	32013-32027	non-parametric	_	_	
109-123	32027-32028	.	_	_	

#Text=Voxelwise connectivity of striatal subregions in patients and healthy controls
110-1	32029-32038	Voxelwise	_	_	
110-2	32039-32051	connectivity	_	_	
110-3	32052-32054	of	_	_	
110-4	32055-32063	striatal	_	_	
110-5	32064-32074	subregions	_	_	
110-6	32075-32077	in	_	_	
110-7	32078-32086	patients	_	_	
110-8	32087-32090	and	_	_	
110-9	32091-32098	healthy	_	_	
110-10	32099-32107	controls	_	_	

#Text=Top panel: regions showing significant connectivity with each of the 5 striatal subregions (each in a different color) are depicted in controls (left) and patients (right) and overlaid onto an inflated brain surface (using the PALS-B12 atlas in Caret 5.65). Connectivity maps show effects corresponding to p<0.05, FDR-corrected. Bottom panel: t maps show regions with significantly stronger connectivity to the anterior caudate than to the other 4 striatal subregions in warm colors in controls (left) and patients (right).
111-1	32108-32111	Top	_	_	
111-2	32112-32117	panel	_	_	
111-3	32117-32118	:	_	_	
111-4	32119-32126	regions	_	_	
111-5	32127-32134	showing	_	_	
111-6	32135-32146	significant	_	_	
111-7	32147-32159	connectivity	_	_	
111-8	32160-32164	with	_	_	
111-9	32165-32169	each	_	_	
111-10	32170-32172	of	_	_	
111-11	32173-32176	the	_	_	
111-12	32177-32178	5	_	_	
111-13	32179-32187	striatal	_	_	
111-14	32188-32198	subregions	_	_	
111-15	32199-32200	(	_	_	
111-16	32200-32204	each	_	_	
111-17	32205-32207	in	_	_	
111-18	32208-32209	a	_	_	
111-19	32210-32219	different	_	_	
111-20	32220-32225	color	_	_	
111-21	32225-32226	)	_	_	
111-22	32227-32230	are	_	_	
111-23	32231-32239	depicted	_	_	
111-24	32240-32242	in	_	_	
111-25	32243-32251	controls	_	_	
111-26	32252-32253	(	_	_	
111-27	32253-32257	left	_	_	
111-28	32257-32258	)	_	_	
111-29	32259-32262	and	_	_	
111-30	32263-32271	patients	_	_	
111-31	32272-32273	(	_	_	
111-32	32273-32278	right	_	_	
111-33	32278-32279	)	_	_	
111-34	32280-32283	and	_	_	
111-35	32284-32292	overlaid	_	_	
111-36	32293-32297	onto	_	_	
111-37	32298-32300	an	_	_	
111-38	32301-32309	inflated	_	_	
111-39	32310-32315	brain	_	_	
111-40	32316-32323	surface	_	_	
111-41	32324-32325	(	_	_	
111-42	32325-32330	using	_	_	
111-43	32331-32334	the	_	_	
111-44	32335-32343	PALS-B12	_	_	
111-45	32344-32349	atlas	_	_	
111-46	32350-32352	in	_	_	
111-47	32353-32358	Caret	_	_	
111-48	32359-32363	5.65	_	_	
111-49	32363-32364	)	_	_	
111-50	32364-32365	.	_	_	
111-51	32366-32378	Connectivity	_	_	
111-52	32379-32383	maps	_	_	
111-53	32384-32388	show	_	_	
111-54	32389-32396	effects	_	_	
111-55	32397-32410	corresponding	_	_	
111-56	32411-32413	to	_	_	
111-57	32414-32415	p	_	_	
111-58	32415-32416	<	_	_	
111-59	32416-32420	0.05	_	_	
111-60	32420-32421	,	_	_	
111-61	32422-32435	FDR-corrected	_	_	
111-62	32435-32436	.	_	_	
111-63	32437-32443	Bottom	_	_	
111-64	32444-32449	panel	_	_	
111-65	32449-32450	:	_	_	
111-66	32451-32452	t	_	_	
111-67	32453-32457	maps	_	_	
111-68	32458-32462	show	_	_	
111-69	32463-32470	regions	_	_	
111-70	32471-32475	with	_	_	
111-71	32476-32489	significantly	_	_	
111-72	32490-32498	stronger	_	_	
111-73	32499-32511	connectivity	_	_	
111-74	32512-32514	to	_	_	
111-75	32515-32518	the	_	_	
111-76	32519-32527	anterior	_	_	
111-77	32528-32535	caudate	_	_	
111-78	32536-32540	than	_	_	
111-79	32541-32543	to	_	_	
111-80	32544-32547	the	_	_	
111-81	32548-32553	other	_	_	
111-82	32554-32555	4	_	_	
111-83	32556-32564	striatal	_	_	
111-84	32565-32575	subregions	_	_	
111-85	32576-32578	in	_	_	
111-86	32579-32583	warm	_	_	
111-87	32584-32590	colors	_	_	
111-88	32591-32593	in	_	_	
111-89	32594-32602	controls	_	_	
111-90	32603-32604	(	_	_	
111-91	32604-32608	left	_	_	
111-92	32608-32609	)	_	_	
111-93	32610-32613	and	_	_	
111-94	32614-32622	patients	_	_	
111-95	32623-32624	(	_	_	
111-96	32624-32629	right	_	_	
111-97	32629-32630	)	_	_	
111-98	32630-32631	.	_	_	

#Text=Global brain connectivity of striatal subregions in patients and healthy controls
112-1	32632-32638	Global	_	_	
112-2	32639-32644	brain	_	_	
112-3	32645-32657	connectivity	_	_	
112-4	32658-32660	of	_	_	
112-5	32661-32669	striatal	_	_	
112-6	32670-32680	subregions	_	_	
112-7	32681-32683	in	_	_	
112-8	32684-32692	patients	_	_	
112-9	32693-32696	and	_	_	
112-10	32697-32704	healthy	_	_	
112-11	32705-32713	controls	_	_	

#Text=Absolute beta values averaged across all extrastriatal brain voxels (± S.E.M.) are plotted by striatal subregion and group.
113-1	32714-32722	Absolute	_	_	
113-2	32723-32727	beta	_	_	
113-3	32728-32734	values	_	_	
113-4	32735-32743	averaged	_	_	
113-5	32744-32750	across	_	_	
113-6	32751-32754	all	_	_	
113-7	32755-32768	extrastriatal	_	_	
113-8	32769-32774	brain	_	_	
113-9	32775-32781	voxels	_	_	
113-10	32782-32783	(	_	_	
113-11	32783-32784	±	_	_	
113-12	32785-32790	S.E.M	_	_	
113-13	32790-32791	.	_	_	
113-14	32791-32792	)	_	_	
113-15	32793-32796	are	_	_	
113-16	32797-32804	plotted	_	_	
113-17	32805-32807	by	_	_	
113-18	32808-32816	striatal	_	_	
113-19	32817-32826	subregion	_	_	
113-20	32827-32830	and	_	_	
113-21	32831-32836	group	_	_	
113-22	32836-32837	.	_	_	

#Text=Sociodemographic, clinical, and other relevant characteristics of healthy controls and patients with schizophrenia
114-1	32838-32854	Sociodemographic	_	_	
114-2	32854-32855	,	_	_	
114-3	32856-32864	clinical	_	_	
114-4	32864-32865	,	_	_	
114-5	32866-32869	and	_	_	
114-6	32870-32875	other	_	_	
114-7	32876-32884	relevant	_	_	
114-8	32885-32900	characteristics	_	_	
114-9	32901-32903	of	_	_	
114-10	32904-32911	healthy	_	_	
114-11	32912-32920	controls	_	_	
114-12	32921-32924	and	_	_	
114-13	32925-32933	patients	_	_	
114-14	32934-32938	with	_	_	
114-15	32939-32952	schizophrenia	_	_	

#Text=Means ± S.E.M. are presented for continuous variables. P-values correspond to two-sample t-tests for continuous variables and χ2 tests for categorical variables. Mean framewise displacement is given for scrubbed fMRI frames. All 18 patients met DSM-IV criteria for schizophrenia (versus other disorders in the schizophrenia spectrum). C: Caucasian; AA: African-American; Hisp: Hispanic; As: Asian. See eTable 1 relevant information for the subset of participants with fMRI and PET data. See eTable 2 for PET scanning parameters and additional data.
115-1	32953-32958	Means	_	_	
115-2	32959-32960	±	_	_	
115-3	32961-32966	S.E.M	_	_	
115-4	32966-32967	.	_	_	
115-5	32968-32971	are	_	_	
115-6	32972-32981	presented	_	_	
115-7	32982-32985	for	_	_	
115-8	32986-32996	continuous	_	_	
115-9	32997-33006	variables	_	_	
115-10	33006-33007	.	_	_	
115-11	33008-33016	P-values	_	_	
115-12	33017-33027	correspond	_	_	
115-13	33028-33030	to	_	_	
115-14	33031-33041	two-sample	_	_	
115-15	33042-33049	t-tests	_	_	
115-16	33050-33053	for	_	_	
115-17	33054-33064	continuous	_	_	
115-18	33065-33074	variables	_	_	
115-19	33075-33078	and	_	_	
115-20	33079-33081	χ2	_	_	
115-21	33082-33087	tests	_	_	
115-22	33088-33091	for	_	_	
115-23	33092-33103	categorical	_	_	
115-24	33104-33113	variables	_	_	
115-25	33113-33114	.	_	_	
115-26	33115-33119	Mean	_	_	
115-27	33120-33129	framewise	_	_	
115-28	33130-33142	displacement	_	_	
115-29	33143-33145	is	_	_	
115-30	33146-33151	given	_	_	
115-31	33152-33155	for	_	_	
115-32	33156-33164	scrubbed	_	_	
115-33	33165-33169	fMRI	_	_	
115-34	33170-33176	frames	_	_	
115-35	33176-33177	.	_	_	
115-36	33178-33181	All	_	_	
115-37	33182-33184	18	_	_	
115-38	33185-33193	patients	_	_	
115-39	33194-33197	met	_	_	
115-40	33198-33204	DSM-IV	_	_	
115-41	33205-33213	criteria	_	_	
115-42	33214-33217	for	_	_	
115-43	33218-33231	schizophrenia	_	_	
115-44	33232-33233	(	_	_	
115-45	33233-33239	versus	_	_	
115-46	33240-33245	other	_	_	
115-47	33246-33255	disorders	_	_	
115-48	33256-33258	in	_	_	
115-49	33259-33262	the	_	_	
115-50	33263-33276	schizophrenia	_	_	
115-51	33277-33285	spectrum	_	_	
115-52	33285-33286	)	_	_	
115-53	33286-33287	.	_	_	
115-54	33288-33289	C	_	_	
115-55	33289-33290	:	_	_	
115-56	33291-33300	Caucasian	_	_	
115-57	33300-33301	;	_	_	
115-58	33302-33304	AA	_	_	
115-59	33304-33305	:	_	_	
115-60	33306-33322	African-American	_	_	
115-61	33322-33323	;	_	_	
115-62	33324-33328	Hisp	_	_	
115-63	33328-33329	:	_	_	
115-64	33330-33338	Hispanic	_	_	
115-65	33338-33339	;	_	_	
115-66	33340-33342	As	_	_	
115-67	33342-33343	:	_	_	
115-68	33344-33349	Asian	_	_	
115-69	33349-33350	.	_	_	
115-70	33351-33354	See	_	_	
115-71	33355-33361	eTable	_	_	
115-72	33362-33363	1	_	_	
115-73	33364-33372	relevant	_	_	
115-74	33373-33384	information	_	_	
115-75	33385-33388	for	_	_	
115-76	33389-33392	the	_	_	
115-77	33393-33399	subset	_	_	
115-78	33400-33402	of	_	_	
115-79	33403-33415	participants	_	_	
115-80	33416-33420	with	_	_	
115-81	33421-33425	fMRI	_	_	
115-82	33426-33429	and	_	_	
115-83	33430-33433	PET	_	_	
115-84	33434-33438	data	_	_	
115-85	33438-33439	.	_	_	
115-86	33440-33443	See	_	_	
115-87	33444-33450	eTable	_	_	
115-88	33451-33452	2	_	_	
115-89	33453-33456	for	_	_	
115-90	33457-33460	PET	_	_	
115-91	33461-33469	scanning	_	_	
115-92	33470-33480	parameters	_	_	
115-93	33481-33484	and	_	_	
115-94	33485-33495	additional	_	_	
115-95	33496-33500	data	_	_	
115-96	33500-33501	.	_	_	

#Text=Sociodemographic and clinical characteristics\tControls (n=24)\tPatients (n=18)\tp-value\t \tAge (years)\t33.7 ± 8.8\t35.6 ± 11.8\t0.54\t \tSex (female/male)\t14/10\t9/9\t0.59\t \tEthnicity (C/AA/Hisp/As/mixed)\t6/8/5/3/2\t1/9/4/1/2\t0.28\t \tParental SES\t39.0 ± 13.9\t45.6 ± 11.7\t0.13\t \tHandedness (right/left)\t23/1\t16/2\t0.39\t \tNicotine smoking (no/yes)\t21/3\t13/5\t0.21\t \tPANSS positive symptoms total [range, 7–49]\t7.0 ± 0.0 [7–8]\t13.6 ± 6.4 [9–23]\t<0.001\t \tPANSS negative symptoms total [range, 7–49]\t8.8 ± 1.4 [7–16]\t15.1 ± 5.8 [7–25]\t<0.001\t \tPANSS general symptoms total [range, 16–112]\t17.0 ± 1.4 [16–25]\t29.1 ± 7.8 [18–53]\t<0.001\t \tMATRICS (MCBB) composite T scores\t46.3 ± 2.5\t33.3 ± 3.7\t0.02\t \tMedication status (drug-naïve/drug-free)\t-\t6/12\t\t \tOnset psychotic symptoms (years)\t-\t16.4 ± 5.2\t\t \tDuration of psychotic illness (years)\t-\t18.7 ± 12.2\t\t \tCensored data (number of ‘scrubbed’ volumes)\t64.3 ± 13.5\t99.5 ± 21.7\t0.16\t \tFramewise displacement after censoring (FD)\t0.29 ± 0.0\t0.30 ± 0.0\t0.76\t \tInterval between MRI and PET scans (days)\t20.5 ± 24.8\t7.2 ± 2.6\t0.67
116-1	33502-33518	Sociodemographic	_	_	
116-2	33519-33522	and	_	_	
116-3	33523-33531	clinical	_	_	
116-4	33532-33547	characteristics	_	_	
116-5	33548-33556	Controls	_	_	
116-6	33557-33558	(	_	_	
116-7	33558-33559	n	_	_	
116-8	33559-33560	=	_	_	
116-9	33560-33562	24	_	_	
116-10	33562-33563	)	_	_	
116-11	33564-33572	Patients	_	_	
116-12	33573-33574	(	_	_	
116-13	33574-33575	n	_	_	
116-14	33575-33576	=	_	_	
116-15	33576-33578	18	_	_	
116-16	33578-33579	)	_	_	
116-17	33580-33587	p-value	_	_	
116-18	33590-33593	Age	_	_	
116-19	33594-33595	(	_	_	
116-20	33595-33600	years	_	_	
116-21	33600-33601	)	_	_	
116-22	33602-33606	33.7	_	_	
116-23	33607-33608	±	_	_	
116-24	33609-33612	8.8	_	_	
116-25	33613-33617	35.6	_	_	
116-26	33618-33619	±	_	_	
116-27	33620-33624	11.8	_	_	
116-28	33625-33629	0.54	_	_	
116-29	33632-33635	Sex	_	_	
116-30	33636-33637	(	_	_	
116-31	33637-33643	female	_	_	
116-32	33643-33644	/	_	_	
116-33	33644-33648	male	_	_	
116-34	33648-33649	)	_	_	
116-35	33650-33652	14	_	_	
116-36	33652-33653	/	_	_	
116-37	33653-33655	10	_	_	
116-38	33656-33657	9	_	_	
116-39	33657-33658	/	_	_	
116-40	33658-33659	9	_	_	
116-41	33660-33664	0.59	_	_	
116-42	33667-33676	Ethnicity	_	_	
116-43	33677-33678	(	_	_	
116-44	33678-33679	C	_	_	
116-45	33679-33680	/	_	_	
116-46	33680-33682	AA	_	_	
116-47	33682-33683	/	_	_	
116-48	33683-33687	Hisp	_	_	
116-49	33687-33688	/	_	_	
116-50	33688-33690	As	_	_	
116-51	33690-33691	/	_	_	
116-52	33691-33696	mixed	_	_	
116-53	33696-33697	)	_	_	
116-54	33698-33699	6	_	_	
116-55	33699-33700	/	_	_	
116-56	33700-33701	8	_	_	
116-57	33701-33702	/	_	_	
116-58	33702-33703	5	_	_	
116-59	33703-33704	/	_	_	
116-60	33704-33705	3	_	_	
116-61	33705-33706	/	_	_	
116-62	33706-33707	2	_	_	
116-63	33708-33709	1	_	_	
116-64	33709-33710	/	_	_	
116-65	33710-33711	9	_	_	
116-66	33711-33712	/	_	_	
116-67	33712-33713	4	_	_	
116-68	33713-33714	/	_	_	
116-69	33714-33715	1	_	_	
116-70	33715-33716	/	_	_	
116-71	33716-33717	2	_	_	
116-72	33718-33722	0.28	_	_	
116-73	33725-33733	Parental	_	_	
116-74	33734-33737	SES	_	_	
116-75	33738-33742	39.0	_	_	
116-76	33743-33744	±	_	_	
116-77	33745-33749	13.9	_	_	
116-78	33750-33754	45.6	_	_	
116-79	33755-33756	±	_	_	
116-80	33757-33761	11.7	_	_	
116-81	33762-33766	0.13	_	_	
116-82	33769-33779	Handedness	_	_	
116-83	33780-33781	(	_	_	
116-84	33781-33786	right	_	_	
116-85	33786-33787	/	_	_	
116-86	33787-33791	left	_	_	
116-87	33791-33792	)	_	_	
116-88	33793-33795	23	_	_	
116-89	33795-33796	/	_	_	
116-90	33796-33797	1	_	_	
116-91	33798-33800	16	_	_	
116-92	33800-33801	/	_	_	
116-93	33801-33802	2	_	_	
116-94	33803-33807	0.39	_	_	
116-95	33810-33818	Nicotine	_	_	
116-96	33819-33826	smoking	_	_	
116-97	33827-33828	(	_	_	
116-98	33828-33830	no	_	_	
116-99	33830-33831	/	_	_	
116-100	33831-33834	yes	_	_	
116-101	33834-33835	)	_	_	
116-102	33836-33838	21	_	_	
116-103	33838-33839	/	_	_	
116-104	33839-33840	3	_	_	
116-105	33841-33843	13	_	_	
116-106	33843-33844	/	_	_	
116-107	33844-33845	5	_	_	
116-108	33846-33850	0.21	_	_	
116-109	33853-33858	PANSS	_	_	
116-110	33859-33867	positive	_	_	
116-111	33868-33876	symptoms	_	_	
116-112	33877-33882	total	_	_	
116-113	33883-33884	[	_	_	
116-114	33884-33889	range	_	_	
116-115	33889-33890	,	_	_	
116-116	33891-33892	7	_	_	
116-117	33892-33893	–	_	_	
116-118	33893-33895	49	_	_	
116-119	33895-33896	]	_	_	
116-120	33897-33900	7.0	_	_	
116-121	33901-33902	±	_	_	
116-122	33903-33906	0.0	_	_	
116-123	33907-33908	[	_	_	
116-124	33908-33909	7	_	_	
116-125	33909-33910	–	_	_	
116-126	33910-33911	8	_	_	
116-127	33911-33912	]	_	_	
116-128	33913-33917	13.6	_	_	
116-129	33918-33919	±	_	_	
116-130	33920-33923	6.4	_	_	
116-131	33924-33925	[	_	_	
116-132	33925-33926	9	_	_	
116-133	33926-33927	–	_	_	
116-134	33927-33929	23	_	_	
116-135	33929-33930	]	_	_	
116-136	33931-33932	<	_	_	
116-137	33932-33937	0.001	_	_	
116-138	33940-33945	PANSS	_	_	
116-139	33946-33954	negative	_	_	
116-140	33955-33963	symptoms	_	_	
116-141	33964-33969	total	_	_	
116-142	33970-33971	[	_	_	
116-143	33971-33976	range	_	_	
116-144	33976-33977	,	_	_	
116-145	33978-33979	7	_	_	
116-146	33979-33980	–	_	_	
116-147	33980-33982	49	_	_	
116-148	33982-33983	]	_	_	
116-149	33984-33987	8.8	_	_	
116-150	33988-33989	±	_	_	
116-151	33990-33993	1.4	_	_	
116-152	33994-33995	[	_	_	
116-153	33995-33996	7	_	_	
116-154	33996-33997	–	_	_	
116-155	33997-33999	16	_	_	
116-156	33999-34000	]	_	_	
116-157	34001-34005	15.1	_	_	
116-158	34006-34007	±	_	_	
116-159	34008-34011	5.8	_	_	
116-160	34012-34013	[	_	_	
116-161	34013-34014	7	_	_	
116-162	34014-34015	–	_	_	
116-163	34015-34017	25	_	_	
116-164	34017-34018	]	_	_	
116-165	34019-34020	<	_	_	
116-166	34020-34025	0.001	_	_	
116-167	34028-34033	PANSS	_	_	
116-168	34034-34041	general	_	_	
116-169	34042-34050	symptoms	_	_	
116-170	34051-34056	total	_	_	
116-171	34057-34058	[	_	_	
116-172	34058-34063	range	_	_	
116-173	34063-34064	,	_	_	
116-174	34065-34067	16	_	_	
116-175	34067-34068	–	_	_	
116-176	34068-34071	112	_	_	
116-177	34071-34072	]	_	_	
116-178	34073-34077	17.0	_	_	
116-179	34078-34079	±	_	_	
116-180	34080-34083	1.4	_	_	
116-181	34084-34085	[	_	_	
116-182	34085-34087	16	_	_	
116-183	34087-34088	–	_	_	
116-184	34088-34090	25	_	_	
116-185	34090-34091	]	_	_	
116-186	34092-34096	29.1	_	_	
116-187	34097-34098	±	_	_	
116-188	34099-34102	7.8	_	_	
116-189	34103-34104	[	_	_	
116-190	34104-34106	18	_	_	
116-191	34106-34107	–	_	_	
116-192	34107-34109	53	_	_	
116-193	34109-34110	]	_	_	
116-194	34111-34112	<	_	_	
116-195	34112-34117	0.001	_	_	
116-196	34120-34127	MATRICS	_	_	
116-197	34128-34129	(	_	_	
116-198	34129-34133	MCBB	_	_	
116-199	34133-34134	)	_	_	
116-200	34135-34144	composite	_	_	
116-201	34145-34146	T	_	_	
116-202	34147-34153	scores	_	_	
116-203	34154-34158	46.3	_	_	
116-204	34159-34160	±	_	_	
116-205	34161-34164	2.5	_	_	
116-206	34165-34169	33.3	_	_	
116-207	34170-34171	±	_	_	
116-208	34172-34175	3.7	_	_	
116-209	34176-34180	0.02	_	_	
116-210	34183-34193	Medication	_	_	
116-211	34194-34200	status	_	_	
116-212	34201-34202	(	_	_	
116-213	34202-34212	drug-naïve	_	_	
116-214	34212-34213	/	_	_	
116-215	34213-34222	drug-free	_	_	
116-216	34222-34223	)	_	_	
116-217	34224-34225	-	_	_	
116-218	34226-34227	6	_	_	
116-219	34227-34228	/	_	_	
116-220	34228-34230	12	_	_	
116-221	34234-34239	Onset	_	_	
116-222	34240-34249	psychotic	_	_	
116-223	34250-34258	symptoms	_	_	
116-224	34259-34260	(	_	_	
116-225	34260-34265	years	_	_	
116-226	34265-34266	)	_	_	
116-227	34267-34268	-	_	_	
116-228	34269-34273	16.4	_	_	
116-229	34274-34275	±	_	_	
116-230	34276-34279	5.2	_	_	
116-231	34283-34291	Duration	_	_	
116-232	34292-34294	of	_	_	
116-233	34295-34304	psychotic	_	_	
116-234	34305-34312	illness	_	_	
116-235	34313-34314	(	_	_	
116-236	34314-34319	years	_	_	
116-237	34319-34320	)	_	_	
116-238	34321-34322	-	_	_	
116-239	34323-34327	18.7	_	_	
116-240	34328-34329	±	_	_	
116-241	34330-34334	12.2	_	_	
116-242	34338-34346	Censored	_	_	
116-243	34347-34351	data	_	_	
116-244	34352-34353	(	_	_	
116-245	34353-34359	number	_	_	
116-246	34360-34362	of	_	_	
116-247	34363-34364	‘	_	_	
116-248	34364-34372	scrubbed	_	_	
116-249	34372-34373	’	_	_	
116-250	34374-34381	volumes	_	_	
116-251	34381-34382	)	_	_	
116-252	34383-34387	64.3	_	_	
116-253	34388-34389	±	_	_	
116-254	34390-34394	13.5	_	_	
116-255	34395-34399	99.5	_	_	
116-256	34400-34401	±	_	_	
116-257	34402-34406	21.7	_	_	
116-258	34407-34411	0.16	_	_	
116-259	34414-34423	Framewise	_	_	
116-260	34424-34436	displacement	_	_	
116-261	34437-34442	after	_	_	
116-262	34443-34452	censoring	_	_	
116-263	34453-34454	(	_	_	
116-264	34454-34456	FD	_	_	
116-265	34456-34457	)	_	_	
116-266	34458-34462	0.29	_	_	
116-267	34463-34464	±	_	_	
116-268	34465-34468	0.0	_	_	
116-269	34469-34473	0.30	_	_	
116-270	34474-34475	±	_	_	
116-271	34476-34479	0.0	_	_	
116-272	34480-34484	0.76	_	_	
116-273	34487-34495	Interval	_	_	
116-274	34496-34503	between	_	_	
116-275	34504-34507	MRI	_	_	
116-276	34508-34511	and	_	_	
116-277	34512-34515	PET	_	_	
116-278	34516-34521	scans	_	_	
116-279	34522-34523	(	_	_	
116-280	34523-34527	days	_	_	
116-281	34527-34528	)	_	_	
116-282	34529-34533	20.5	_	_	
116-283	34534-34535	±	_	_	
116-284	34536-34540	24.8	_	_	
116-285	34541-34544	7.2	_	_	
116-286	34545-34546	±	_	_	
116-287	34547-34550	2.6	_	_	
116-288	34551-34555	0.67	_	_	
